Anti-ΑvΒ6 antibody conjugates, compositions comprising Anti- ΑvΒ6 antibody conjugates and methods of making and using Anti-ΑvΒ6 antibody conjugates
Antibody conjugates targeting avP6 provide a solution to systemic and on-target toxicities by selectively binding and delivering payload moieties to avP6-expressing malignancies, effectively inhibiting TGF-β pathway activation and reducing tumor growth.
Patent Information
- Application Number
- PCT/US2026/027033
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-07
- Filing Date
- 2026-05-07
- Publication Date
- 2026-11-12
AI Technical Summary
Current anti-avP6 therapeutic agents face challenges such as dose-limiting systemic toxicities and on-target toxicities, necessitating the development of therapeutics that specifically target avP6-expressing cells and tissues.
Development of antibody conjugates that selectively bind avP6, comprising an antibody linked to a payload moiety through covalent or linker bonds, with specific sequences and variants, for targeted delivery to avP6-expressing malignancies.
The antibody conjugates effectively inhibit TGF-β pathway activation and demonstrate significant tumor growth reduction in avP6-expressing cancers, reducing systemic and on-target toxicities while maintaining therapeutic efficacy.
Smart Images

Figure US2026027033_12112026_PF_FP_ABST
Abstract
Description
[0001] Attorney Docket No.: 108843.00627
[0002] ANTI-avp6 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI-avp6 ANTIBODY CONJUGATES AND METHODS OF MAKING AND USING ANTI-avp6
[0003] ANTIBODY CONJUGATES
[0004] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U. S. Provisional Application 63 / 801,579 filed May 7, 2025. This application is incorporated for all purposes in its entirety.
[0005] FIELD OF THE INVENTION
[0006] The present disclosure generally relates to antibody conjugates with binding specificity for Integrin avP6 and compositions comprising the antibody conjugates, including pharmaceutical compositions, diagnostic compositions, and kits. Also provided are methods of making anti-avP6 antibody conjugates, and methods of using anti-avP6 antibody conjugates, for example, for therapeutic purposes, diagnostic purposes, and research purposes.
[0007] BACKGROUND
[0008] Integrin avP6 is a heterodimer formed by the subunits av and P6 (ITGB6). Integrin avP6 is a key activator of TGF-P and plays a crucial role in cell adhesion, migration and motility. ITGB6 has normal low constitutive expression limited to epithelial lining in the gastrointestinal tract, lung, kidney, urinary bladder and salivary gland (Lyon RP et al., Mol Cancer Ther. 2023 Dec 1,22(12): 1444-1453). Expression of ITGB6 is also upregulated during wound repair and tissue remodeling. Malignant cells exploit these functions of ITGB6 as overexpression of cell surface ITGB6 has been reported in numerous solid malignancies, such as non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), esophageal cancer, ovarian cancer and breast cancer (Lyon, et al. 2023). In fact, ITGB6 is highly expressed in indications such as squamous cell carcinoma of the head and neck (HNSCC, 91%), breast cancer (68%), non-small cell lung cancer (NSCLC, 70%), esophageal cancer (74%), and colon cancer (62%). In NSCLC and HNSCC, where there is the greatest evidence of ITGB6-targeted activity, there is a respective annual incidence of approximately 197,000 and 65,000 patients in the U. S. alone. Functionally, ITGB6 has also been reported to prevent anoikis and to promote epithelial to mesenchymal transition (Ramos et al. Anticancer Res. 2009 Jan;29(l): 125-30).
[0009] In the clinic, sigvotatug vedotin (SV, Seagen / Pfizer), a DAR4 mc-val-cit-pAB-MMAE ADC, has observed anti-tumor response in NSCLC, HNSCC, and esophageal cancers. Peters S., et al., Journal of Clinical Oncology, Vol 42, No. 16_suppl (ASCO 2024 Abstract). CurrentAttorney Docket No.: 108843.00627
[0010] anti-avP6 therapeutic agents face challenges, e.g., dose-limiting systemic toxicities, such as diarrhea and neutropenia, and on-target toxicities, such as stomatitis.
[0011] Accordingly, there is a need for improved therapeutics that specifically target cells and tissues that express avP6.
[0012] SUMMARY
[0013] Provided herein are antibody conjugates that selectively bind avP6. The antibody conjugates comprise an antibody that binds avP6 linked site-specifically to at least one payload moiety. The antibody can be linked to the at least one payload directly by a covalent bond or indirectly by way of a linker. Anti-avP6 antibodies are described in detail herein, as are useful payload moieties, and useful linkers.
[0014] In some embodiments, the antibody conjugates comprise an illustrative CDR, VH, VL, heavy chain, or light chain sequence provided in this disclosure, or a variant thereof. In some aspects, the variant is a variant with one or more conservative amino acid substitutions. In some aspects, the variant has sequence identity to the illustrative sequence or sequences.
[0015] In another aspect, provided are compositions comprising the antibody conjugates. In some embodiments, the compositions are pharmaceutical compositions. In some embodiments, the pharmaceutical composition is for parenteral administration. Any suitable pharmaceutical composition may be used. In some embodiments, the pharmaceutical composition is a composition for parenteral administration. In a further aspect, provided herein are kits comprising the antibody conjugates or pharmaceutical compositions.
[0016] This disclosure also provides methods of using the anti-avP6 antibody conjugates provided herein. In some embodiments, the methods are methods of delivering one or more payload moieties to a target cell or tissue expressing avP6. In some embodiments, the method is a method of treatment. In some embodiments, the method is a diagnostic method.
[0017] In some embodiments, antibody conjugates or pharmaceutical compositions thereof are used to treat a disease or condition. In some aspects, the disease or condition is cancer. In some aspects, the disease or condition is an avP6-expressing malignancy, including, but not limited to NSCLC (non-small cell lung cancer) and HNSCC (head and neck squamous cell carcinoma).
[0018] In some embodiments, the antibody conjugates bind human avP6. In some embodiments, the antibody conjugates also bind homologs of human avP6. In some aspects, the antibody conjugates also bind homologs of cynomolgus monkey and / or mouse avP6.Attorney Docket No.: 108843.00627
[0019] BRIEF DESCRIPTION OF THE FIGURES FIG. 1A provides a comparison of the Kabat and Chothia numbering systems for CDR-Hl. Adapted from Martin A. C. R. (2010). Protein Sequence and Structure Analysis of Antibody Variable Domains. In R. Kontermann & S. Diibel (Eds.), Antibody Engineering vol. 2 (pp. 33-51). Springer-Verlag, Berlin Heidelberg.
[0020] FIG. IB provides a general schematic design for a representative antibody conjugate of the present disclosure where (1) is avP6, (2) is a non-natural amino acid, para-azidomethyl-L-phenylalanine (pAMF), (3) is a P-glucuronidase linker and (4) is an exatecan payload.
[0021] FIG. 2 shows the effect of the anti-avP6 antibodies on TGF-P pathway as measured using a TGF-P reporter cell line co-cultured with avP6 positive Shmac4 cells. Three anti-avP6 antibodies inhibited the TGF-P pathway similar to LAP while one anti-avP6 antibody did not affect TGF-P pathway.
[0022] FIG. 3 shows the anti-avP6 antibody internalization activity measured by live imaging using avP6 positive HCC38 cells.
[0023] FIG. 4 shows the anti-avP6 Antibody 11 Control Antibody internalization activity measured by live imaging using avP6 positive HCC38 cells.
[0024] FIG. 5A provides SW780 tumor growth curves in response to treatment with a single i.v. dose of 0.5, 1, or 5 mg / kg of conjugate 14. The graph is presented as individual values or mean ± SEM.
[0025] FIG. 5B provides SW780 tumor growth curves in response to treatment with a single i.v. dose of 0.5, 1, or 5 mg / kg of conjugate 15. The graph is presented as individual values or mean ± SEM.
[0026] FIG. 5C provides SW780 tumor growth curves in response to treatment with a single i.v. dose of 0.5, 1, or 5 mg / kg of or conjugate 12. The graph is presented as individual values or mean ± SEM.
[0027] FIG. 5D provides scatter plots of individual SW780 tumor volumes on day 13 post treatment of conjugate 14, conjugate 15, or conjugate 12. Statistical analysis was performed on tumor volumes on day 13 using a Welch’s ANOVA with Dunnett’s T3 multiple comparisons test versus the vehicle group. A probability of less than 5% (p<0.05) was considered significant. * = p<0.05; ** = p<0.01; *** = p<0.001; **** = pO. OOOl. All graphs are presented as individual values or mean ± SEM.
[0028] FIG. 6A provides Detroit 562 tumor growth curves in response to treatment with a single i.v. dose of 1, 3, 5, or 10 mg / kg of conjugate 14 or a single i.v. dose of 2.7 mg / kg of conjugate 16. The graph is presented as individual values or mean ± SEM.Attorney Docket No.: 108843.00627
[0029] FIG. 6B provides Detroit 562 tumor growth curves in response to treatment with a single i.v. dose of 1, 3, 5, or 10 mg / kg of conjugate 15 or a single i.v. dose of 2.7 mg / kg of conjugate 16. The graph is presented as individual values or mean ± SEM.
[0030] FIG. 6C provides scatter plots of individual Detroit 562 tumor volumes on day 15 post treatment of conjugate 14, conjugate 15, or conjugate 16. Statistical analysis was performed on tumor volumes on day 15 using a Welch’s ANOVA with Dunnett’s T3 multiple comparisons test versus the vehicle group. A probability of less than 5% (p<0.05) was considered significant. * = p<0.05;** = p<0.01; *** = p<0.001. All graphs are presented as individual values or mean ± SEM.
[0031] FIG. 7A provides NCI-H1975 tumor growth curves in response to treatment with a single i.v. dose of 0.5, 1, or 5 mg / kg of conjugate 15 or a single i.v. dose of 2.7 mg / kg of conjugate 16. The graph is presented as individual values or mean ± SEM.
[0032] FIG. 7B provides scatter plots of individual NCI-H1975 tumor volumes on day 18 post treatment of conjugate 15 or conjugate 16. Statistical analysis was performed on tumor volumes on day 18 using a Welch’s ANOVA with Dunnett’s T3 multiple comparisons test versus the vehicle group. A probability of less than 5% (p<0.05) was considered significant. ****=p<o 0001. All graphs are presented as individual values or mean ± SEM.
[0033] FIG. 8A provides HPAF-II tumor growth curves in response to treatment with a single i.v. dose of 0.5, 1, 2, or 5 mg / kg of conjugate 15. The graph is presented as individual values or mean ± SEM.
[0034] FIG. 8B provides scatter plots of individual HPAF-II tumor volumes on day 29 post treatment of conjugate 15. Statistical analysis was performed on tumor volumes on day 29 using a Welch’s ANOVA with Dunnett’s T3 multiple comparisons test versus the vehicle group. A probability of less than 5% (p<0.05) was considered significant. ** = p<0.01; **** = p<0.0001. All graphs are presented as individual values or mean ± SEM.
[0035] FIG. 9A provides SW780 tumor growth curves in response to treatment with a single i.v. dose of 0.5, 1, or 3 mg / kg of conjugate 15. The graph is presented as individual values or mean ± SEM.
[0036] FIG. 9B provides SW780 tumor growth curves in response to treatment with a single i.v. dose of 0.5, 1, or 3 mg / kg of conjugate 17. The graph is presented as individual values or mean ± SEM.
[0037] FIG. 9C provides scatter plots of individual SW780 tumor volumes on day 17 post treatment of conjugate 15 or conjugate 17. Statistical analysis was performed on tumor volumes on day 17 using a Welch’s ANOVA with Dunnett’s T3 multiple comparisons test versus theAttorney Docket No.: 108843.00627
[0038] vehicle group. A probability of less than 5% (p<0.05) was considered significant. **** = p<0.0001. All graphs are presented as individual values or mean ± SEM.
[0039] FIG. 10A provides LXFE 1066 tumor growth curves in response to treatment with a single i.v. dose of 5 mg / kg of conjugate 15 or conjugate 16.
[0040] FIG. 10B provides LXFE 2478 tumor growth curves in response to treatment with a single i.v. dose of 5 mg / kg of conjugate 15 or conjugate 16.
[0041] FIG. 11A provides CXF 533 tumor growth curves in response to treatment with a single i.v. dose of 5 mg / kg of conjugate 15.
[0042] FIG. 11B provides CXF 1034 tumor growth curves in response to treatment with a single i.v. dose of 5 mg / kg of conjugate 15.
[0043] DETAILED DESCRIPTION OF THE EMBODIMENTS
[0044] 1. Definitions
[0045] When referring to the conjugates and compounds provided herein, the following terms have the following meanings unless indicated otherwise. Unless otherwise defined, all terms of art, notations and other scientific terminology used herein are intended to have the meanings commonly understood by those of skill in the art to which this disclosure pertains. In the event that there is a plurality of definitions for a term herein, those in this section prevail unless stated otherwise. In some cases, terms with commonly understood meanings are defined herein for clarity and / or for ready reference, and the inclusion of such definitions herein should not necessarily be construed to represent a difference over what is generally understood in the art. The techniques and procedures described or referenced herein are generally well understood and commonly employed using conventional methodologies by those skilled in the art, such as, for example, the widely utilized molecular cloning methodologies described in Sambrook et al., Molecular Cloning: A Laboratory Manual 2nd ed. (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. As appropriate, procedures involving the use of commercially available kits and reagents are generally carried out in accordance with manufacturer-defined protocols and conditions unless otherwise noted.
[0046] As used herein, the singular forms “a,” “an,” and “the” include the plural referents unless the context clearly indicates otherwise.
[0047] The term “about” indicates and encompasses an indicated value and a range above and below that value. In certain embodiments, the term “about” indicates the designated
[0048] value ± 10%, ± 5%, or ± 1%. In certain embodiments, the term “about” indicates the designated value ± one standard deviation of that value.Attorney Docket No.: 108843.00627
[0049] The term “combinations thereof’ includes every possible combination of elements to which the term refers to. For example, a sentence stating “A, B, C, and combinations thereof’ includes the following combinations: (1) A, (2) A and B, (3) A, B and C, (4) A and C, (5) B, (6) B and C, and (7) C.
[0050] The term “Integrin avP6” or “avP6” refers to the protein complex formed by heterodimerization of Integrin P6 (ITGB6) and Integrin av (ITGAV). The term “ITGB6” refers to, unless specified otherwise, any variants, isoforms and species homologs of human ITGB6 proteins that are naturally expressed by cells, or that are expressed by cells transfected with a ITGB6 gene. ITGB6 proteins include, for example, human ITGB6 (SEQ ID NO: 1, UniProt Accession No. Pl 8564). In some embodiments, ITGB6 proteins include cynomolgus monkey ITGB6 (SEQ ID NO: 2, UniProt Accession No. A0A2K5TZ36). In some embodiments, ITGB6 proteins include murine ITGB6 (SEQ ID NO: 3, UniProt Accession No. Q9Z0T9). The term “ITGAV” refers to, unless specified otherwise, any variants, isoforms and species homologs of human ITGAV proteins that are naturally expressed by cells, or that are expressed by cells transfected with a ITGAV gene. ITGAV proteins include, for example, human ITGAV (SEQ ID NO: 1512, UniProt Accession No. P06756). In some embodiments, ITGAV proteins include cynomolgus monkey ITGB6 (SEQ ID NO: 1513, UniProt Accession No.
[0051] A0A2K5WCD3). In some embodiments, ITGAV proteins include murine ITGB6 (SEQ ID NO: 1514, UniProt Accession No. P43406).
[0052] The term “immunoglobulin” refers to a class of structurally related proteins generally comprising two pairs of polypeptide chains: one pair of light (L) chains and one pair of heavy (H) chains. In an “intact immunoglobulin,” all four of these chains are interconnected by disulfide bonds. The structure of immunoglobulins has been well characterized. See, e.g, Paul, Fundamental Immunology 7th ed., Ch. 5 (2013) Lippincott Williams & Wilkins, Philadelphia, PA. Briefly, each heavy chain typically comprises a heavy chain variable region (VH) and a heavy chain constant region (CH). The heavy chain constant region typically comprises three domains, abbreviated CHI, CH2, and CH3. Each light chain typically comprises a light chain variable region (VL) and a light chain constant region. The light chain constant region typically comprises one domain, abbreviated CL.
[0053] The term “antibody” describes a type of immunoglobulin molecule and is used herein in its broadest sense. An antibody specifically includes intact antibodies (e.g., intact immunoglobulins), and antibody fragments. Antibodies comprise at least one antigen-binding domain. One example of an antigen-binding domain is an antigen binding domain formed by a VH -VL dimer. An “avP6 antibody,” “avP6 antibody,” “avP6 Ab,” “avP6-specific antibody” or “anti-avP6 Ab” or the equivalent is an antibody, as described herein, which binds specificallyAttorney Docket No.: 108843.00627
[0054] to the antigen avP6. In some embodiments, the antibody binds the extracellular domain of avP6.
[0055] The VH and VL regions may be further subdivided into regions of hypervariability (“hypervariable regions (HVRs);” also called “complementarity determining regions” (CDRs)) interspersed with regions that are more conserved. The more conserved regions are called framework regions (FRs). Each VH and VL generally comprises three CDRs and four FRs, arranged in the following order (from N-terminus to C-terminus): FR1 - CDR1 - FR2 - CDR2 -FR3 - CDR3 - FR4. The CDRs are involved in antigen binding, and influence antigen specificity and binding affinity of the antibody. See Kabat et al., Sequences of Proteins of Immunological Interest 5th ed. (1991) Public Health Service, National Institutes of Health, Bethesda, MD, incorporated by reference in its entirety.
[0056] The light chain from any vertebrate species can be assigned to one of two types, called kappa and lambda, based on the sequence of the constant domain.
[0057] The heavy chain from any vertebrate species can be assigned to one of five different classes (or isotypes): IgA, IgD, IgE, IgG, and IgM. These classes are also designated a, 8, a, y, and p, respectively. The IgG and IgA classes are further divided into subclasses on the basis of differences in sequence and function. Humans express the following subclasses: IgGl, IgG2, IgG3, IgG4, IgAl, and IgA2.
[0058] The amino acid sequence boundaries of a CDR can be determined by one of skill in the art using any of a number of known numbering schemes, including those described by Kabat et al., supra (“Kabat” numbering scheme); Al-Lazikani et al., 1997, J. Mol. BioL, 273:927-948 (“Chothia” numbering scheme); MacCallum et al., 1996, J. Mol. Biol. 262:732-745 (“Contact” numbering scheme); Lefranc et al., Dev. Comp. Immunol., 2003, 27:55-77 (“IMGT” numbering scheme); and Honegge and Pliickthun, J. Mol. Biol., 2001, 309:657-70 (“AHo” numbering scheme), each of which is incorporated by reference in its entirety.
[0059] Table A provides the positions of CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2, and CDR-H3 as identified by the Kabat and Chothia schemes. For CDR-H1, residue numbering is provided using both the Kabat and Chothia numbering schemes.
[0060] Table A. Residues in CDRs according to Kabat and Chothia numbering schemes.
[0061]
[0062] Attorney Docket No.: 108843.00627
[0063]
[0064] * The C-terminus of CDR-H1, when numbered using the Kabat numbering convention, varies between H32 and H34, depending on the length of the CDR, as illustrated in FIG. 1 A.
[0065] Unless otherwise specified, the numbering scheme used for identification of a particular CDR herein is the Kabat / Chothia numbering scheme. Where the residues encompassed by these two numbering schemes diverge (e.g., CDR-H1 and / or CDR-H2), the numbering scheme is specified as either Kabat or Chothia. For convenience, CDR-H3 is sometimes referred to herein as either Kabat or Chothia. However, this is not intended to imply differences in sequence where they do not exist, and one of skill in the art can readily confirm whether the sequences are the same or different by examining the sequences.
[0066] CDRs may be assigned, for example, using antibody numbering software, such as Abnum, available at www.bioinf.org.uk / abs / abnum / , and described in Abhinandan and Martin, Immunology, 2008, 45:3832-3839, incorporated by reference in its entirety.
[0067] The “EU numbering scheme” is generally used when referring to a residue in an antibody heavy chain constant region (e.g., as reported in Kabat et al., supra). Unless stated otherwise, the EU numbering scheme is used to refer to residues in antibody heavy chain constant regions described herein.
[0068] An “antibody fragment” comprises a portion of an intact antibody, such as the antigen binding or variable region of an intact antibody. Antibody fragments include, for example, Fv fragments, Fab fragments, F(ab’)2 fragments, Fab’ fragments, scFv (sFv) fragments, and scFv-Fc fragments.
[0069] “Fv” fragments comprise a non-covalently-linked dimer of one heavy chain variable domain and one light chain variable domain.
[0070] “Fab” fragments comprise, in addition to the heavy and light chain variable domains, the constant domain of the light chain and the first constant domain (CHI) of the heavy chain. Fab fragments may be generated, for example, by recombinant methods or by papain digestion of a full-length antibody.
[0071] “F(ab’)2” fragments contain two Fab’ fragments joined, near the hinge region, by disulfide bonds. F(ab’)2 fragments may be generated, for example, by recombinant methods or by pepsin digestion of an intact antibody. The F(ab’) fragments can be dissociated, for example, by treatment with B-mercaptoethanol.
[0072] “Single-chain Fv” or “sFv” or “scFv” antibody fragments comprise a VH domain and a VL domain in a single polypeptide chain. The VH and VL are generally linked by a peptideAttorney Docket No.: 108843.00627
[0073] linker. See Pliickthun A. (1994). Antibodies from Escherichia coli. In Rosenberg M. & Moore G. P. (Eds.), The Pharmacology of Monoclonal Antibodies vol. 113 (pp. 269-315). Springer-Verlag, New York, incorporated by reference in its entirety.
[0074] “scFv-Fc” fragments comprise an scFv attached to an Fc domain. For example, an Fc domain may be attached to the C-terminus of the scFv. The Fc domain may follow the VH or VL, depending on the orientation of the variable domains in the scFv (i.e., VH-VL or VL-VH). Any suitable Fc domain known in the art or described herein may be used. In some cases, the Fc domain comprises an IgGl Fc domain.
[0075] The term “monoclonal antibody” refers to an antibody from a population of substantially homogeneous antibodies. A population of substantially homogeneous antibodies comprises antibodies that are substantially similar and that bind the same epitope(s), except for variants that may normally arise during production of the monoclonal antibody. Such variants are generally present in only minor amounts. A monoclonal antibody is typically obtained by a process that includes the selection of a single antibody from a plurality of antibodies. For example, the selection process can be the selection of a unique clone from a plurality of clones, such as a pool of hybridoma clones, phage clones, yeast clones, bacterial clones, or other recombinant DNA clones. The selected antibody can be further altered, for example, to improve affinity for the target (“affinity maturation”), to humanize the antibody, to improve its production in cell culture, and / or to reduce its immunogenicity in a subject.
[0076] The term “chimeric antibody” refers to an antibody in which a portion of the heavy and / or light chain is derived from a particular source or species, while the remainder of the heavy and / or light chain is derived from a different source or species.
[0077] “Humanized” forms of non-human antibodies are chimeric antibodies that contain minimal sequence derived from the non-human antibody. A humanized antibody is generally a human immunoglobulin (recipient antibody) in which residues from one or more CDRs are replaced by residues from one or more CDRs of a non-human antibody (donor antibody). The donor antibody can be any suitable non-human antibody, such as a mouse, rat, rabbit, chicken, or non-human primate antibody having a desired specificity, affinity, or biological effect. In some instances, selected framework region residues of the recipient antibody are replaced by the corresponding framework region residues from the donor antibody. Humanized antibodies may also comprise residues that are not found in either the recipient antibody or the donor antibody. Such modifications may be made to further refine antibody function. For further details, see Jones et al., Nature, 1986, 321:522-525; Riechmann et al., Nature, 1988, 332:323-329; and Presta, Curr. Op. Struct. BioL, 1992, 2:593-596, each of which is incorporated by reference in its entirety.Attorney Docket No.: 108843.00627
[0078] A “human antibody” is one which possesses an amino acid sequence corresponding to that of an antibody produced by a human or a human cell, or derived from a non-human source that utilizes a human antibody repertoire or human antibody-encoding sequences (e.g., obtained from human sources or designed de novo). Human antibodies specifically exclude humanized antibodies.
[0079] An “isolated antibody” is one that has been separated and / or recovered from a component of its natural environment. Components of the natural environment may include enzymes, hormones, and other proteinaceous or nonproteinaceous materials. In some embodiments, an isolated antibody is purified to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence, for example by use of a spinning cup sequenator. In some embodiments, an isolated antibody is purified to homogeneity by gel electrophoresis (e.g., SDS-PAGE) under reducing or nonreducing conditions, with detection by Coomassie blue or silver stain. An isolated antibody includes an antibody in situ within recombinant cells, since at least one component of the antibody’s natural environment is not present. In some aspects, an isolated antibody is prepared by at least one purification step.
[0080] In some embodiments, an isolated antibody is purified to at least 80%, 85%, 90%, 95%, or 99% by weight. In some embodiments, an isolated antibody is purified to at least 80%, 85%, 90%, 95%, or 99% by volume. In some embodiments, an isolated antibody is provided as a solution comprising at least 85%, 90%, 95%, 98%, 99% to 100% by weight. In some embodiments, an isolated antibody is provided as a solution comprising at least 85%, 90%, 95%, 98%, 99% to 100% by volume.
[0081] “Affinity” refers to the strength of the sum total of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless indicated otherwise, as used herein, “binding affinity” refers to intrinsic binding affinity, which reflects a 1: 1 interaction between members of a binding pair (e.g., antibody and antigen). The affinity of a molecule X for its partner Y can be represented by the dissociation constant (KD). Affinity can be measured by common methods known in the art, including those described herein. Affinity can be determined, for example, using surface plasmon resonance (SPR) technology, such as a Biacore® instrument. In some embodiments, the affinity is determined at 25°C.
[0082] With regard to the binding of an antibody to a target molecule, the terms “specific binding,” “specifically binds to,” “specific for,” “selectively binds,” and “selective for” a particular antigen (e.g., a polypeptide target) or an epitope on a particular antigen mean binding that is measurably different from a non-specific or non-selective interaction. Specific binding can be measured, for example, by determining binding of a molecule compared toAttorney Docket No.: 108843.00627
[0083] binding of a control molecule. Specific binding can also be determined by competition with a control molecule that mimics the antibody binding site on the target. In that case, specific binding is indicated if the binding of the antibody to the target is competitively inhibited by the control molecule.
[0084] The term “ka” (sec-1), as used herein, refers to the dissociation rate constant of a particular antibody-antigen interaction. This value is also referred to as the koff value.
[0085] The term “ka” (M-1*sec-1), as used herein, refers to the association rate constant of a particular antibody-antigen interaction. This value is also referred to as the kon value.
[0086] The term “KD” (M), as used herein, refers to the dissociation equilibrium constant of a particular antibody-antigen interaction. KD = kd / ka.
[0087] The term “KA” (M-1), as used herein, refers to the association equilibrium constant of a particular antibody-antigen interaction. KA = ka / kd.
[0088] An “affinity matured” antibody is one with one or more alterations in one or more CDRs or FRs that result in an improvement in the affinity of the antibody for its antigen, compared to a parent antibody which does not possess the alteration(s). In one embodiment, an affinity matured antibody has nanomolar or picomolar affinity for the target antigen. Affinity matured antibodies may be produced using a variety of methods known in the art. For example, Marks et al. (Bio Technology, 1992, 10:779-783, incorporated by reference in its entirety) describes affinity maturation by VH and VL domain shuffling. Random mutagenesis of CDR and / or framework residues is described by, for example, Barbas et al. (Proc. Nat. Acad. Set. U. S. A., 1994, 91:3809-3813); Schier et al., Gene, 1995, 169:147-155; Yelton et al., J.
[0089] Immunol., 1995, 155:1994-2004; Jackson et al., J. Immunol., 1995, 154:3310-33199; and Hawkins et al, J. Mol. Biol., 1992, 226:889-896, each of which is incorporated by reference in its entirety.
[0090] When used herein in the context of two or more antibodies, the term “competes with” or “cross-competes with” indicates that the two or more antibodies compete for binding to an antigen (e.g., avP6). In one exemplary assay, avP6 is coated on a plate and allowed to bind a first antibody, after which a second, labeled antibody is added. If the presence of the first antibody reduces binding of the second antibody, then the antibodies compete. In another exemplary assay, a first antibody is coated on a plate and allowed to bind the antigen, and then the second antibody is added. The term “competes with” also includes combinations of antibodies where one antibody reduces binding of another antibody, but where no competition is observed when the antibodies are added in the reverse order. However, in some embodiments, the first and second antibodies inhibit binding of each other, regardless of theAttorney Docket No.: 108843.00627
[0091] order in which they are added. In some embodiments, one antibody reduces binding of another antibody to its antigen by at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%.
[0092] The term “epitope” means a portion of an antigen capable of specific binding to an antibody. Epitopes frequently consist of surface-accessible amino acid residues and / or sugar side chains and may have specific three-dimensional structural characteristics, as well as specific charge characteristics. Conformational and non-conformational epitopes are distinguished in that the binding to the former but not the latter is lost in the presence of denaturing solvents. An epitope may comprise amino acid residues that are directly involved in the binding, and other amino acid residues, which are not directly involved in the binding. The epitope to which an antibody binds can be determined using known techniques for epitope determination such as, for example, testing for antibody binding to avP6 variants with different point-mutations, or to chimeric avP6 variants as described further in the Examples provided herein.
[0093] Percent “identity” between a polypeptide sequence and a reference sequence, is defined as the percentage of amino acid residues in the polypeptide sequence that are identical to the amino acid residues in the reference sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN, MEGALIGN (DNASTAR), CLUSTALW, CLUSTAL OMEGA, or MUSCLE software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared.
[0094] A “conservative substitution” or a “conservative amino acid substitution,” refers to the substitution of an amino acid with a chemically or functionally similar amino acid.
[0095] Conservative substitution tables providing similar amino acids are well known in the art.
[0096] Polypeptide sequences having such substitutions are known as “conservatively modified variants.” Such conservatively modified variants are in addition to and do not exclude polymorphic variants, interspecies homologs, and alleles. By way of example, the groups of amino acids provided in Tables B-D are, in some embodiments, considered conservative substitutions for one another.Attorney Docket No.: 108843.00627 Table B. Selected groups of amino acids that are considered conservative substitutions for one another, in certain embodiments.
[0097]
[0098] Table C. Additional selected groups of amino acids that are considered conservative substitutions
[0099]
[0100] Table D. Further selected groups of amino acids that are considered conservative substitutions for one another, in certain embodiments.
[0101]
[0102] Attorney Docket No.: 108843.00627
[0103]
[0104] Additional conservative substitutions may be found, for example, in Creighton, Proteins: Structures and Molecular Properties 2nd ed. (1993) W. H. Freeman & Co., New York, NY. An antibody generated by making one or more conservative substitutions of amino acid residues in a parent antibody is referred to as a “conservatively modified variant.” The term “payload,” “payload moiety” or “drug moiety” refers to a molecular moiety that can be conjugated to an antibody. In particular embodiments, payloads are selected from the group consisting of therapeutic moieties and labelling moieties.
[0105] As used herein, the term “inhibits growth” (e.g., referring to cells, such as tumor cells) is intended to include any measurable decrease in cell growth (e.g., tumor cell growth) when contacted with an avP6 antibody or antibody conjugate described herein, as compared to the growth of the same cells not in contact with an avP6 antibody. In some embodiments, growth may be inhibited by at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 99%, or 100%. The decrease in cell growth can occur by a variety of mechanisms, including but not limited to antibody internalization, apoptosis, necrosis, and / or effector function-mediated activity.
[0106] “Alkoxy” and “alkoxyl,” refer to the group -OR" where R" is alkyl or cycloalkyl. Alkoxy groups include, in certain embodiments, methoxy, ethoxy, w-propoxy, isopropoxy, / / -butoxy, Ze / 'Z-butoxy,.sec-butoxy, / / -pentoxy, / / -hexoxy, 1,2-dimethylbutoxy, and the like.
[0107] The term “alkoxyamine,” as used herein, refers to the group -alkylene-O-NEh, wherein alkylene is as defined herein. In some embodiments, alkoxyamine groups can react with aldehydes to form oxime residues. Examples of alkoxyamine groups include
[0108] -CH2CH2-O-NH2, -CH2-O-NH2, and -O-NH2.
[0109] The term “alkyl,” as used herein, unless otherwise specified, refers to a saturated straight or branched hydrocarbon. In certain embodiments, the alkyl group is a primary, secondary, or tertiary hydrocarbon. In certain embodiments, the alkyl group includes one to ten carbon atoms (i.e., Ci to C10 alkyl). In certain embodiments, the alkyl is a lower alkyl, for example, Ci-ealkyl, and the like. In certain embodiments, the alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl, ec-butyl, / -butyl, pentyl, isopentyl, neopentyl, hexyl, isohexyl, 3 -methylpentyl, 2,2-dimethylbutyl, and 2,3-Attorney Docket No.: 108843.00627
[0110] dimethylbutyl. In certain embodiments, “substituted alkyl” refers to an alkyl substituted with, for example, one, two, or three groups independently selected from a halogen (e.g., fluoro (F), chloro (Cl), bromo (Br), or iodo (I)), alkyl, -CN, -NO2, amido, -C(O)-, -C(S)-, ester, carbamate, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, dialkylamino, haloalkyl, hydroxyl, amino, alkylamino, and alkoxy. In some embodiments, alkyl is unsubstituted.
[0111] The term “alkylene,” as used herein, unless otherwise specified, refers to a divalent alkyl group, as defined herein. “Substituted alkylene” refers to an alkylene group substituted as described herein for alkyl. In some embodiments, alkylene is unsubstituted.
[0112] “Alkenyl” refers to an olefinically unsaturated hydrocarbon group, in certain embodiments, having up to about eleven carbon atoms or from two to six carbon atoms (e.g., “lower alkenyl”), which can be straight-chained or branched, and having at least one or from one to two sites of olefinic unsaturation. “Substituted alkenyl” refers to an alkenyl group substituted as described herein for alkyl.
[0113] “Alkenylene” refers to a divalent alkenyl as defined herein. Lower alkenylene is, for example, C2-C6-alkenylene.
[0114] “Alkynyl” refers to acetylenically unsaturated hydrocarbon groups, in certain embodiments, having up to about eleven carbon atoms or from two to six carbon atoms (e.g., “lower alkynyl”), which can be straight-chained or branched, and having at least one or from one to two sites of acetylenic unsaturation. Non-limiting examples of alkynyl groups include acetylene (-C=CH), propargyl (-CH2OCH), and the like. “Substituted alkynyl” refers to an alkynyl group substituted as described herein for alkyl.
[0115] “Alkynylene” refers to a divalent alkynyl as defined herein. Lower alkynylene is, for example, C2-C6-alkynylene.
[0116] “Amino” refers to -NH2.
[0117] The term “alkylamino,” as used herein, and unless otherwise specified, refers to the group -NHR" where R" is, for example, Ci-ioalkyl, C2-10 alkenyl, C2-10 alkynyl, C3-12 carbocycle, 3- to 12-membered heterocycle, C1-10 haloalkyl, and the like as defined herein. In certain embodiments, alkylamino is Ci-ealkylamino.
[0118] The term “dialkylamino,” as used herein, and unless otherwise specified, refers to the group -NR" R" where each R" is independently Ci-ioalkyl, as defined herein. In certain embodiments, dialkylamino is, for example, di-Ci-ealkylamino, C2-10 alkenyl, C2-10 alkynyl, C3-12 carbocycle, 3- to 12-membered heterocycle, C1-10 haloalkyl, and the like.
[0119] The term “aryl,” as used herein, and unless otherwise specified, refers to phenyl, biphenyl, or naphthyl. The term includes both substituted and unsubstituted moieties. An aryl group can be substituted with any described moiety including, but not limited to, one or moreAttorney Docket No.: 108843.00627
[0120] moi eties (e.g., in some embodiments one, two, or three moi eties) selected from the group consisting of halogen (e.g., fluoro (F), chloro (Cl), bromo (Br), or iodo (I)), alkyl, haloalkyl, hydroxyl, amino, alkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, sulfate, phosphonic acid, phosphate, and phosphonate, wherein each moiety is independently either unprotected, or protected as necessary, as would be appreciated by those skilled in the art (see, e.g., Greene, et al., Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991); and wherein the aryl in the arylamino and aryloxy substituents are not further substituted.
[0121] The term “arylamino,” as used herein, and unless otherwise specified, refers to an -NR'R" group where R' is hydrogen or Ci-Ce-alkyl; and R" is aryl, as defined herein.
[0122] The term “arylene,” as used herein, and unless otherwise specified, refers to a divalent aryl group, as defined herein.
[0123] The term “aryloxy,” as used herein, and unless otherwise specified, refers to an -OR group where R is aryl, as defined herein.
[0124] “Alkarylene” refers to an arylene group, as defined herein, wherein the aryl ring is substituted with one or two alkyl groups. “Substituted alkarylene” refers to an alkarylene, as defined herein, where the arylene group is further substituted, as defined herein for aryl.
[0125] “Aralkylene” refers to a -CEE-arylene-, -arylene-CEE-, or -CEE-arylene-CEE- group, where arylene is as defined herein. “Substituted aralkylene” refers to an aralkylene, as defined herein, where the aralkylene group is substituted, as defined herein for aryl.
[0126] “Carboxyl” or “carboxy” refers to -C(O)OH or -COOH.
[0127] The term “cycloalkyl” as used herein, unless otherwise specified, refers to a saturated cyclic hydrocarbon. In certain embodiments, the cycloalkyl group may be saturated, and / or bridged, and / or non-bridged, and / or a fused bicyclic group and / or a spirocyclic bicyclic group. In certain embodiments, the cycloalkyl group includes three to ten carbon atoms (i.e., C3 to C10 cycloalkyl). In some embodiments, the cycloalkyl has from three to fifteen carbons (C3-15), from three to ten carbons (C3-10), from three to seven carbons (C3-7), or from three to six carbons (C3-C6) (i.e., “lower cycloalkyl”). In certain embodiments, the cycloalkyl group is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexylmethyl, cycloheptyl, bicyclo[2.1.1]hexyl, bicyclo[2.2.1]heptyl, decalinyl, or adamantyl. Exemplary “cycloalkyl” or “carbocycles” include cyclopentyl, cyclohexyl, cyclohexenyl, adamantyl, phenyl, indanyl, and naphthyl. “Cycloalkyl” includes 3- to 10-membered monocyclic rings, 6- to 12-membered bicyclic rings, and 6- to 12-membered bridged rings. Each ring of a bicyclic cycloalkyl or carbocycle may be selected from saturated, unsaturated, and aromatic rings. A bicyclic cycloalkyl or carbocycle includes any combination of saturated, unsaturated and aromaticAttorney Docket No.: 108843.00627
[0128] bicyclic rings, as valence permits. A bicyclic cycloalkyl or carbocycle includes any combination of ring sizes such as 4-5 fused ring systems, 5-5 fused ring systems, 5-6 fused ring systems, 6-6 fused ring systems, 5-7 fused ring systems, 6-7 fused ring systems, 5-8 fused ring systems, and 6-8 fused ring systems. Non-limiting examples of bridged bicyclic cycloalkyl or carbocycle groups include, but are not limited to, bicyclo[l.l.l]pentyl, bicyclo[2.1.1]hexyl, bicyclo[2.1.1]hexyl, bicyclo[3.1.1]heptyl, bicyclo[2.2.1]heptyl, bicyclo[3.2.1]octyl, bicyclo[2.2.2]octyl, bicyclo[3.3.1]nonyl, bicyclo[3.3.2]decyl, and 2-oxabicyclo[2.2.2]octyl. Non-limiting examples of spirocyclic cycloalkyl or carbocycle groups include, but are not limited to, spiro[3.3]heptyl, spiro[3.4]octyl, spiro[3.5]nonyl, spiro[3.6]decyl, spiro[4.4]nonyl, spiro[4.5]decyl, spiro[5.5]undecyl, spiro[5.6]dodecyl, and spiro[5.7]tridecyl.
[0129] The term “carbocycle” as used herein, unless otherwise specified, refers to a saturated, unsaturated, or aromatic ring in which atom of the ring is carbon. In certain embodiments, the carbocycle group may be saturated, and / or bridged, and / or non-bridged, and / or a fused bicyclic group, and / or a spirocyclic bicyclic group. In certain embodiments, the carbocycle group includes three to ten carbon atoms (i.e., C3 to C10 carbocycle). In some embodiments, the carbocycle has from three to fifteen carbons (C3-15), from three to ten carbons (C3-10), from three to seven carbons (C3-7), or from three to six carbons (Cs-Ce). In certain embodiments, the carbocycle group is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexylmethyl, cycloheptyl, bicyclo[2.1.1]hexyl, bicyclo[2.2.1]heptyl, decalinyl, or adamantyl.
[0130] The term “bicyclic ring system” includes 6-12 (e.g., 8-12 or 9-, 10-, or 11-) membered structures that form two rings, wherein the two rings have at least one atom in common (e.g., two atoms in common). Bicyclic rings can be fused, bridged, or spirocyclic. Bicyclic ring systems include bicycloaliphatics (e.g., bicycloalkyl or bicycloalkenyl), bicycloheteroaliphatics, bicyclic aryls, and bicyclic heteroaryls.
[0131] The term “bridged bicyclic ring system” refers to a bicyclic heterocyclicalipahtic ring system or bicyclic cycloaliphatic ring system in which the rings are bridged. Examples of bridged bicyclic ring systems include, but are not limited to, adamantanyl, norbomanyl, bicyclo[l.l.l]pentyl, bicyclo[2.1.1]hexyl, bicyclo[2.1.1]hexyl, bicyclo[3.1.1]heptyl, bicyclo[2.2.1]heptyl, bicyclo[3.2.1]octyl, bicyclo[2.2.2]octyl, bicyclo[3.3.1]nonyl, bicyclo[3.3.2]decyl, 2-oxabicyclo[2.2.2]octyl, 6-azabicyclo[3.1.1]heptyl, 6-azabicyclo[3.1.1]heptyl, l-azabicyclo[2.2.1]heptyl, 2-azabicyclo[2.2.1]heptyl, 7-azabicyclo[2.2.1]heptyl, l-azabicyclo[2.2.2]octyl, 3-azabicyclo[3.2.1]octyl, and 2-oxabicyclo[3.1.1]heptyl, 2,6-dioxa-tricyclo[3.3.1.03’7]nonyl. A bridged bicyclic ring system can be optionally substituted with one or more substituents such as alkyl (includingAttorney Docket No.: 108843.00627
[0132] carboxyalkyl, hydroxyalkyl, and haloalkyl such as trifluoromethyl), alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, aryl, heteroaryl, alkoxy, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroaralkyloxy, aroyl, heteroaroyl, nitro, carboxy, alkoxycarbonyl, alkylcarbonyloxy, aminocarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino, (cycloalkylalkyl)carbonylamino, arylcarbonylamino, aralkylcarbonylamino, (heterocycloalkyl)carbonylamino, (heterocycloalkylalkyl)carbonylamino, heteroarylcarbonylamino, heteroaralkylcarbonylamino, cyano, halo, hydroxy, acyl, mercapto, alkylsulfanyl, sulfoxy, urea, thiourea, sulfamoyl, sulfamide, oxo, or carbamoyl.
[0133] The term “spiro bicyclic ring system” refers to a bicyclic heterocyclicalipahtic ring system or bicyclic cycloaliphatic ring system in which 2 or 3 rings are linked together by one common atom. Spiro compounds depicted with overlapping rings indicate that the rings can
[0134] bond at any vertex. For instance, in the spiro group
[0135]
[0136] , the two rings can bond at any of the three available vertex atoms in either ring.
[0137] The term “cycloalkylene,” as used herein refers to a divalent cycloalkyl group, as § defined herein. In certain embodiments, the cycloalkylene group is cyclopropylene ®
[0138]
[0139] ,
[0140] cyclobutylene, cyclopentylene
[0141]
[0142] , cyclohexylene
[0143]
[0144] , cycloheptylene
[0145]
[0146] , and the like. Lower cycloalkylene refers to a Cs-Ce-cycloalkylene.
[0147] The term “cycloalkylalkyl,” as used herein, unless otherwise specified, refers to an alkyl group, as defined herein, substituted with one or two cycloalkyl, as defined herein.
[0148] The term “ester,” as used herein, refers to -C(O)OR or -COOR where R is alkyl, as defined herein. The term “haloalkyl” refers to an alkyl group, as defined herein, substituted with one or more halogen atoms (e.g., in some embodiments one, two, three, four, or five) which are independently selected.
[0149] The term “heteroalkyl” refers to an alkyl, as defined herein, in which one or more carbon atoms are replaced by heteroatoms. As used herein, “heteroalkenyl” refers to an alkenyl, as defined herein, in which one or more carbon atoms are replaced by heteroatoms. As used herein, “heteroalkynyl” refers to an alkynyl, as defined herein, in which one or moreAttorney Docket No.: 108843.00627
[0150] carbon atoms are replaced by heteroatoms. Suitable heteroatoms include, but are not limited to, nitrogen (N), oxygen (O), and sulfur (S) atoms. Heteroalkyl, heteroalkenyl, and heteroalkynyl are optionally substituted. Examples of heteroalkyl moi eties include, but are not limited to, aminoalkyl, sulfonylalkyl, and sulfinylalkyl. Examples of heteroalkyl moi eties also include, but are not limited to, methylamino, methyl sulfonyl, and methyl sulfinyl. “Substituted heteroalkyl” refers to heteroalkyl substituted with one, two, or three groups independently selected from halogen (e.g., fluoro (F), chloro (Cl), bromo (Br), or iodo (I)), alkyl, haloalkyl, hydroxyl, amino, alkylamino, and alkoxy. In some embodiments, a heteroalkyl group may comprise one, two, three, or four heteroatoms. Those of skill in the art will recognize that a 4-membered heteroalkyl may generally comprise one or two heteroatoms, a 5- or 6-membered heteroalkyl may generally comprise one, two, or three heteroatoms, and a 7- to 10-membered heteroalkyl may generally comprise one, two, three, or four heteroatoms.
[0151] The term “heteroalkylene,” as used herein, refers to a divalent heteroalkyl, as defined herein. “Substituted heteroalkylene” refers to a divalent heteroalkyl, as defined herein, substituted as described for heteroalkyl.
[0152] The term “heterocycloalkyl” refers to a monovalent, monocyclic, or multicyclic nonaromatic ring system, wherein one or more of the ring atoms are heteroatoms independently selected from oxygen (O), sulfur (S), and nitrogen (N) (e.g., where the nitrogen or sulfur atoms may be optionally oxidized, and the nitrogen atoms may be optionally quatemized) and the remaining ring atoms of the non-aromatic ring are carbon atoms. In certain embodiments, heterocycloalkyl is a monovalent, monocyclic, or multicyclic fully-saturated ring system. In certain embodiments, the heterocycloalkyl group has from three to twenty, from three to fifteen, from three to ten, from three to eight, from four to seven, from four to eleven, or from five to six ring atoms. The heterocycloalkyl may be attached to a core structure at any heteroatom or carbon atom which results in the creation of a stable compound. In certain embodiments, the heterocycloalkyl is a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may include a fused, and / or bridged bicyclic group, and / or a spirocyclic bicyclic group ring system and in which the nitrogen or sulfur atoms may be optionally oxidized, and / or the nitrogen atoms may be optionally quatemized. In some embodiments, heterocycloalkyl radicals include, but are not limited to, 2,5-diazabicyclo[2.2.2]octanyl, decahydroisoquinolinyl, dihydrobenzisoxazinyl, dihydrofuryl, dihydroisoindolyl, dihydropyranyl, dihydropyrazolyl, dihydropyrazinyl, dihydropyridinyl, dihydropyrimidinyl, dihydropyrrolyl, dioxolanyl, 1,4-dithianyl, furanonyl, imidazolidinyl, imidazolinyl, indolinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, oxazolidinonyl, oxazolidinyl, oxiranyl, piperazinyl, piperidinyl, 4-piperidonyl, pyrazolidinyl,Attorney Docket No.: 108843.00627
[0153] pyrazolinyl, pyrrolidinyl, pyrrolinyl, quinuclidinyl, tetrahydrofuryl, tetrahydroisoquinolinyl, tetrahydropyranyl, tetrahydrothienyl, thiamorpholinyl, thiazolidinyl, tetrahydroquinolinyl, and 1,3,5-trithianyl. In certain embodiments, heterocycloalkyl may also be optionally substituted as described herein. In certain embodiments, heterocycloalkyl is substituted with one, two, or three groups independently selected from halogen (e.g., fluoro (F), chloro (Cl), bromo (Br), or iodo (I)), alkyl, haloalkyl, hydroxyl, amino, alkylamino, and alkoxy. In some embodiments, a heterocycloalkyl group may comprise one, two, three, or four heteroatoms. Those of skill in the art will recognize that a 4-membered heterocycloalkyl may generally comprise one or two heteroatoms, a 5- or 6-membered heterocycloalkyl may generally comprise one, two, or three heteroatoms, and a 7- to 10-membered heterocycloalkyl may generally comprise one, two, three, or four heteroatoms. In some embodiments, “heterocycloalkyl” radicals include, but are not limited to, 2,5-diazabicyclo[2.2.2]octanyl, decahydroisoquinolinyl, dihydrobenzisoxazinyl, dihydrofuryl, dihydroisoindolyl, dihydropyranyl, dihydropyrazolyl, dihydropyrazinyl, dihydropyridinyl, dihydropyrimidinyl, dihydropyrrolyl, dioxolanyl, 1,4-dithianyl, furanonyl, imidazolidinyl, imidazolinyl, indolinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, oxazolidinonyl, oxazolidinyl, oxiranyl, piperazinyl, piperidinyl, 4-piperidonyl, pyrazolidinyl, pyrazolinyl, pyrrolidinyl, pyrrolinyl, quinuclidinyl, tetrahydrofuryl, tetrahydroisoquinolinyl, tetrahydropyranyl, tetrahydrothienyl, thiamorpholinyl, thiazolidinyl, tetrahydroquinolinyl, and 1,3,5-trithianyl. Non-limiting examples of bridged heterocycloalkyl or heterocycle groups include, but are not limited to, 6-azabicyclo[3.1.1]heptyl, 6-azabicyclo[3.1.1]heptyl, l-azabicyclo[2.2.1]heptyl, 2-azabicyclo[2.2.1]heptyl, 7-azabicyclo[2.2.1]heptyl, l-azabicyclo[2.2.2]octyl, 3-azabicyclo[3.2.1]octyl, and 2-oxabicyclo[3.1.1]heptyl, 2,6-dioxa-tricyclo[3.3.1.03’7]nonyl. Non-limiting examples of spirocyclic heterocycloalkyl or heterocycle groups include, but are not limited to, 2,8-diazaspiro[4.5]decyl; 2,7-diazaspiro[3.5]nonyl; 3,9-diazaspiro[5.5]undecyl; 3-azaspiro[5.5]undecyl; 2-oxa-6-azaspiro[3.4]octyl; 2-oxa-9-azaspiro[5.5]undecyl; 3-oxa-9-azaspiro[5.5]undecyl; 7-azaspiro[3.5]nonyl; 2-azaspiro[3.5]nonyl; 7-oxaspiro[3.5]nonyl; and, 2-oxaspiro[3.5]nonyl.
[0154] The term “heterocycle” refers to a saturated, unsaturated or aromatic ring comprising one or more heteroatoms. Exemplary heteroatoms include N, O, Si, P, B, and S atoms where the nitrogen or sulfur atoms may be optionally oxidized, and the nitrogen atoms may be optionally quatemized and the remaining ring atoms of the non-aromatic ring are carbon atoms. Heterocycles include 3- to 10-membered monocyclic rings, 6- to 12-membered bicyclic rings, and 6- to 12-membered bridged rings. In certain embodiments, heterocycle is a monovalent, monocyclic, or multicyclic fully-saturated ring system. In certain embodiments,Attorney Docket No.: 108843.00627
[0155] the heterocycloalkyl or “heterocycle” group may be unsaturated, and / or bridged, and / or nonbridged, and / or a fused bicyclic group, and / or a spirocyclic bicyclic group.
[0156] “Heterocycloalkylene” refers to a divalent heterocycloalkyl as defined herein.
[0157] The term “heteroaryl” refers to a monovalent, monocyclic aromatic group and / or multicyclic aromatic group, wherein at least one aromatic ring contains one or more heteroatoms independently selected from oxygen, sulfur, and nitrogen within the ring. Each ring of a heteroaryl group can contain one or two oxygen atoms, one or two sulfur atoms, and / or one to four nitrogen atoms, provided that the total number of heteroatoms in each ring is four or less and each ring contains at least one carbon atom. In certain embodiments, the heteroaryl has from five to twenty, from five to fifteen, or from five to ten ring atoms. A heteroaryl may be attached to the rest of the molecule via a nitrogen or a carbon atom. In some embodiments, monocyclic heteroaryl groups include, but are not limited to, furanyl, imidazolyl, isothiazolyl, isoxazolyl, oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, triazolyl, thiadiazolyl, thiazolyl, thienyl, tetrazolyl, and triazinyl. Examples of bicyclic heteroaryl groups include, but are not limited to, benzofuranyl, benzimidazolyl, benzoisoxazolyl, benzopyranyl, benzothiadiazolyl, benzothiazolyl, benzothienyl, benzotriazolyl, benzoxazolyl, furopyridyl, imidazopyridinyl, imidazothiazolyl, indolizinyl, indolyl, indazolyl, isobenzofuranyl, isobenzothienyl, isoindolyl, isoquinolinyl, naphthyridinyl, oxazolopyridinyl, phthalazinyl, pteridinyl, purinyl, pyridopyridyl,
[0158] pyrrol opyridyl, quinolinyl, quinoxalinyl, quinazolinyl, thiadiazolopyrimidyl, and
[0159] thi enopyridyl. Examples of tricyclic heteroaryl groups include, but are not limited to, acridinyl, benzindolyl, carbazolyl, dibenzofuranyl, perimidinyl, phenanthrolinyl, phenanthridinyl, phenarsazinyl, phenazinyl, phenothiazinyl, phenoxazinyl, and xanthenyl. In certain embodiments, heteroaryl may also be optionally substituted as described herein. “Substituted heteroaryl” is a heteroaryl substituted as defined for aryl.
[0160] The term “heteroarylene” refers to a divalent heteroaryl group, as defined herein.
[0161] “Substituted heteroarylene” is a heteroarylene substituted as defined for aryl.
[0162] As used herein, “alkyl,” “alkylene,” “alkylamino,” “dialkylamino,” “cycloalkyl,” “aryl,” “arylene,” “alkoxy,” “amino,” “carboxyl,” “heterocycloalkyl,” “heteroaryl,” “heteroarylene,” “carboxyl,” and “amino acid” groups optionally comprise deuterium (D) at one or more positions where hydrogen (H) atoms are present, and wherein the deuterium composition of the atom or atoms is other than the natural isotopic composition.
[0163] Also as used herein, “alkyl,” “alkylene,” “alkylamino,” “dialkylamino,” “cycloalkyl,” “aryl,” “arylene,” “alkoxy,” “amino,” “carboxyl,” “heterocycloalkyl,” “heteroaryl,”Attorney Docket No.: 108843.00627
[0164] “heteroarylene,” “carboxyl,” and “amino acid” groups optionally comprise carbon- 13 (13C) at an amount other than the natural isotopic composition.
[0165] The term “protecting group,” as used herein, and unless otherwise specified, refers to a group that is added to an oxygen, nitrogen, or phosphorus atom to prevent further reaction at the (protected) oxygen, nitrogen, or phosphorus, or for other purposes. A wide variety of oxygen and nitrogen protecting groups are known to those skilled in the art of organic synthesis (see, e.g., Greene, et al., Protective Groups in Organic Synthesis, John Wiley and Sons, Fourth Edition, 2006, which is incorporated herein by reference in its entirety).
[0166] “Pharmaceutically acceptable salt” refers to any salt of a compound provided herein which retains its biological properties and which is not toxic or otherwise undesirable for pharmaceutical use. Such salts may be derived from a variety of organic and inorganic counterions well known in the art. Such salts include, but are not limited to (1) acid addition salts formed with organic or inorganic acids such as hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, sulfamic, acetic, trifluoroacetic, trichloroacetic, propionic, hexanoic, cyclopentylpropionic, glycolic, glutaric, pyruvic, lactic, malonic, succinic, sorbic, ascorbic, malic, maleic, fumaric, tartaric, citric, benzoic, 3-(4-hydroxybenzoyl)benzoic, picric, cinnamic, mandelic, phthalic, lauric, methanesulfonic, ethanesulfonic, 1,2-ethane-disulfonic, 2-hydroxyethanesulfonic, benzenesulfonic, 4-chlorobenzenesulfonic, 2-naphthalenesulfonic, 4-toluenesulfonic, camphoric, camphorsulfonic, 4-methylbicyclo[2.2.2]-oct-2-ene-l -carboxylic, glucoheptonic, 3 -phenylpropionic, trimethylacetic, tert-butyl acetic, lauryl sulfuric, gluconic, glutamic, hydroxynaphthoic, salicylic, stearic, cyclohexylsulfamic, quinic, and muconic acids, and the like; or (2) salts formed when an acidic proton present in the parent compound either (a) is replaced by a metal ion, for example, an alkali metal ion, an alkaline earth ion, or an aluminum ion, or alkali metal or alkaline earth metal hydroxides, such as sodium, potassium, calcium, magnesium, aluminum, lithium, zinc, and barium hydroxide, or ammonia; or (b) coordinates with an organic base, such as aliphatic, alicyclic, or aromatic organic amines, including, without limitation, ammonia, methylamine, dimethylamine, diethylamine, picoline, ethanolamine, diethanolamine, triethanolamine, ethylenediamine, lysine, arginine, ornithine, choline, A. A'-dibenzylethylene-diamine, chloroprocaine, procaine, A-benzylphenethylamine, / ' / -methylglucamine piperazine, tris(hydroxymethyl)-aminomethane, tetramethylammonium hydroxide, and the like.
[0167] Pharmaceutically acceptable salts further include, by way of example and without limitation, sodium, potassium, calcium, magnesium, ammonium, and tetraalkylammonium salts, and the like, and when the compound contains a basic functionality, salts of non-toxic organic or inorganic acids, such as hydrohalides, for example, hydrochloride andAttorney Docket No.: 108843.00627
[0168] hydrobromide, sulfate, phosphate, sulfamate, nitrate, acetate, trifluoroacetate, tri chloroacetate, propionate, hexanoate, cyclopentylpropionate, glycolate, glutarate, pyruvate, lactate, malonate, succinate, sorbate, ascorbate, malate, maleate, fumarate, tartarate, citrate, benzoate, 3 -(4-hydroxybenzoyl)benzoate, picrate, cinnamate, mandelate, phthalate, laurate, methanesulfonate (mesylate), ethanesulfonate, 1,2-ethane-di sulfonate, 2-hydroxy ethanesulfonate, benzenesulfonate (besylate), 4-chlorobenzenesulfonate, 2-naphthalenesulfonate, 4-toluenesulfonate, camphorate, camphorsulfonate, 4-methylbicyclo[2.2.2]-oct-2-ene-l-carboxylate, glucoheptonate, 3 -phenylpropionate, trimethylacetate, tert-butyl acetate, lauryl sulfate, gluconate, glutamate, hydroxynaphthoate, salicylate, stearate, cyclohexyl sulfamate, quinate, muconate, and the like.
[0169] The term “substantially free of’ or “substantially in the absence of’ with respect to a composition refers to a composition that includes at least 85% or 90% by weight, in certain embodiments 95%, 98%, 99%, or 100% by weight; or in certain embodiments, 95%, 98%, 99%, or 100% of the designated enantiomer or diastereomer of a compound. In certain embodiments, in the methods and compounds provided herein, the compounds are substantially free of one of two enantiomers. In certain embodiments, in the methods and compounds provided herein, the compounds are substantially free of one of two diastereomers. In certain embodiments, in the methods and compounds provided herein, the compounds are substantially free of enantiomers (i.e., the compounds are not a racemic or 50:50 mixture of compounds).
[0170] Similarly, the term “isolated” with respect to a composition refers to a composition that includes at least 85%, 90%, 95%, 98%, or 99% to 100% by weight, of the compound, the remainder comprising other chemical species, enantiomers, or diastereomers.
[0171] “Solvate” refers to a compound provided herein, or a salt thereof, that further includes a stoichiometric or non-stoichiometric amount of solvent bound by non-covalent intermolecular forces. Where the solvent is water, the solvate is a hydrate.
[0172] “Isotopic composition” refers to the amount of each isotope present for a given atom, and “natural isotopic composition” refers to the naturally occurring isotopic composition or abundance for a given atom. Atoms containing their natural isotopic composition may also be referred to herein as “non-enriched” atoms. Unless otherwise designated, the atoms of the compounds recited herein are meant to represent any stable isotope of that atom. For example, unless otherwise stated, when a position is designated specifically as hydrogen (H), the position is understood to have hydrogen at its natural isotopic composition.
[0173] “Isotopic enrichment” refers to the percentage of incorporation of an amount of a specific isotope at a given atom in a molecule in the place of that atom’s natural isotopicAttorney Docket No.: 108843.00627
[0174] abundance. For example, deuterium (D) enrichment of 1% at a given position means that 1% of the molecules in a given sample contain deuterium at the specified position. Because the naturally occurring distribution of deuterium is about 0.0156%, deuterium enrichment at any position in a compound synthesized using non-enriched starting materials is about 0.0156%. The isotopic enrichment of the compounds provided herein can be determined using conventional analytical methods known to one of ordinary skill in the art, including mass spectrometry and nuclear magnetic resonance spectroscopy.
[0175] “Isotopically enriched” refers to an atom having an isotopic composition other than the natural isotopic composition of that atom. “Isotopically enriched” may also refer to a compound containing at least one atom having an isotopic composition other than the natural isotopic composition of that atom.
[0176] The term “macromolecule” or “macromolecular moiety” refers to a protein, peptide, antibody, nucleic acid, carbohydrate, or other large molecule composed of polymerized monomers. They include peptides of two or more residues, or ten or more residues. In certain embodiments, a macromolecule is at least 1000 Da in mass. In certain embodiments, a macromolecule has at least 1000 atoms. In certain embodiments, a macromolecule can be modified. For instance, a protein, peptide, or antibody can be modified with one or more carbohydrates and / or small molecule therapeutic compounds.
[0177] The term “amino acid” refers to the twenty common naturally occurring amino acids. Naturally occurring amino acids include pyrrolysine and selenocysteine. Natural amino acids also include citrulline. Naturally encoded amino acids include post-translational variants of the 22 naturally occurring amino acids such as prenylated amino acids, isoprenylated amino acids, myrisoylated amino acids, palmitoylated amino acids, N-linked glycosylated amino acids, O-linked glycosylated amino acids, phosphorylated amino acids, and acylated amino acids. The term “amino acid” also includes “non-natural amino acids” and “modified amino acids.” The terms “non-natural amino acids” and “modified amino acids” are used herein interchangeably.
[0178] The terms “non-natural amino acid,” (or “unnatural amino acid”) “synthetic amino acid,” or “modified amino acid” are a, b, g, or d amino acids, and includes but is not limited to, amino acids found in proteins, i.e., glycine, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, proline, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartate, glutamate, lysine, arginine and histidine. In certain embodiments, the amino acid is in the L-configuration. Alternatively, the amino acid can be a derivative of alanyl, valinyl, leucinyl, isoleucinyl, prolinyl, phenylalaninyl, tryptophanyl, methioninyl, glycinyl, serinyl, threoninyl, cysteinyl, tyrosinyl, asparaginyl, glutaminyl, aspartoyl, glutaroyl, lysinyl, argininyl, histidinyl, b-alanyl, b-valinyl, b-leucinyl, b-isoleuccinyl, b-prolinyl, b-phenylalaninyl, b-Attorney Docket No.: 108843.00627
[0179] tryptophanyl, b-methioninyl, b-glycinyl, b-serinyl, b-threoninyl, b-cysteinyl, b-tyrosinyl, b-asparaginyl, b-glutaminyl, b-aspartoyl, b-glutaroyl, b-lysinyl, b-argininyl or b-histidinyl. Unnatural amino acids are not proteinogenic amino acids, or post translationally modified variants thereof that either occur naturally or are chemically synthesized. In particular, the term unnatural amino acid refers to an amino acid that is not one of the 20 common amino acids or pyrrolysine or selenocysteine, or post translationally modified variants thereof. Non-limiting examples of unnatural amino acids include sulfoalanine, hydroxyproline (Hyp), beta-alanine, citrulline (Cit), ornithine (Om), norleucine (Nle), 3 -nitrotyrosine, nitroarginine, pyroglutamic acid (Pyr), naphtylalanine (Nal), 2,4-diaminobutyric acid (DAB), methionine sulfoxide, and methionine sulfone.
[0180] The terms “non-natural amino acid,” “unnatural amino acid,” “synthetic amino acid,” or “modified amino acid” can also refer to an amino acid that comprises a reactive group capable of forming a covalent bond to a linker payload. The reactive group can be an amino, carboxy, acetyl, hydrazino, hydrazido, hydroxylamine, semicarbazido, sulfanyl, azido or alkynyl group. Non-limiting examples of non-natural amino acids include p-acetyl-L-phenylalanine, O-methyl-L-tyrosine, 3-methyl-phenylalanine, O-4-allyl-L-tyrosine, 4-propyl-L-tyrosine, fluorinated phenylalanine, isopropyl-L-phenylalanine, p-azido-L-phenylalanine, p-benzoyl-L-phenylalanine, p-iodo-phenylalanine, p-bromophenylalanine, p-amino-L-phenylalanine, isopropyl-L-phenylalanine, p-propargyloxy-phenylalanine, and p-azidomethyl-L-phenylalanine.
[0181] The term “site-specific” refers to a modification of a polypeptide at a predetermined sequence location in the polypeptide. The modification is at a single, predictable residue of the polypeptide with little or no variation. In particular embodiments, a modified amino acid is introduced at that sequence location, for instance recombinantly or synthetically. Similarly, a moiety can be “site-specifically” linked to a residue at a particular sequence location in the polypeptide. In certain embodiments, a polypeptide can comprise more than one site-specific modification.
[0182] The term “conjugate” or “antibody conjugate” refers to a compound or drug moiety described herein linked to one or more macromolecular moieties. The macromolecular moiety is as defined herein or is any macromolecule deemed suitable to the person of skill in the art. The compound or drug moiety can be any compound or drug moiety described herein. The compound or drug moiety can be directly linked to the macromolecular moiety via a covalent bond, or the compound or drug moiety can be linked to the macromolecular moiety indirectly via a linker. Typically, the linker is covalently bonded to the macromolecular moiety and also covalently bonded to the compound or drug moiety.Attorney Docket No.: 108843.00627
[0183] “pAMF,” “pAzMeF,” “pAMF residue,” or “pAMF mutation” refer to a variant phenylalanine residue (i.e., para-azidomethyl-L-phenylalanine) added or substituted into a polypeptide.
[0184] “pAcF,” “pAcetylF,” “pAcF residue,” or “pAcF mutation” refer to a variant phenylalanine residue, (i.e., para-acetyl-L-phenylalanine) added or substituted into a polypeptide.
[0185] “pAzF” mutation refers to a variant phenylalanine residue, i.e., para-azido-L-phenylalanine) added or substituted into a polypeptide.
[0186] The term “linker” refers to a molecular moiety that is capable of forming at least two covalent bonds. Typically, a linker is capable of forming at least one covalent bond to a macromolecular moiety and at least another covalent bond to a compound or drug moiety. In certain embodiments, a linker can form more than one covalent bond to a macromolecular moiety. In certain embodiments, a linker can form more than one covalent bond to a compound or drug moiety or can form covalent bonds to more than one compound or drug moiety. After a linker forms a bond to a macromolecular moiety, or a compound or drug moiety, or both, the remaining structure (i.e. the residue of the linker (“linker residue”) after one or more covalent bonds are formed) may still be referred to as a “linker” herein. The term “linker precursor” refers to a linker having one or more reactive groups capable of forming a covalent bond with a macromolecule, or compound or drug moiety, or both. A person of ordinary skill in the art, given the context of how the term linker is used, would understand whether “linker” means linker precursor with one reactive group, a linker precursor with more than one reactive groups, a linker residue which is covalently bonded to the macromolecule, a linker residue which is covalently bonded to a compound or drug moiety, and / or a linker residue which is covalently bonded to the macromolecule and is covalently bonded to a compound or drug moiety. In some embodiments, the linker is a cleavable linker. For example, a cleavable linker can be one that is released by a bio-labile or enzymatic function, which may or may not be engineered. In some embodiments, the linker is a non-cleavable linker. For example, a non-cleavable linker can be one that is released upon degradation of the macromolecular moiety.
[0187] As used herein, term “EC50” refers to a dosage, concentration, or amount of a particular test compound that elicits a dose-dependent response at 50% of maximal expression of a particular response that is induced, provoked, or potentiated by the particular test compound.
[0188] As used herein, and unless otherwise specified, the term “IC50” refers to an amount, concentration, or dosage of a particular test compound that achieves a 50% inhibition of a maximal response in an assay that measures such response.Attorney Docket No.: 108843.00627
[0189] As used herein, the terms “subject” and “patient” are used interchangeably. The terms “subject” and “subjects” refer to an animal, such as a mammal including a non-primate (e.g., a cow, pig, horse, cat, dog, rat, mouse, camel, avian, goat, and sheep) and a primate (e.g., a monkey, such as a cynomolgous monkey, a chimpanzee, and a human), and in certain embodiments, a human. In certain embodiments, the subject is a farm animal (e.g., a horse, a cow, a pig, etc.) or a pet (e.g., a dog or a cat). In certain embodiments, the subject is a human. In some embodiments, the subject has a disease that can be treated or diagnosed with an antibody or antibody conjugate provided herein. In some embodiments, the disease is gastric carcinoma, colorectal carcinoma, renal cell carcinoma, cervical carcinoma, non-small cell lung carcinoma, ovarian cancer, breast cancer, triple-negative breast cancer, endometrial cancer, prostate cancer, and / or a cancer of epithelial origin.
[0190] As used herein, the terms “therapeutic agent” and “therapeutic agents” refer to any agent(s) which can be used in the treatment or prevention of a disorder or one or more symptoms thereof. In certain embodiments, the term “therapeutic agent” includes an antibody or antibody conjugate provided herein. In certain embodiments, a therapeutic agent is an agent which is known to be useful for, or has been or is currently being used for the treatment or prevention of a disorder or one or more symptoms thereof.
[0191] “Treating” or “treatment” of any disease or disorder refers, in certain embodiments, to ameliorating a disease or disorder that exists in a subject. In another embodiment, “treating” or “treatment” includes ameliorating at least one physical parameter, which may be indiscernible by the subject. In yet another embodiment, “treating” or “treatment” includes modulating the disease or disorder, either physically (e.g., stabilization of a discernible symptom) or physiologically (e.g., stabilization of a physical parameter) or both. In yet another embodiment, “treating” or “treatment” includes delaying or preventing the onset of the disease or disorder, or delaying or preventing recurrence of the disease or disorder. In yet another embodiment, “treating” or “treatment” includes the reduction or elimination of either the disease or disorder, or retarding the progression of the disease or disorder or of one or more symptoms of the disease or disorder, or reducing the severity of the disease or disorder or of one or more symptoms of the disease or disorder.
[0192] As used herein, the terms “prophylactic agent” and “prophylactic agents” as used refer to any agent(s) which can be used in the prevention of a disorder or one or more symptoms thereof. In certain embodiments, the term “prophylactic agent” includes a compound, drug moiety, or conjugate provided herein. In certain other embodiments, the term “prophylactic agent” does not refer a compound, drug moiety, or conjugate provided herein. For example, a prophylactic agent is an agent which is known to be useful for, or has been or is currentlyAttorney Docket No.: 108843.00627
[0193] being used to prevent or impede the onset, development, progression, and / or severity of a disorder.
[0194] As used herein, the term “therapeutically effective amount” or “effective amount” refers to an amount of an antibody, antibody conjugate, or composition that when administered to a subject is effective to treat a disease or disorder. In some embodiments, a therapeutically effective amount or effective amount refers to an amount of an antibody, antibody conjugate, or composition that when administered to a subject is effective to prevent or ameliorate a disease or the progression of the disease, or result in amelioration of symptoms. A “therapeutically effective amount” can vary depending on, inter alia, the compound, the disease or disorder and its severity, and the age, weight, etc., of the subject to be treated.
[0195] As used herein, the phrase “prophylactically effective amount” refers to the amount of a therapy (e.g., prophylactic agent) which is sufficient to result in the prevention or reduction of the development, recurrence, or onset of one or more symptoms associated with a disorder or to enhance or improve the prophylactic effect(s) of another therapy (e.g., another prophylactic agent).
[0196] In some chemical structures illustrated herein, certain substituents, chemical groups,
[0197] and atoms are depicted with a curvy / wavy / wiggly line (e.g.,
[0198]
[0199] or ) that intersects a bond or bonds to indicate the atom through which the substituents, chemical groups, and atoms are
[0200] bonded. For example, in some structures, such as but not limited to,
[0201]
[0202]
[0203] or, this curvy / wavy / wiggly line indicates the atoms in the backbone
[0204]
[0205] conjugate, compound, or drug moiety structure to which the illustrated chemical entity is
[0206] bonded. In some structures, such as but not limited
[0207]
[0208] , this curvy / wavy / wiggly line indicates the atoms in the macromolecule as well as the atoms in theAttorney Docket No.: 108843.00627
[0209] backbone of a conjugate, compound, or drug moiety structure to which the illustrated chemical entity is bonded.
[0210] As used herein, illustrations showing substituents bonded to a cyclic group (e.g., aromatic, heteroaromatic, fused ring, and saturated or unsaturated cycloalkyl or heterocycloalkyl) through a bond between ring atoms are meant to indicate, unless specified otherwise, that the cyclic group may be substituted with that substituent at any ring position in the cyclic group or on any ring in the fused ring group, according to techniques set forth herein or which are known in the field to which the instant disclosure pertains. For example, the
[0211] group,
[0212]
[0213] wherein subscript q is an integer from zero to four and in which the positions of substituent R1are described generically, i.e., not directly attached to any vertex of the bond line structure, i.e., specific ring carbon atom, includes the following, nonlimiting examples of groups in which the substituent R1is bonded to a specific ring carbon
[0214]
[0215] Attorney Docket No.: 108843.00627
[0216] 2. Antibodies and Antibody Specificity
[0217] Provided herein are conjugates that comprise antibodies that selectively bind human avP6. In some aspects, the antibody of the conjugate selectively binds to the extracellular domain of human avP6.
[0218] In some embodiments, the antibody binds to a homolog of human avP6. In some aspects, the antibody binds to a homolog of human avP6 from a species selected from monkeys, mice, dogs, cats, rats, cows, horses, goats and sheep. In some aspects, the homolog is a cynomolgus monkey homolog.
[0219] In some embodiments, the antibody has one or more CDRs having particular lengths, in terms of the number of amino acid residues. In some embodiments, the Chothia CDR-H1 of the antibody is 6, 7, or 8 residues in length. In some embodiments, the Kabat CDR-H1 of the antibody is 4, 5, or 6 residues in length. In some embodiments, the Chothia CDR-H2 of the antibody is 5, 6, or 7 residues in length. In some embodiments, the Kabat CDR-H2 of the antibody is 16, 17, or 18 residues in length. In some embodiments, the Kabat / Chothia CDR-H3 of the antibody is 7, 8, 9, 10, 11, 12, or 13 residues in length.
[0220] In some aspects, the Kabat / Chothia CDR-L1 of the antibody is 10, 11, 12, 13, 14, 15, or 16 residues in length. In some aspects, the Kabat / Chothia CDR-L2 of the antibody is 6, 7, or 8 residues in length. In some aspects, the Kabat / Chothia CDR-L3 of the antibody is 8, 9, or 10 residues in length.
[0221] In some embodiments, the antibody comprises a light chain. In some aspects, the light chain is a kappa light chain. In some aspects, the light chain is a lambda light chain.
[0222] In some embodiments, the antibody comprises a heavy chain. In some aspects, the heavy chain is an IgA. In some aspects, the heavy chain is an IgD. In some aspects, the heavy chain is an IgE. In some aspects, the heavy chain is an IgG. In some aspects, the heavy chain is an IgM. In some aspects, the heavy chain is an IgGl. In some aspects, the heavy chain is an IgG2. In some aspects, the heavy chain is an IgG3. In some aspects, the heavy chain is an IgG4. In some aspects, the heavy chain is an IgAl. In some aspects, the heavy chain is an IgA2.
[0223] In some embodiments, the antibody is an antibody fragment. In some aspects, the antibody fragment is an Fv fragment. In some aspects, the antibody fragment is a Fab fragment. In some aspects, the antibody fragment is a F(ab’)2 fragment. In some aspects, the antibody fragment is a Fab’ fragment. In some aspects, the antibody fragment is an scFv (sFv) fragment. In some aspects, the antibody fragment is an scFv-Fc fragment.
[0224] In some embodiments, the antibody of any one of the preceding embodiments comprises at least one constant region domain. In some embodiments, the antibody, of any oneAttorney Docket No.: 108843.00627
[0225] of the preceding embodiments, comprises a constant region in a heavy chain sequence set forth in one of SEQ ID NOS: 1497-1511. In some embodiments, the antibody, of any one of the preceding embodiments, comprises a constant region in a light chain sequence set forth in SEQ ID NO: 1496. In some embodiments, the antibody, of any one of the preceding embodiments, comprises a constant region in a heavy chain sequence set forth in one of SEQ ID NOS: 1497-1511 and in a light chain sequence set forth in SEQ ID NO: 1496. However, a skilled person will recognize that the antibodies provide herein may comprise any suitable constant region and that the constant region sequences provided herein are for illustrative purposes.
[0226] In some embodiments, the antibody is a monoclonal antibody. In some embodiments, the antibody is a polyclonal antibody.
[0227] In some embodiments, the antibody is a chimeric antibody. In some embodiments, the antibody is a humanized antibody. In some embodiments, the antibody is a human antibody.
[0228] In some embodiments, the antibody is an affinity matured antibody. In some aspects, the antibody is an affinity matured antibody derived from an illustrative sequence provided in this disclosure.
[0229] The antibodies provided herein may be useful for the treatment of a variety of diseases and conditions including cancers. In some embodiments, the antibodies provided herein may be useful for the treatment of cancers of solid tumors. For example, the antibodies provided herein can be useful for the treatment of colorectal cancer.
[0230] 2.1 VH Sequences Comprising Illustrative CDRs
[0231] In some embodiments, the antibody comprises a VH sequence comprising one or more CDR-H sequences comprising, consisting of, or consisting essentially of one or more illustrative CDR-H sequences provided in this disclosure, and variants thereof. In some embodiments, the CDR-H sequences comprise, consist of, or consist essentially of one or more CDR-H sequences provided in a VH sequence selected from SEQ ID NOs: 1246, 1258, 1373, 1406, 1407, 1408, 1424, 1464, 1474, 1487, 1488, 1489, and 1491.
[0232] 2.1.1. VH Sequences Comprising Illustrative Kabat CDRs
[0233] In some embodiments, the antibody comprises a VH sequence comprising one or more Kabat CDR-H sequences comprising, consisting of, or consisting essentially of one or more illustrative Kabat CDR-H sequences provided in this disclosure, and variants thereof.
[0234] 2.1.1.1. Kabat CDR-H1 + Kabat CDR-H2 + Kabat CDR-H3
[0235] In some embodiments, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 6, 18, 133, 166, 167, 168, 184, 224, 234, 247, 248, 249, and 251, a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selectedAttorney Docket No.: 108843.00627
[0236] from SEQ ID NOs: 502, 514, 629, 662, 663, 664, 680, 720, 730, 743, 744, 745, and 747, and a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 998, 1010, 1125, 1158, 1159, 1160, 1176, 1216, 1226, 1239, 1240, 1241, and 1243. In some aspects, the Kabat CDR-H1 sequence, Kabat CDR-H2 sequence, and Kabat CDR-H3 sequence are all from a single illustrative VH sequence provided in this disclosure. For example, in some aspects, the Kabat CDR-H1, Kabat CDR-H2, and Kabat CDR-H3 are all from a single illustrative VH sequence selected from SEQ ID NOs: 1246, 1258, 1373, 1406, 1407, 1408, 1424, 1464, 1474, 1487, 1488, 1489, and 1491.
[0237] 2.1.1.2. Variants of VH Sequences Comprising Illustrative Kabat CDRs In some embodiments, the VH sequences provided herein comprise a variant of an illustrative Kabat CDR-H3, CDR-H2, and / or CDR-H1 sequence provided in this disclosure.
[0238] In some aspects, the Kabat CDR-H3 sequence comprises, consists of, or consists essentially of a variant of an illustrative Kabat CDR-H3 sequence provided in this disclosure. In some aspects, the Kabat CDR-H3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with any of the illustrative Kabat CDR-H3 sequences provided in this disclosure. In some aspects, the Kabat CDR-H3 sequence comprises, consists of, or consists essentially of any of the illustrative Kabat CDR-H3 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
[0239] In some aspects, the Kabat CDR-H2 sequence comprises, consists of, or consists essentially of a variant of an illustrative Kabat CDR-H2 sequence provided in this disclosure. In some aspects, the Kabat CDR-H2 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with any of the illustrative Kabat CDR-H2 sequences provided in this disclosure. In some aspects, the Kabat CDR-H2 sequence comprises, consists of, or consists essentially of any of the illustrative Kabat CDR-H2 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
[0240] In some aspects, the Kabat CDR-H1 sequence comprises, consists of, or consists essentially of a variant of an illustrative Kabat CDR-H1 sequence provided in this disclosure. In some aspects, the Kabat CDR-H1 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with any of the illustrative Kabat CDR-H1 sequences provided in this disclosure. In some aspects, the Kabat CDR-H1 sequence comprises, consists of, or consists essentially of any ofAttorney Docket No.: 108843.00627
[0241] the illustrative Kabat CDR-H1 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
[0242] 2.1.2. VH Sequences Comprising Illustrative Chothia CDRs
[0243] In some embodiments, the antibody comprises a VH sequence comprising one or more Chothia CDR-H sequences comprising, consisting of, or consisting essentially of one or more illustrative Chothia CDR-H sequences provided in this disclosure, and variants thereof.
[0244] 2.1.2.1. Chothia CDR-H1 + Chothia CDR-H2 + Chothia CDR-H3 In some embodiments, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 254, 266, 381, 414, 415, 416, 432, 472, 482, 495, 496, 497, and 499, a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 750, 762, 877, 910, 911, 912, 928, 968, 978, 991, 992, 993, and 995, and a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 998, 1010, 1125, 1158, 1159, 1160, 1176, 1216, 1226, 1239, 1240, 1241, and 1243. In some aspects, the Chothia CDR-H1 sequence, Chothia CDR-H2 sequence, and Chothia CDR-H3 sequence are all from a single illustrative VH sequence provided in this disclosure. For example, in some aspects, the Chothia CDR-H1, Chothia CDR-H2, and Chothia CDR-H3 are all from a single illustrative VH sequence selected from SEQ ID NOs: 1246, 1258, 1373, 1406, 1407, 1408, 1424, 1464, 1474, 1487, 1488, 1489, and 1491.
[0245] 2.1.2.2. Variants of VH Sequences Comprising Illustrative Chothia CDRs In some embodiments, the VH sequences provided herein comprise a variant of an illustrative Chothia CDR-H3, CDR-H2, and / or CDR-H1 sequence provided in this disclosure.
[0246] In some aspects, the Chothia CDR-H3 sequence comprises, consists of, or consists essentially of a variant of an illustrative Chothia CDR-H3 sequence provided in this disclosure. In some aspects, the Chothia CDR-H3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with any of the illustrative Chothia CDR-H3 sequences provided in this disclosure. In some aspects, the Chothia CDR-H3 sequence comprises, consists of, or consists essentially of any of the illustrative Chothia CDR-H3 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
[0247] In some aspects, the Chothia CDR-H2 sequence comprises, consists of, or consists essentially of a variant of an illustrative Chothia CDR-H2 sequence provided in this disclosure. In some aspects, the Chothia CDR-H2 sequence comprises, consists of, or consists essentiallyAttorney Docket No.: 108843.00627
[0248] of a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with any of the illustrative Chothia CDR-H2 sequences provided in this disclosure. In some aspects, the Chothia CDR-H2 sequence comprises, consists of, or consists essentially of any of the illustrative Chothia CDR-H2 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
[0249] In some aspects, the Chothia CDR-H1 sequence comprises, consists of, or consists essentially of a variant of an illustrative Chothia CDR-H1 sequence provided in this disclosure. In some aspects, the Chothia CDR-H1 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with any of the illustrative Chothia CDR-H1 sequences provided in this disclosure. In some aspects, the Chothia CDR-H1 sequence comprises, consists of, or consists essentially of any of the illustrative Chothia CDR-H1 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
[0250] 2.2. VH Sequences
[0251] In some embodiments, the antibody comprises, consists of, or consists essentially of a VHsequence provided in SEQ ID NOs.: 1246, 1258, 1373, 1406, 1407, 1408, 1424, 1464, 1474, 1487, 1488, 1489, and 1491.
[0252] In some embodiments, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 1246, 1258, 1373, 1406, 1407, 1408, 1424, 1464, 1474, 1487, 1488, 1489, and 1491.
[0253] In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 1246. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 1258. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 1373. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 1406. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 1407. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 1408. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 1424. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 1464. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 1474. In some aspects, theAttorney Docket No.: 108843.00627
[0254] antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 1487. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 1488. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 1489. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 1491.
[0255] 2.2.1. Variants of VH Sequences
[0256] In some embodiments, the VH sequences provided herein comprise, consist of, or consist essentially of a variant of an illustrative VH sequence provided in this disclosure.
[0257] In some aspects, the VH sequence comprises, consists of, or consists essentially of a variant of an illustrative VH sequence provided in this disclosure. In some aspects, the VH sequence comprises, consists of, or consists essentially of a sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% identity with any of the illustrative VH sequences provided in this disclosure.
[0258] In some embodiments, the VH sequence comprises, consists of, or consists essentially of any of the illustrative VH sequences provided in this disclosure having 20 or fewer, 19 or fewer, 18 or fewer, 17 or fewer, 16 or fewer, 15 or fewer, 14 or fewer, 13 or fewer, 12 or fewer, 11 or fewer, 10 or fewer, 9 or fewer, 8 or fewer, 7 or fewer, 6 or fewer, 5 or fewer, 4 or fewer, 3 or fewer, 2 or fewer, or 1 or fewer amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
[0259] 2.3. VL Sequences Comprising Illustrative CD Rs
[0260] In some embodiments, the antibody comprises a VL sequence comprising one or more CDR-L sequences comprising, consisting of, or consisting essentially of one or more illustrative CDR-L sequences provided in this disclosure, and variants thereof.
[0261] 2.3.1. VL Sequences Comprising Illustrative Kabat CD Rs
[0262] In some embodiments, the antibody comprises a VL sequence comprising one or more Kabat CDR-L sequences comprising, consisting of, or consisting essentially of one or more illustrative Kabat CDR-L sequences provided in this disclosure, and variants thereof.
[0263] 2.3.1.1. Kabat CDR-L1 + Kabat CDR-L2 + Kabat CDR-L3
[0264] In some embodiments, the antibody comprises a VL sequence comprising a Kabat CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 1492, a Kabat CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 1493, and a Kabat CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 1494. In some aspects, the Kabat CDR-L1 sequence, Kabat CDR-L2 sequence, and Kabat CDR-L3 sequence are all from a single illustrative VL sequence provided in thisAttorney Docket No.: 108843.00627
[0265] disclosure. For example, in some aspects, the Kabat CDR-L1, Kabat CDR-L2, and Kabat CDR-L3 are all from the single illustrative VL sequence SEQ ID NO: 1495.
[0266] 2.3.1.2. Variants O VL Sequences Comprising Illustrative Kabat CD Rs
[0267] In some embodiments, the VL sequences provided herein comprise a variant of an illustrative Kabat CDR-L3, CDR-L2, and / or CDR-L1 sequence provided in this disclosure.
[0268] In some aspects, the Kabat CDR-L3 sequence comprises, consists of, or consists essentially of a variant of an illustrative Kabat CDR-L3 sequence provided in this disclosure. In some aspects, the Kabat CDR-L3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with any of the illustrative Kabat CDR-L3 sequences provided in this disclosure. In some aspects, the Kabat CDR-L3 sequence comprises, consists of, or consists essentially of any of the illustrative Kabat CDR-L3 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
[0269] In some aspects, the Kabat CDR-L2 sequence comprises, consists of, or consists essentially of a variant of an illustrative Kabat CDR-L2 sequence provided in this disclosure. In some aspects, the Kabat CDR-L2 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with any of the illustrative Kabat CDR-L2 sequences provided in this disclosure. In some aspects, the Kabat CDR-L2 sequence comprises, consists of, or consists essentially of any of the illustrative Kabat CDR-L2 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
[0270] In some aspects, the Kabat CDR-L1 sequence comprises, consists of, or consists essentially of a variant of an illustrative Kabat CDR-L1 sequence provided in this disclosure. In some aspects, the Kabat CDR-L1 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with any of the illustrative Kabat CDR-L1 sequences provided in this disclosure. In some aspects, the Kabat CDR-L1 sequence comprises, consists of, or consists essentially of any of the illustrative Kabat CDR-L1 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.Attorney Docket No.: 108843.00627
[0271] 2.3.2. VL Sequences Comprising Illustrative Chothia CD Rs
[0272] In some embodiments, the antibody comprises a VL sequence comprising one or more Chothia CDR-L sequences comprising, consisting of, or consisting essentially of one or more illustrative Chothia CDR-L sequences provided in this disclosure, and variants thereof.
[0273] 2.3.2.1. Chothia CDR-L1 + Chothia CDR-L2 + Chothia CDR-L3 In some embodiments, the antibody comprises a VL sequence comprising a Chothia CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 1492, a Chothia CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 1493, and a Chothia CDR-L3 sequence comprising, consisting of, or consisting essentially of a SEQ ID NO: 1494. In some aspects, the Chothia CDR-L1 sequence, Chothia CDR-L2 sequence, and Chothia CDR-L3 sequence are all from a single illustrative VL sequence provided in this disclosure. For example, in some aspects, the Chothia CDR-L1, Chothia CDR-L2, and Chothia CDR-L3 are all from the single illustrative VL SEQ ID NO: 1495.
[0274] 2.3.2.2. Variants O VL Sequences Comprising Illustrative Chothia CD Rs In some embodiments, the VH sequences provided herein comprise a variant of an illustrative Chothia CDR-L3, CDR-L2, and / or CDR-L1 sequence provided in this disclosure.
[0275] In some aspects, the Chothia CDR-L3 sequence comprises, consists of, or consists essentially of a variant of an illustrative Chothia CDR-L3 sequence provided in this disclosure. In some aspects, the Chothia CDR-L3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with any of the illustrative Chothia CDR-L3 sequences provided in this disclosure. In some aspects, the Chothia CDR-L3 sequence comprises, consists of, or consists essentially of any of the illustrative Chothia CDR-L3 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
[0276] In some aspects, the Chothia CDR-L2 sequence comprises, consists of, or consists essentially of a variant of an illustrative Chothia CDR-L2 sequence provided in this disclosure. In some aspects, the Chothia CDR-L2 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with any of the illustrative Chothia CDR-L2 sequences provided in this disclosure. In some aspects, the Chothia CDR-L2 sequence comprises, consists of, or consists essentially of any of the illustrative Chothia CDR-L2 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.Attorney Docket No.: 108843.00627
[0277] In some aspects, the Chothia CDR-L1 sequence comprises, consists of, or consists essentially of a variant of an illustrative Chothia CDR-L1 sequence provided in this disclosure. In some aspects, the Chothia CDR-L1 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with any of the illustrative Chothia CDR-L1 sequences provided in this disclosure. In some aspects, the Chothia CDR-L1 sequence comprises, consists of, or consists essentially of any of the illustrative Chothia CDR-L1 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
[0278] 2.4. VL Sequences
[0279] In some embodiments, the antibody comprises, consists of, or consists essentially of the VL sequence provided in SEQ ID NOs.: 1495.
[0280] In some embodiments, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of the sequence SEQ ID NOs: 1495.
[0281] 2.4.1. Variants of VL Sequences
[0282] In some embodiments, the VL sequences provided herein comprise, consist of, or consist essentially of a variant of an illustrative VL sequence provided in this disclosure.
[0283] In some aspects, the VL sequence comprises, consists of, or consists essentially of a variant of an illustrative VL sequence provided in this disclosure. In some aspects, the VL sequence comprises, consists of, or consists essentially of a sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% identity with any of the illustrative VL sequences provided in this disclosure.
[0284] In some embodiments, the VL sequence comprises, consists of, or consists essentially of any of the illustrative VL sequences provided in this disclosure having 20 or fewer, 19 or fewer, 18 or fewer, 17 or fewer, 16 or fewer, 15 or fewer, 14 or fewer, 13 or fewer, 12 or fewer, 11 or fewer, 10 or fewer, 9 or fewer, 8 or fewer, 7 or fewer, 6 or fewer, 5 or fewer, 4 or fewer, 3 or fewer, 2 or fewer, or 1 or fewer amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
[0285] 2.5. Pairs
[0286] 2.5.1. VH — VL Pairs
[0287] In some embodiments, the antibody comprises a VH sequence and a VL sequence.
[0288] In some aspects, the VH sequence is a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 1246, 1258, 1373, 1406, 1407, 1408, 1424, 1464, 1474, 1487, 1488, 1489, and 1491, and the VL sequence is a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 1495.Attorney Docket No.: 108843.00627
[0289] In some embodiments, the antibody comprises a VH / VL pair together comprising, consisting of, or consisting essentially of the sequences of any pair selected from the group consisting of SEQ ID NOs: 1246 / 1495, 1258 / 1495, 1373 / 1495, 1406 / 1495, 1407 / 1495, 1408 / 1495, 1424 / 1495, 1464 / 1495, 1474 / 1495, 1487 / 1495, 1488 / 1495, 1489 / 1495, and 1491 / 1495.
[0290] In some aspects, the antibody comprises a VH / VL pair together comprising, consisting of, or consisting essentially of the sequences of any pair as shown in Table E below:
[0291] Table E. VH / VL pairs.
[0292]
[0293] 2.5.1.1. Variants of VH — VL Pairs
[0294] In some embodiments, the VH - VL pairs provided herein comprise a variant of an illustrative VH and / or VL sequence provided in this disclosure.
[0295] In some aspects, the VH sequence comprises, consists of, or consists essentially of a variant of an illustrative VH sequence provided in this disclosure. In some aspects, the VH sequence comprises, consists of, or consists essentially of a sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% identity with any of the illustrative VH sequences provided in this disclosure.
[0296] In some embodiments, the VH sequence comprises, consists of, or consists essentially of any of the illustrative VH sequences provided in this disclosure having 20 or fewer, 19 or fewer, 18 or fewer, 17 or fewer, 16 or fewer, 15 or fewer, 14 or fewer, 13 or fewer, 12 orAttorney Docket No.: 108843.00627
[0297] fewer, 11 or fewer, 10 or fewer, 9 or fewer, 8 or fewer, 7 or fewer, 6 or fewer, 5 or fewer, 4 or fewer, 3 or fewer, 2 or fewer, or 1 or fewer amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
[0298] In some aspects, the VL sequence comprises, consists of, or consists essentially of a variant of an illustrative VL sequence provided in this disclosure. In some aspects, the VL sequence comprises, consists of, or consists essentially of a sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% identity with any of the illustrative VL sequences provided in this disclosure.
[0299] In some embodiments, the VL sequence comprises, consists of, or consists essentially of any of the illustrative VL sequences provided in this disclosure having 20 or fewer, 19 or fewer, 18 or fewer, 17 or fewer, 16 or fewer, 15 or fewer, 14 or fewer, 13 or fewer, 12 or fewer, 11 or fewer, 10 or fewer, 9 or fewer, 8 or fewer, 7 or fewer, 6 or fewer, 5 or fewer, 4 or fewer, 3 or fewer, 2 or fewer, or 1 or fewer amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
[0300] 2.6. Antibodies Comprising All Six CDRs
[0301] In some embodiments, the antibody comprises a CDR-H1 sequence, a CDR-H2 sequence, a CDR-H3 sequence, a CDR-L1 sequence, and a CDR-L3 sequence. In some aspects, the CDR sequences are part of a VH (for CDR-H) or VL (for CDR-L).
[0302] In some aspects, the CDR-H1 sequence is a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 254, 266, 381, 414, 415, 416, 432, 472, 482, 495, 496, 497, and 499; the CDR-H2 sequence is a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 750, 762, 877, 910, 911, 912, 928, 968, 978, 991, 992, 993, and 995; the CDR-H3 sequence is a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 998, 1010, 1125, 1158, 1159, 1160, 1176, 1216, 1226, 1239, 1240, 1241, and 1243; the CDR-L1 sequence is a Chothia CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 1492; the CDR-L2 sequence is a Chothia CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 1493; and the CDR-L3 sequence is a Chothia CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 1494.
[0303] In some aspects, the CDR-H 1 sequence is a Kabat CDR-H 1 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 6, 18, 133, 166, 167, 168, 184, 224, 234, 247, 248, 249, and 251; the CDR-H2 sequence is a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 502, 514, 629, 662, 663, 664, 680, 720, 730, 743, 744, 745, and 747; the CDR-H3 sequence is a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 998, 1010, 1125, 1158, 1159, 1160,Attorney Docket No.: 108843.00627
[0304] 1176, 1216, 1226, 1239, 1240, 1241, and 1243; the CDR-L1 sequence is a Kabat CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 1492; the CDR-L2 sequence is a Kabat CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 1493; and the CDR-L3 sequence is a Kabat CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 1494.
[0305] In some aspects, the antibody comprises three heavy chain CDRs from a VH sequence selected from SEQ ID NOs: 1246, 1258, 1373, 1406, 1407, 1408, 1424, 1464, 1474, 1487, 1488, 1489, and 1491, or variants thereof, and three light chain CDRs from a VL sequence provided in SEQ ID NO: 1495, or variants thereof. The CDRs can be according to any CDR scheme known to the person of skill. In certain embodiments, the CDRs are Kabat CDRs. In certain embodiments, the CDRs are Chothia CDRs.
[0306] In some embodiments, the antibody comprises three heavy chain CDRs, or variants thereof, and three light chain CDRs, or variants thereof, from a VH / VL pair selected from the group consisting of the group consisting of SEQ ID NOs: 1246 / 1495, 1258 / 1495, 1373 / 1495, 1406 / 1495, 1407 / 1495, 1408 / 1495, 1424 / 1495, 1464 / 1495, 1474 / 1495, 1487 / 1495, 1488 / 1495, 1489 / 1495, and 1491 / 1495.
[0307] In some embodiments, the antibody comprises three heavy chain CDRs, or variants thereof, and three light chain CDRs, or variants thereof, from a VH / VL pair selected from the group consisting of the group consisting of SEQ ID NOs: 1373 / 1495 and 1487 / 1495. In some embodiments, the antibody comprises three heavy chain CDRs, or variants thereof, and three light chain CDRs, or variants thereof, from the VH / VL pair of SEQ ID NOs: 1373 / 1495.
[0308] The CDRs can be according to any CDR scheme known to the person of skill. In certain embodiments, the CDRs are Kabat CDRs. In certain embodiments, the CDRs are Chothia CDRs. In certain embodiments, the antibody further comprises the framework regions of the VH / VL pair.
[0309] 2.6.1. Variants of Antibodies Comprising All Six CDRs
[0310] In some embodiments, the CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 provided herein comprise a variant of an illustrative CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and / or CDR-L3 sequence provided in this disclosure.
[0311] In some aspects, the CDR-H1 sequence comprises, consists of, or consists essentially of a variant of an illustrative Chothia or Kabat CDR-H1 sequence provided in this disclosure. In some aspects, the CDR-H1 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with any of the illustrative Chothia or Kabat CDR-H1 sequences provided in this disclosure. In some aspects, the CDR-H1 sequence comprises, consists of, or consists essentially of any ofAttorney Docket No.: 108843.00627
[0312] the illustrative Chothia or Kabat CDR-H1 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
[0313] In some aspects, the CDR-H2 sequence comprises, consists of, or consists essentially of a variant of an illustrative Chothia or Kabat CDR-H2 sequence provided in this disclosure. In some aspects, the CDR-H2 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with any of the illustrative Chothia or Kabat CDR-H2 sequences provided in this disclosure. In some aspects, the CDR-H2 sequence comprises, consists of, or consists essentially of any of the illustrative Chothia or Kabat CDR-H2 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
[0314] In some aspects, the CDR-H3 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-H3 sequence provided in this disclosure. In some aspects, the CDR-H3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with any of the illustrative CDR-H3 sequences provided in this disclosure. In some aspects, the CDR-H3 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-H3 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
[0315] In some aspects, the CDR-L1 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-L1 sequence provided in this disclosure. In some aspects, the CDR-L1 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with any of the illustrative CDR-L1 sequences provided in this disclosure. In some aspects, the CDR-L1 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-L1 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
[0316] In some aspects, the CDR-L2 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-L2 sequence provided in this disclosure. In some aspects, the CDR-L2 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with any of the illustrative CDR-L2 sequences provided in this disclosure. In some aspects, the CDR-L2 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-L2 sequencesAttorney Docket No.: 108843.00627
[0317] provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
[0318] In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-L3 sequence provided in this disclosure. In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with any of the illustrative CDR-L3 sequences provided in this disclosure. In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-L3 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
[0319] 3. Conjugates
[0320] Provided herein are conjugates of antibodies to avP6. The conjugates comprise an antibody to avP6 covalently linked directly or indirectly, via a linker, to a payload moiety. In some embodiments, the conjugate comprises an antibody that specifically binds to avP6 linked site-specifically to at least one payload moiety, and the antibody comprises one or more nonnatural and / or modified amino acids. In certain embodiments, the antibody is linked to one payload moiety. In further embodiments, the antibody is linked to more than one payload. In certain embodiments, the antibody is linked to two, three, four, five, six, seven, eight, nine, ten, or more payload moieties.
[0321] The payload moiety can be a moiety of any payload deemed useful by the practitioner of skill. In certain embodiments, the payload is a therapeutic moiety. In certain embodiments, the payload is a diagnostic moiety, e.g., a label. Useful payloads are described in the sections and examples below.
[0322] The linker can be any linker capable of forming at least one bond to the antibody and at least one bond to a payload. Useful linkers are described the sections and examples below.
[0323] In the conjugates provided herein, the antibody can be any antibody with binding specificity for avP6. The avP6 can be from any species. In certain embodiments, the avP6 is a vertebrate avP6. In certain embodiments, the avP6 is a mammalian avP6. In certain embodiments, the avP6 is human avP6. In certain embodiments, the avP6 is mouse avP66. In certain embodiments, the avP6 is cynomolgus avP6.
[0324] In certain embodiments, the antibody to avP6 competes with an antibody described herein for binding. In certain embodiments, the antibody to avP6 binds to the same epitope as an antibody described herein.Attorney Docket No.: 108843.00627
[0325] The antibody is typically a protein comprising multiple polypeptide chains. In certain embodiments, the antibody is a heterotetramer comprising two identical light (L) chains and two identical heavy (H) chains. Each light chain can be linked to a heavy chain by one covalent disulfide bond. Each heavy chain can be linked to the other heavy chain by one or more covalent disulfide bonds. Each heavy chain and each light chain can also have one or more intrachain disulfide bonds. As is known to those of skill in the art, each heavy chain typically comprises a variable domain (VH) followed by a number of constant domains. Each light chain typically comprises a variable domain at one end (VL) and a constant domain. As is known to those of skill in the art, antibodies typically have selective affinity for their target molecules, i.e., antigens.
[0326] The antibodies provided herein can have any antibody form known to those of skill in the art. They can be full-length, or fragments. Exemplary full-length antibodies include IgA, IgAl, IgA2, IgD, IgE, IgG, IgGl, IgG2, IgG3, IgG4, IgM, etc. Exemplary fragments include Fv, Fab, Fc, scFv, scFv-Fc, and etc.
[0327] In certain embodiments, the antibody of the conjugate comprises one, two, three, four, five, or six of the CDR sequences described herein. In certain embodiments, the antibody of the conjugate comprises a heavy chain variable domain (VH) described herein. In certain embodiments, the antibody of the conjugate comprises a light chain variable domain (VL) described herein. In certain embodiments, the antibody of the conjugate comprises a heavy chain variable domain (VH) described herein and a light chain variable domain (VL) described herein. In certain embodiments, the antibody of the conjugate comprises a paired heavy chain variable domain and a light chain variable domain described herein (VH - VL pair). In certain embodiments, the antibody of the conjugate comprises a heavy chain (HC) described herein. In certain embodiments, the antibody of the conjugate comprises a light chain (LC) described herein. In certain embodiments, the antibody of the conjugate comprises a heavy chain (HC) described herein and a light chain (LC) described herein. In certain embodiments, the antibody of the conjugate comprises a paired heavy chain and a light chain described herein (HC - LC pair). In certain embodiments, the antibody of the conjugate comprises a heavy chain (HC) described herein. In certain embodiments, the antibody of the conjugate comprises a light chain (LC) described herein. In certain embodiments, the antibody of the conjugate comprises a heavy chain (HC) described herein and a light chain (LC) described herein. In certain embodiments, the antibody of the conjugate comprises a paired heavy chain and a light chain described herein (HC - LC pair).
[0328] In certain embodiments, the antibody of the conjugate comprises any of the amino acid sequences of the antibodies described above. In certain embodiments, the antibody comprisesAttorney Docket No.: 108843.00627
[0329] any of the amino acid sequences above with up to 10 amino acid substitutions. In certain embodiments, the antibody comprises any of the amino acid sequences above with up to 9 amino acid substitutions. In certain embodiments, the antibody comprises any of the amino acid sequences above with up to 8 amino acid substitutions. In certain embodiments, the antibody comprises any of the amino acid sequences above with up to 7 amino acid substitutions. In certain embodiments, the antibody comprises any of the amino acid sequences above with up to 6 amino acid substitutions. In certain embodiments, the antibody comprises any of the amino acid sequences above with up to 5 amino acid substitutions. In certain embodiments, the antibody comprises any of the amino acid sequences above with up to 4 amino acid substitutions. In certain embodiments, the antibody comprises any of the amino acid sequences above with up to 3 amino acid substitutions. In certain embodiments, the antibody comprises any of the amino acid sequences above with up to 2 amino acid substitutions. In certain embodiments, the antibody comprises any of the amino acid sequences above with up to 1 conservative amino acid substitution. In some embodiments, the amino acid substitutions are conservative amino acid substitutions. For example, in certain embodiments, the antibody comprises any of the amino acid sequences above with up to 10 conservative amino acid substitutions. In certain embodiments, the antibody comprises any of the amino acid sequences above with up to 9 conservative amino acid substitutions. In certain embodiments, the antibody comprises any of the amino acid sequences above with up to 8 conservative amino acid substitutions. In certain embodiments, the antibody comprises any of the amino acid sequences above with up to 7 conservative amino acid substitutions. In certain embodiments, the antibody comprises any of the amino acid sequences above with up to 6 conservative amino acid substitutions. In certain embodiments, the antibody comprises any of the amino acid sequences above with up to 5 conservative amino acid substitutions. In certain embodiments, the antibody comprises any of the amino acid sequences above with up to 4 conservative amino acid substitutions. In certain embodiments, the antibody comprises any of the amino acid sequences above with up to 3 conservative amino acid substitutions. In certain embodiments, the antibody comprises any of the amino acid sequences above with up to 2 conservative amino acid substitutions. In certain embodiments, the antibody comprises any of the amino acid sequences above with up to 1 conservative amino acid substitution.
[0330] In certain embodiments, the antibody conjugate can be formed from an antibody that comprises one or more reactive groups. In certain embodiments, the antibody conjugate can be formed from an antibody comprising all naturally encoded amino acids. Those of skill in the art will recognize that several naturally encoded amino acids include reactive groups capable of conjugation to a payload or to a linker. These reactive groups include cysteine side chains,Attorney Docket No.: 108843.00627
[0331] lysine side chains, and amino-terminal groups. In these embodiments, the antibody conjugate can comprise a payload or linker linked to the residue of an antibody reactive group. In these embodiments, the payload precursor or linker precursor comprises a reactive group capable of forming a bond with an antibody reactive group. Typical reactive groups include maleimide groups, activated carbonates (including but not limited to, p-nitrophenyl ester), activated esters (including but not limited to, N-hydroxysuccinimide, p-nitrophenyl ester, and aldehydes). Particularly useful reactive groups include maleimide and succinimide, for instance N-hydroxysuccinimide, for forming bonds to cysteine and lysine side chains. Additional reactive groups include alkynes, for example strained alkynes, and azide groups and oxyamine groups, for forming bonds to amino acids incorporated in antibody polypeptide chains. Further reactive groups are described in the sections and examples below.
[0332] In certain embodiments, the antibody comprises one or more non-natural and / or modified amino acids having a reactive group, as described herein. Typically, the modified amino acid is not a naturally encoded amino acid. These modified amino acids can comprise a reactive group useful for forming a covalent bond to a linker precursor or to a payload precursor. One of skill in the art can use the reactive group to link the polypeptide to any molecular entity capable of forming a covalent bond to the modified amino acid. Thus, provided herein are conjugates comprising an antibody comprising a modified amino acid residue linked to a payload directly or indirectly via a linker. Exemplary modified amino acids are described in the sections below. Generally, the modified amino acids have reactive groups capable of forming bonds to linkers or payloads with complementary reactive groups.
[0333] The non-natural amino acids or modified amino acids are positioned at select locations in a polypeptide chain of the antibody. These locations were identified as providing optimum sites for substitution with the non-natural amino acid or modified amino acid. Each site is capable of bearing a non-natural amino acid or modified amino acid with optimum structure, function and / or methods for producing the antibody.
[0334] In certain embodiments, a site-specific position for substitution provides an antibody that is stable. Stability can be measured by any technique apparent to those of skill in the art.
[0335] In certain embodiments, a site-specific position for substitution provides an antibody that has optimal functional properties. For instance, the antibody can show little or no loss of binding affinity for its target antigen compared to an antibody without the site-specific non-natural or modified amino acid. In certain embodiments, the antibody can show enhanced binding compared to an antibody without the site-specific non-natural or modified amino acid.
[0336] In certain embodiments, a site-specific position for substitution provides an antibody that can be made advantageously. For instance, in certain embodiments, the antibody showsAttorney Docket No.: 108843.00627
[0337] advantageous properties in its methods of synthesis, discussed below. In certain embodiments, the antibody can show little or no loss in yield in production compared to an antibody without the site-specific non-natural amino acid or modified amino acid. In certain embodiments, the antibody can show enhanced yield in production compared to an antibody without the sitespecific non-natural amino acid or modified amino acid. In certain embodiments, the antibody can show little or no loss of tRNA suppression compared to an antibody without the sitespecific non-natural amino acid or modified amino acid. In certain embodiments, the antibody can show enhanced tRNA suppression in production compared to an antibody without the sitespecific non-natural amino acid or modified amino acid.
[0338] In certain embodiments, a site-specific position for substitution provides an antibody that has advantageous solubility. In certain embodiments, the antibody can show little or no loss in solubility compared to an antibody without the site-specific non-natural amino acid or modified amino acid. In certain embodiments, the antibody can show enhanced solubility compared to an antibody without the site-specific non-natural amino acid or modified amino acid.
[0339] In certain embodiments, a site-specific position for substitution provides an antibody that has advantageous expression. In certain embodiments, the antibody can show little or no loss in expression compared to an antibody without the site-specific non-natural amino acid or modified amino acid. In certain embodiments, the antibody can show enhanced expression compared to an antibody without the site-specific non-natural amino acid or modified amino acid.
[0340] In certain embodiments, a site-specific position for substitution provides an antibody that has advantageous folding. In certain embodiments, the antibody can show little or no loss in proper folding compared to an antibody without the site-specific non-natural amino acid or modified amino acid. In certain embodiments, the antibody can show enhanced folding compared to an antibody without the site-specific non-natural amino acid or modified amino acid.
[0341] In certain embodiments, a site-specific position for substitution provides an antibody that is capable of advantageous conjugation. As described below, several non-natural amino acids have side chains or functional groups that facilitate conjugation of the antibody to a second agent, either directly or via a linker. In certain embodiments, the antibody can show enhanced conjugation efficiency compared to an antibody without the same or other non-natural amino acids / modified amino acids at other positions. In certain embodiments, the antibody can show enhanced conjugation yield compared to an antibody without the same or other non-natural amino acids / modified amino acids at other positions. In certainAttorney Docket No.: 108843.00627
[0342] embodiments, the antibody can show enhanced conjugation specificity compared to an antibody without the same or other non-natural amino acids / modified amino acids at other positions.
[0343] The one or more non-natural amino acids and / or modified amino acids are located at selected site-specific positions in at least one polypeptide chain of the antibody. The polypeptide chain can be any polypeptide chain of the antibody without limitation, including either light chain or either heavy chain. The site-specific position can be in any domain of the antibody, including any variable domain and any constant domain.
[0344] In certain embodiments, the antibodies provided herein comprise one non-natural amino acid and / or modified amino acid at a site-specific position. In certain embodiments, the antibodies provided herein comprise two non-natural amino acids and / or modified amino acid at site-specific positions. In certain embodiments, the antibodies provided herein comprise three non-natural amino acids and / or modified amino acids at site-specific positions. In certain embodiments, the antibodies provided herein comprise more than three non-natural amino acids and / or modified amino acids at site-specific positions. In certain embodiments, the antibodies provided herein comprise four non-natural amino acids and / or modified amino acids at site-specific positions.
[0345] In certain embodiments, the antibodies provided herein comprise one or more non-natural amino acids and / or modified amino acids each at a position selected from the group consisting of heavy chain or light chain residues HC-F404, HC-K121, HC-Y180, HC-F241, HC-221, HC-Y391, LC-T22, LC-S7, LC-N152, LC-K42, LC-E161, LC-D170, HC-S136, HC-S25, HC-A40, HC-S119, HC-S190, HC-K222, HC-R19, HC-Y52, or HC-S70 according to the Kabat or Chothia or EU numbering scheme, or a post-translationally modified variant thereof. In certain embodiments, the antibodies provided herein comprise one or more non-natural amino acids and / or modified amino acids each at a position selected from the group consisting of heavy chain or light chain residues HC-F404, HC-Y180, HC-F241, HC-Y391, LC-K42, and LC-E161, according to the Kabat or Chothia or EU numbering scheme, or a post-translationally modified variant thereof. In certain embodiments, the antibodies provided herein comprise one or more non-natural amino acids and / or modified amino acids each at a position selected from the group consisting of heavy chain or light chain residues HC-F404, HC-Y180, LC-K42, and LC-E161, according to the Kabat or Chothia or EU numbering scheme, or a post-translationally modified variant thereof. In certain embodiments, the antibodies provided herein comprise one or more non-natural amino acids and / or modified amino acids each at a position selected from the group consisting of heavy chain or light chain residues HC-F404, HC-Y180, HC-Y391, HC-F241, and LC-K42, according to the Kabat orAttorney Docket No.: 108843.00627
[0346] Chothia or EU numbering scheme, or a post-translationally modified variant thereof. In certain embodiments, the antibodies provided herein comprise a non-natural amino acid or modified amino acid at position HC-F404 according to the Kabat or Chothia or EU numbering scheme, or a post-translationally modified variant thereof. In certain embodiments, the antibodies provided herein comprise a non-natural amino acid or modified amino acid at position HC-Y180, according to the Kabat or Chothia or EU numbering scheme, or a post-translationally modified variant thereof. In certain embodiments, the antibodies provided herein comprise two non-natural amino acids and / or modified amino acids at positions HC-F404 and HC-Y180, according to the Kabat or Chothia or EU numbering scheme, or a post-translationally modified variant thereof. In certain embodiments, the antibodies provided herein comprise a non-natural amino acid or modified amino acid at position HC-F241 according to the Kabat or Chothia or EU numbering scheme, or a post-translationally modified variant thereof. In certain embodiments, the antibodies provided herein comprise a non-natural amino acid or modified amino acid at position LC-K42 according to the Kabat or Chothia or EU numbering scheme, or a post-translationally modified variant thereof. In certain embodiments, the antibodies provided herein comprise a non-natural amino acid or modified amino acid at position LC-E161 according to the Kabat or Chothia or EU numbering scheme, or a post-translationally modified variant thereof. In certain embodiments, the antibodies provided herein comprise three non-natural amino acids and / or modified amino acids at positions HC-F404, HC-Y180, and LC-K42, according to the Kabat or Chothia or EU numbering scheme, or a post-translationally modified variant thereof. In certain embodiments, the antibodies provided herein comprise four non-natural amino acids and / or modified amino acids at positions HC-F404, HC-Y180, LC-K42, and LC-E161, according to the Kabat or Chothia or EU numbering scheme, or a post-translationally modified variant thereof. In certain embodiments, the antibodies provided herein comprise three non-natural amino acids and / or modified amino acids at positions HC-F404, HC-Y180, and HC-F241, according to the Kabat or Chothia or EU numbering scheme, or a post-translationally modified variant thereof. In certain embodiments, the antibodies provided herein comprise four non-natural amino acids and / or modified amino acids at positions HC-F404, HC-Y180, HC-F241, and LC-K42, according to the Kabat or Chothia or EU numbering scheme, or a post-translationally modified variant thereof. In certain embodiments, the antibodies provided herein comprise four non-natural amino acids and / or modified amino acids at positions HC-F404, HC-Y180, HC-F241, and LC-K42, according to the Kabat or Chothia or EU numbering scheme, or a post-translationally modified variant thereof. In certain embodiments, the antibodies provided herein comprise two non-natural amino acids and / or modified amino acids at positions HC-F241 and HC-F404, according to theAttorney Docket No.: 108843.00627
[0347] Kabat or Chothia or EU numbering scheme, or a post-translationally modified variant thereof. In certain embodiments, the antibodies provided herein comprise four non-natural amino acids and / or modified amino acids at positions HC-Y180, HC-F404, LC-K42 and LC-E161, according to the Kabat or Chothia or EU numbering scheme, or a post-translationally modified variant thereof. In certain embodiments, the antibodies provided herein comprise four nonnatural amino acids and / or modified amino acids at positions HC-Y180, HC-F241, HC-F404 and HC-Y391, according to the Kabat or Chothia or EU numbering scheme, or a post-translationally modified variant thereof.
[0348] In certain embodiments, the antibodies provided herein comprise non-natural amino acids and / or modified amino acids at positions selected from the group consisting of HC-S113 according to Kabat numbering, HC-A118, HC-T120, HC-K121, HC-G138, HC-A140, HC-T155, HC-S160, HC-A162, HC-L163, HC-Q196, HC-I199, HC-N203, HC-T209, HC-K210, HC-E258, HC-K290, HC-Y296, HC-T335, HC-I336, HC-S337, HC-R344, HC-E345, HC-R355, HC-M358, HC-Q362, HC-E382, HC-E388, HC-N390, HC-Y391, HC-K392, HC-T393, HC-T411, HC- N421, HC-S424, HC-Q438, HC-L443 according to EU index of Kabat, LC-T109, LC-V110, LC-A111, LC-A112, LC-D122, LC-Q124, LC-K126, LC-S127, LC-T129, LC-N138, LC-R142, LC-E143, LC-Q147, LC-K149, LC-D151, LC-A153, LC-L154, LC-Q155, LC-S159, LC-E165, LC-Q166, LC-S168, LC-K169, LC-S171, LC-T172, LC-T180, LC-A184, LC-E187, LC-H189, LC-K190, LC-V191, LC-E195, LC-L201, LC-S202, LC-S203, LC-V205, and LC-T206 according to Kabat numbering, or a post-translationally modified variant thereof.
[0349] In these designations, HC indicates a heavy chain residue, and LC indicates a light chain residue.
[0350] In some aspects, the present disclosure provides antibody conjugates according to the
[0351]
[0352] following formula:Jn2or a pharmaceutically acceptable salt, solvate, stereoisomer, regioisomer, or tautomer thereof, wherein:
[0353] COMP is a residue of an anti-integrin beta 6 antibody;
[0354] PAY is a payload moiety;
[0355] LINK is a linker; and
[0356] n2 is an integer from 1 to 10,
[0357] wherein COMP comprises one or more non-natural amino acids and / or modified amino acids.Attorney Docket No.: 108843.00627
[0358] In certain embodiments, provided herein are conjugates according to Formula (Cl) or (C2):
[0359]
[0360] or a pharmaceutically acceptable salt, solvate, stereoisomer, regioisomer, or tautomer thereof, wherein:
[0361] COMP is a residue of an integrin beta 6 antibody;
[0362] PAY is a payload moiety;
[0363] W1, W2, W3, W4, and W5are each independently a single bond, absent, or a divalent attaching group;
[0364] EG is absent, or an eliminator group;
[0365] each RT is a release trigger group, in the backbone of Formula (Cl) or (C2) or bonded to EG, wherein each RT is optional;
[0366] HP is a single bond, absent, or a divalent hydrophilic group;
[0367] each SG is a single bond, absent, or a divalent spacer group;
[0368] R is hydrogen, a terminal conjugating group, or a divalent residue of a terminal conjugating group; and
[0369] n2 is an integer from 1 to 10.
[0370] In some embodiments, a conjugate according to Formula (Cl) or (C2) comprises n2 number of linked PAY moi eties, wherein n2 is an integer from 1 to 10. In some embodiments, n2 is 1. In some embodiments, n2 is 2. In some embodiments, n2 is 3. In some embodiments, n2 is 4. In some embodiments, n2 is 5. In some embodiments, n2 is 6. In some embodiments, n2 is 7. In some embodiments, n2 is 8. In some embodiments, n2 is 10.
[0371] 3.1 Attaching Groups
[0372] Attaching groups facilitate incorporation of eliminator groups, release trigger groups, hydrophobic groups, spacer groups, and / or conjugating groups into a compound. Useful attaching groups are known to, and are apparent to, those of skill in the art. Examples of useful attaching groups are provided herein. In certain embodiments, attaching groups are designated w1, w2, w3, w4, or W5. In certain embodiments, an attaching group can comprise a divalent ketone, divalent ester, divalent ether, divalent amide, divalent amine, alkylene, arylene, sulfide, disulfide, carbonylene, or a combination thereof. In certain embodiments an attaching groupAttorney Docket No.: 108843.00627
[0373] can comprise -C(O)-, -O-, -C(O)NH-, -C(O)NH-alkyl- -OC(O)NH-, -SC(O)NH- -NH-, -NH-alkyl- -N(CH3)CH2CH2N(CH3)- -S-, -S-S-, -OCH2CH2O-, or the reverse (e.g. -NHC(O)-) thereof, or a combination thereof.
[0374] 3.2 Eliminator Groups
[0375] Eliminator groups facilitate separation of a biologically active portion of a compound or conjugate described herein from the remainder of the compound or conjugate in vivo and / or in vitro. Eliminator groups can also facilitate separation of a biologically active portion of a compound or conjugate described herein in conjunction with a release trigger group. For example, the eliminator group and the release trigger group can react in a Releasing Reaction to release a biologically active portion of a compound or conjugate described herein from the compound or conjugate in vivo and / or in vitro. Upon initiation of the Releasing Reaction by the release trigger, the eliminator group cleaves the biologically active moiety, or a prodrug form of the biologically active moiety, and forms a stable, non-toxic entity that has no further effect on the activity of the biologically active moiety.
[0376] In certain embodiments, the eliminator group is designated EG herein. Useful eliminator groups include those described herein. In certain embodiments, the eliminator group
[0377]
[0378] wherein REGis selected from the group consisting of hydrogen, alkyl, biphenyl, -CF3, -NO2, -CN, fluoro, bromo, chloro, alkoxyl, alkylamino, dialkylamino, alkyl-C(O)O-, alkylamino-C(O)-and dialkylaminoC(O)-. In each structure, the phenyl ring can be bound to one, two, three, or in some cases, four REGgroups. In the second and third structures, those of skill will recognize that EG is bonded to an RT that is not within the backbone of formula (Cl) as indicated in the above description of formula (Cl). In some embodiments, REGis selected from the group consisting ofAttorney Docket No.: 108843.00627
[0379] hydrogen, alkyl, biphenyl, -CF3, alkoxyl, alkylamino, dialkylamino, alkyl-C(O)O-, alkylamino-C(O)- and dialkylaminoC(O)-. In further embodiments, REGis selected from the group consisting of hydrogen, -NO2, -CN, fluoro, bromo, and chloro. In certain embodiments, the eliminator
[0380]
[0381]
[0382] In some embodiments, provided herein is a conjugate according to Formula (Cl) or (C2) or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof; wherein EG comprises phenylene, carboxylene, amine, or a combination thereof. In some embodiments, the eliminator group is:
[0383]
[0384] Attorney Docket No.: 108843.00627
[0385]
[0386] wherein Z may be CH or N, REGis selected from the group consisting of hydrogen, alkyl, biphenyl, -CF3, -NO2, -CN, fluoro, bromo, chloro, alkoxyl, alkylamino, dialkylamino, alkyl-C(O)O-, alkylamino-C(O)- and dialkylaminoC(O)-. In each structure, the phenyl ring can be bound to one, two, three, or in some cases, four REGgroups. In the first and second structures, those of skill will recognize that EG is bonded to an RT that is not within the backbone of formula (C 1) as indicated in the above description of formula (Cl). In some embodiments, REGis selected from the group consisting of hydrogen, alkyl, biphenyl, -CF3, alkoxyl, alkylamino, dialkylamino, alkyl-C(O)O-, alkylamino-C(O)- and dialkylaminoC(O)-. In further embodiments, REGis selected from the group consisting of hydrogen, -NO2, -CN, fluoro, bromo, and chloro. In some embodiments, each REGin the EG is hydrogen. In certain embodiments, the eliminator group is
[0387]
[0388] Attorney Docket No.: 108843.00627
[0389] 3.3 Release Trigger Groups
[0390] Release trigger groups facilitate separation of a biologically active portion of a compound or conjugate described herein from the remainder of the compound or conjugate in vivo and / or in vitro. Release trigger groups can also facilitate separation of a biologically active portion of a compound or conjugate described herein in conjunction with an eliminator group. For example, the eliminator group and the release trigger group can react in a Releasing Reaction to release a biologically active portion of a compound or conjugate described herein from the compound or conjugate in vivo and / or in vitro. In certain embodiments, the release trigger can act through a biologically-driven reaction with high tumor: nontumor specificity, such as the proteolytic action of an enzyme overexpressed in a tumor environment.
[0391] In certain embodiments, the release trigger group is designated RT herein. In certain embodiments, RT is divalent and bonded within the backbone of formula (Cl). In other embodiments, RT is monovalent and bonded to EG as depicted above. Useful release trigger groups include those described herein. In certain embodiments, the release trigger group comprises a residue of a natural or non-natural amino acid or residue of a sugar ring. In certain embodiments, the release trigger group is:
[0392]
[0393] Those skilled in the art will recognize that the first structure is divalent and can be bonded within the backbone of Formula (Cl) or as depicted in Formula (C2), and that the second structure is monovalent and can be bonded to EG as depicted in formula (Cl) above.
[0394] In certain embodiments, the release trigger group
[0395]
[0396] certain
[0397] embodiments, the release trigger group i
[0398]
[0399] Attorney Docket No.: 108843.00627
[0400] In some embodiments, the release trigger group is a protease-cleavable Ri-Val-X peptide having the structure of:
[0401]
[0402] wherein
[0403]
[0404] (CH2)3NHCONH2; a legumain-cleavable Ala-Ala-Asn or Ala-Ala-Asp peptide having the structure of:
[0405]
[0406] where Z is OH or NH2; or a P-glucuronidase-cleavable 0-glucuronide having the structure of:
[0407]
[0408] or a Val-Lys-Gly peptide having the structure of:
[0409]
[0410] Those of skill will recognize that
[0411]
[0412]
[0413] are divalent structures and can be bonded within theAttorney Docket No.: 108843.00627
[0414] backbone of Formula (Cl) or as depicted in Formula (C2). The structure
[0415]
[0416] monovalent and can be bonded to EG as depicted in formula (Cl) above.
[0417] In certain embodiments, the release trigger is selected from the group consisting of Vai -Lys-Gly, Val-Ala-Asp, Ala-Ala-Ala, Val-Lys, Gly-Gly-Gly, Vai-Ala, Gly-Gly-Phe-Gly, Val-Cit, Val-Cit, Val-Glu, Ala-Ala-Asn, and Gly. In certain embodiments, the release trigger further comprises a non-natural amino acid. In certain embodiments, the non-natural amino
[0418] acid is according t
[0419]
[0420] polymer, for instance a hydrophilic
[0421] polymer. In certain embodiments, the non-natural amino acid is according t
[0422]
[0423] , where ml is an integer from 1 to 25, for instance 8, 9, 10, 11, 12, 13, 14, 15, 20, or 25.
[0424] 3.4 Hydrophilic Groups
[0425] Hydrophilic groups facilitate increasing the hydrophilicity of the compounds described herein. It is believed that increased hydrophilicity allows for greater solubility in aqueous solutions, such as aqueous solutions found in biological systems. Hydrophilic groups can also function as spacer groups, which are described in further detail herein.
[0426] In certain embodiments, the hydrophilic group is designated HP herein. Useful hydrophilic groups include those described herein. In certain embodiments, the hydrophilic group is a divalent poly(ethylene glycol). In certain embodiments, the hydrophilic group is a divalent poly(ethylene glycol) according to the formula:
[0427]
[0428] wherein ml is an integer from 1 to 13, optionally 1 to 4, optionally 2 to 4, or optionally 4 to 8. In certain embodiments, ml is 4. In certain embodiments, ml is 12. In certain embodiments, ml is 13.
[0429] In some embodiments, the hydrophilic group is a divalent polyethylene glycol) having the following formula:
[0430]
[0431] In some other embodiments, the hydrophilic group is a divalent poly(ethylene glycol) having the following formula:Attorney Docket No.: 108843.00627
[0432]
[0433] In other embodiments, the hydrophilic group is a divalent polyethylene glycol) having the following formula:
[0434]
[0435] In other embodiments, the hydrophilic group is a divalent poly(ethylene glycol) having the following formula:
[0436]
[0437] In some embodiments, the hydrophilic group is sulfonic acid. In some embodiments, the hydrophilic group is the side chain of cysteic acid. In some embodiments, the hydrophilic group can bear a chain-presented sulfonic acid having the formula:
[0438]
[0439] In certain embodiments, the hydrophilic group is the side chain of a non-natural amino
[0440] acid according
[0441]
[0442] integer from 1 to 25, for instance 8, 9, 10, 11, 12, 13, 14, 15, 20, or 25.
[0443] 3. 5 Spacer Groups
[0444] Spacer groups facilitate spacing of the conjugating group from the other groups of the compounds described herein. This spacing can lead to more efficient conjugation of the compounds described herein to an antibody as well as more efficient cleavage of the active catabolite. The spacer group can also stabilize the conjugating group and lead to improved overall antibody-drug conjugate properties.
[0445] In certain embodiments, the spacer group is designated SP herein. Useful spacer groups include those described herein. In certain embodiments, the spacer group is:Attorney Docket No.: 108843.00627
[0446]
[0447] In certain embodiments, the spacer group, W4, and the hydrophilic group combine to form a divalent poly(ethylene glycol) according to the formula:
[0448]
[0449] wherein ml is an integer from 1 to 13, optionally 1 to 4, optionally 2 to 4, or optionally 4 to 8.
[0450] In some embodiments, the
[0451]
[0452] In some embodiments, the divalent polyethylene glycol) has the following formula:
[0453]
[0454] In some other embodiments, the divalent poly(ethylene glycol) has the following formula:
[0455]
[0456] In other embodiments, the divalent polyethylene glycol) has the following formula:
[0457]
[0458] In other embodiments, the divalent poly(ethylene glycol) has the following formula:
[0459]
[0460] In some embodiments, the spacer group can bear a chain-presented sulfonic acid having the formula:
[0461]
[0462] In some embodiments, the spacer group is a diamine. In some embodiments, the spacer
[0463] group is according t
[0464]
[0465] Attorney Docket No.: 108843.00627
[0466] In some embodiments, the spacer group comprises fused rings or spiro rings. In some
[0467] embodiments, the spacer group is according to
[0468]
[0469] , where each na, ma, oa, and pais an integer independently selected from 1, 2, 3, 4, and 5. In some embodiments, the spacer
[0470] group is according to
[0471]
[0472] , where each na, ma, oa, and pais an integer independently selected from 1, 2, 3, 4, and 5. In some embodiments, the spacer group is selected from the group consisting of:
[0473]
[0474] 3.6 Conjugating Groups and Residues Thereof
[0475] Conjugating groups facilitate conjugation of the payloads described herein to a second compound, such as an antibody described herein. In certain embodiments, the conjugating group is designated R herein. Conjugating groups can react via any suitable reaction mechanism known to those of skill in the art. In certain embodiments, a conjugating group reacts through a [3+2] alkyne-azide cycloaddition reaction, inverse-electron demand Diels-Alder ligation reaction, thiol-electrophile reaction, or carbonyl-oxyamine reaction, as described in detail herein. In certain embodiments, the conjugating group comprises an alkyne, strained alkyne, tetrazine, thiol, para-acetyl-phenylalanine residue, oxyamine, maleimide, or azide. In certain embodiments, the conjugating group is:Attorney Docket No.: 108843.00627
[0476]
[0477] wherein R201is lower alkyl. In an embodiment, R201is methyl, ethyl, or propyl. In an embodiment, R201is methyl. Additional conjugating groups are described in, for example, U. S. Patent Publication No. 2014 / 0356385, U. S. Patent Publication No. 2013 / 0189287, U. S. Patent Publication No. 2013 / 0251783, U. S. Patent No. 8,703,936, U. S. Patent No. 9,145,361, U. S. Patent No. 9,222,940, and U. S. Patent No. 8,431,558.
[0478] After conjugation, a divalent residue of the conjugating group is formed and is bonded to the residue of an antibody. The structure of the divalent residue is determined by the type of conjugation reaction employed to form the conjugate.
[0479] 3.6.1. [3+2] Alkyne-Azide Cycloaddition Reaction
[0480]
[0481] Advantageously, the compounds described herein comprising a conjugating alkyne group or an azide group facilitate selective and efficient reactions with a second compound comprising a complementary azide group or alkyne group. It is believed the azide and alkyne groups react in a 1,3-dipolar cycloaddition reaction to form a 1,2,3-triazolylene moiety which links the compounds described herein comprising an alkyne group or an azide group to the second compound. This reaction between an azide and alkyne to form a triazole is generally known to those in the art as a Huisgen cycloaddition reaction or a [3+2] alkyne-azide cycloaddition reaction.
[0482] The unique reactivity of azide and alkyne functional groups makes them useful for the selective modification of polypeptides and other biological molecules. Organic azides, particularly aliphatic azides, and alkynes are generally stable toward common reactiveAttorney Docket No.: 108843.00627
[0483] chemical conditions. In particular, both the azide and the alkyne functional groups are inert toward the side chains of the twenty common amino acids found in naturally-occurring polypeptides. It is believed that, when brought into close proximity, the "spring-loaded" nature of the azide and alkyne groups is revealed and azide and alkyne groups react selectively and efficiently via a [3+2] alkyne-azide cycloaddition reaction to generate the corresponding triazole. See, e.g., Chin J., et al., Science 301:964-7 (2003); Wang, Q., et al., J. Am. Chem. Soc.
[0484] 125, 3192-3193 (2003); Chin, J. W., et al., J. Am. Chem. Soc. 124:9026-9027 (2002).
[0485] Because the [3+2] alkyne-azide cycloaddition reaction involves a selective cycloaddition reaction [see, e.g., Padwa, A., in COMPREHENSIVE ORGANIC SYNTHESIS, Vol. 4, (ed. Trost, B. M., 1991), pp. 1069-1109; Huisgen, R. in 1,3-DIPOLAR CYCLOADDITION CHEMISTRY, (ed. Padwa, A., 1984), pp. 1-176] rather than a nucleophilic substitution, the incorporation of non-naturally encoded or modified amino acids bearing azide and alkyne-containing side chains permits the resultant polypeptides to be modified selectively at the position of the non-naturally encoded or modified amino acid.
[0486] Cycloaddition reactions involving azide or alkyne-containing compounds can be carried out at room temperature under aqueous conditions by the addition of Cu(II) (including, but not limited to, catalytic amounts of CuSCU) in the presence of a reducing agent for reducing Cu(II) to Cu(I), in situ, in catalytic amounts. See, e.g., Wang, Q., et al., J. Am. Chem. Soc. 125, 3192-3193 (2003); Tornoe, C. W., et al., J. Org. Chem. 67:3057-3064 (2002); Rostovtsev, et al., Angew. Chem. Int. Ed. 41:2596-2599 (2002). Exemplary reducing agents include, but are not limited to, ascorbate, metallic copper, quinine, hydroquinone, vitamin K, glutathione, cysteine, Fe2+, Co2+, and an applied electric potential.
[0487] In certain embodiments when a conjugate is formed through a [3+2] alkyne-azide cycloaddition reaction, the divalent residue of the reactive group (e.g., RL) comprises a triazole ring or fused cyclic group comprising a triazole ring. In certain embodiments, when a conjugate is formed through a strain-promoted [3+2] alkyne-azide cycloaddition (SPAAC)
[0488] reaction, the divalent residue of the reactive group
[0489]
[0490]
[0491] Attorney Docket No.: 108843.00627
[0492] If a conjugate is formed by a [3+2] alkyne-azide cycloaddition, the conjugate encompasses both regioisomers. In certain embodiments, a conjugate is a mixture of regioisomers formed from a [3+2] alkyne-azide cycloaddition.
[0493] 3.6.2. Inverse Electron Demand Ligation Reaction
[0494]
[0495] Advantageously, compounds comprising a terminal tetrazine or strained alkene group facilitate selective and efficient reactions with a second compound comprising a strained alkene or tetrazine group. It is believed that the tetrazine and strained alkene react in an inverse-demand Diels-Alder reaction followed by a retro-Di els- Alder reaction which links compounds comprising a terminal tetrazine or strained alkene group to the second compound. The reaction is believed to be specific, with little to no cross-reactivity with functional groups within biomolecules. The reaction may be carried out under mild conditions, for example, at room temperature and without a catalyst. This reaction between a tetrazine and a strained alkene is generally known to those in the art as a tetrazine ligation reaction.
[0496] In certain embodiments, when a conjugate is formed through a tetrazine inverse electron demand Diels- Alder ligation reaction, the divalent residue of the reactive group (e.g., RL) comprises a fused bicyclic ring having at least two adjacent nitrogen atoms in the ring. In certain embodiments, when a conjugate is formed through a tetrazine inverse electron demand Diels- Alder ligation reaction, the divalent residue of the reactive group (e.g., RL) is
[0497]
[0498] If a conjugate is formed by an inverse electron demand ligation reaction, the conjugate encompasses both regioisomers. In certain embodiments, a conjugate is a mixture of regioisomers formed from an inverse electron demand ligation reaction.
[0499]
[0500] Attorney Docket No.: 108843.00627
[0501]
[0502] Advantageously, compounds comprising a terminal thiol group or suitable electrophilic or disulfide-forming group facilitate selective and efficient reactions with a second compound comprising a complementary electrophilic or disulfide-forming group or thiol group. These reactions are believed to be selective with little to no cross-reactivity with functional groups within biomolecules. In some embodiments, the thiol reaction does not include reaction of a maleimide group.
[0503] In certain embodiments, when a conjugate is formed through a thiol-maleimide
[0504] reaction, the divalent residue of the reactive group comprises
[0505]
[0506] sulfur linkage. In certain embodiments, when a conjugate is formed through a thiol-maleimide reaction,
[0507]
[0508] , the divalent residue of the reactive group
[0509]
[0510] certain
[0511] embodiments, when a conjugate is formed through a thiol-maleimide reaction,
[0512]
[0513] the divalent residue of the reactive group
[0514]
[0515] In certain embodiments, a conjugate is formed through a thiol-N-hydroxysuccinimide reaction using the following group:
[0516]
[0517] The reaction involved for formation of the conjugate comprises the following step:
[0518]
[0519] Attorney Docket No.: 108843.00627
[0520] and the resulting divalent residue of the reactive group
[0521]
[0522] 3.6.4. Carbonyl-Oxyamine Reaction
[0523]
[0524] Advantageously, compounds comprising a terminal carbonyl or oxyamine group facilitate selective and efficient reactions with a second compound comprising an oxyamine or carbonyl group. It is believed that the carbonyl and oxyamine react to form an oxime linkage. The reaction is believed to be specific, with little to no cross-reactivity with functional groups within biomolecules.
[0525] In certain embodiments when a conjugate is formed through an oxime conjugation reaction, the divalent residue of the reactive group comprises a divalent residue of a nonnatural or modified amino acid. In certain embodiments when a conjugate is formed through an oxime conjugation reaction, the divalent residue of the reactive group (e.g., RL) is
[0526]
[0527] certain embodiments when a conjugate is formed through an oxime conjugation reaction, the divalent residue of the reactive group comprises an oxime linkage. In certain embodiments when a conjugate is formed through an oxime
[0528] conjugation reaction, the divalent residue of the reactive group
[0529]
[0530] 3.6.5. Other Reactions
[0531] Other suitable conjugation reactions are described in the literature. See, for example, Lang, K. and Chin, J. 2014, Bioorthogonal Reactions for Labeling Proteins, ACS Chem Biol 9, 16-20; Paterson, D. M. et al. 2014, Finding the Right (Bioorthogonal) Chemistry, ACS Chem Biol 9, 592-605; King, M. and Wagner, A. 2014, Developments in the Field of Bioorthogonal Bond Forming Reactions - Past and Present Trends, Bioconjugate Chem., 2014, 25 (5), pp 825-839; and Ramil, C. P. and Lin, Q., 2013, Bioorthogonal chemistry: strategies and recent developments, Chem Commun 49, 11007-11022.Attorney Docket No.: 108843.00627
[0532] In an embodiment, provided herein is a conjugate according to Formula (Cl) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof; wherein R comprises a triazole ring. In an embodiment, provided herein is a conjugate according to Formula (Cl) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof; wherein R is a triazole ring or fused cyclic group comprising a triazole ring. In an embodiment, provided herein is a conjugate according to Formula (Cl) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof; wherein R is:
[0533]
[0534] In an embodiment, provided herein is a conjugate according to Formula (Cl) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof; wherein R comprises a fused bicyclic ring having at least two adjacent nitrogen atoms in the ring. In an embodiment, provided herein is a conjugate according to Formula (Cl) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof; wherein R is:
[0535]
[0536] In an embodiment, provided herein is a conjugate according to Formula (Cl) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof; wherein R comprises a sulfur linkage. In an embodiment, provided herein is a conjugate according to Formula (Cl) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof; wherein R is:
[0537]
[0538] In an embodiment, provided herein is a conjugate according to Formula (Cl) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof; wherein R comprises a divalent residue of a non-natural or modified amino acid. In an embodiment, provided herein is a conjugate according to Formula (Cl) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof; wherein R is:Attorney Docket No.: 108843.00627
[0539]
[0540] In an embodiment, provided herein is a conjugate according to Formula (Cl) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof; wherein comprises an amide linkage. In an embodiment, provided herein is a conjugate according to Formula (Cl) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof; wherein R is:
[0541] H° NH
[0542] In an embodiment, provided herein is a conjugate according to Formula (Cl) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof; wherein comprises an oxime linkage. In an embodiment, provided herein is a conjugate according to Formula (Cl) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof; wherein R is:
[0543]
[0544] In an embodiment, provided herein is a conjugate according to Formula (Cl) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof; wherein R is:
[0545]
[0546] Attorney Docket No.: 108843.00627
[0547]
[0548] In an embodiment, provided herein is a compound according to Formula (Cl) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof; wherein COMP is a residue of any compound known to be useful for conjugation to a payload, described herein, and an optional linker, described herein. In an embodiment, provided herein is a compound according to Formula (Cl) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof; wherein COMP is a residue of an antibody chain.Attorney Docket No.: 108843.00627
[0549] Conjugates
[0550] In an embodiment, provided herein is a conjugate according to any of the following formulas, where COMP indicates a residue of the anti-avP6 antibody and PAY indicates a payload moiety:
[0551]
[0552] Attorney Docket No.: 108843.00627
[0553]
[0554] Attorney Docket No.: 108843.00627
[0555]
[0556] Attorney Docket No.: 108843.00627
[0557] In an embodiment, provided herein is a conjugate according to any of the following formulas, where COMP indicates a residue of the anti-avP6 antibody and PAY indicates a payload moiety:
[0558]
[0559] In an embodiment, provided herein is a conjugate according to any of the following formulas, where COMP indicates a residue of the anti-avP6 antibody and PAY indicates a payload moiety:
[0560]
[0561] Attorney Docket No.: 108843.00627
[0562]
[0563] In an embodiment, provided herein is a conjugate according to any of Formulas 101a- 104b, where COMP indicates a residue of the anti-avP6 antibody and PAY indicates a payload moiety:
[0564]
[0565] Attorney Docket No.: 108843.00627
[0566]
[0567] In some embodiments, provided herein are anti-avP6 conjugates comprising a modified hemiasterlin and linker as described, for example, in PCT Publication No. WO 2016 / 123582. For example, the conjugate can have a structure comprising any of Formulas lOOO-lOOOb, 1001 - 100 lb, 1002-1002b, and I-XIXb-2, 101-11 lb, or 1 -8b as described in PCT Publication No. WO 2016 / 123582. Examples of conjugates comprising a modified hemiasterlin and linker are provided below.Attorney Docket No.: 108843.00627
[0568] In some embodiments, provided herein are anti-avP6 conjugates comprising a Amodified P-glucuronide linker as described, for example, in PCT Publication No. WO 2024 / 006272. For example, the conjugate can have a structure comprising any of Formulas 101-114B, 11 la-11 Iff as described in PCT Publication No. WO 2024 / 006272. Examples of conjugates comprising a modified P-glucuronide linker are provided below.
[0569] In some embodiments, provided is a conjugate of Formula (I):
[0570]
[0571] or a pharmaceutically acceptable salt, solvate, stereoisomer, regioisomer, or mixture of regioisomers thereof; wherein
[0572] COMP is a residue of an anti-avP6 antibody provided herein;
[0573] L1is -C1-6 alkylene- optionally substituted with one or more substituents selected from halogen, -CN, -NO2, -OH, -N(R10)2, -C(O)N(R10)2, -C(O)-, -C(S)-, -C(O)OCH2C6H5, -NHC(O)OCH2C6H5, Ci-io alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-12 carbocycle, 3- to 12-membered heterocycle, and Ci-iohaloalkyl;
[0574] Y is -XJ-C1-6 alkylene-fX^Ci-e alkylenejn-CX1^-,
[0575] - X1-C2-6 alkenylene-[X1-C2-6 alkenylenejn-
[0576]
[0577] , or -X1-C2-6 alkynylene-[X1-C2-6 alkynylenejn-, wherein at least one alkylene, alkenylene or alkynylene in Y is substituted with one or more substituents selected from R50; and
[0578] wherein the alkylene, alkenylene, or alkynylene in Y is optionally substituted with one or more substituents selected from R51;
[0579] R50is -C1-6 alkylene-X2-[C1-6 alkylene]m-POLY, -C2-6 alkenylene-X2-[C2-6 alkenylene]m-POLY, or -C2-6 alkynylene-X2-[C2-6 alkynylene]m-POLY, wherein each alkylene, alkenylene or alkynylene of R50is optionally substituted with one or more substituents selected from halogen, -CN, -NO2, -OH, -N(R10)2, -C(O)N(R10)2, -C(O)-, -C(S)-, -C(O)OCH2C6H5, -NHC(O)OCH2C6H5, Ci-io alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-12 carbocycle, 3- to 12-membered heterocycle, and Ci-iohaloalkyl;
[0580] R51is independently selected from halogen, -CN, -NO2, -OH, -N(R10)2, -C(O)N(R10)2, -C(O)-, -C(S)-, -C(O)OCH2C6H5, -NHC(O)OCH2C6H5, CI-IO alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-12 carbocycle, 3- to 12-membered heterocycle, and Ci-iohaloalkyl;
[0581] X1and X2are independently selected from -N(R10)-, -C(O)- and -N(R10)C(O)-;Attorney Docket No.: 108843.00627
[0582] R10is independently selected at each occurrence from hydrogen, Ci-io alkyl, C2-10 alkenyl, C2-ioalkynyl, C3-12 carbocycle, 3- to 12-membered heterocycle, and C1-10 haloalkyl;
[0583] POLY is a monovalent water-soluble polymer;
[0584] n is an integer selected from zero, one, two, and three;
[0585] m is an integer selected from zero and one;
[0586] p is an integer selected from zero and one;
[0587] Su is a hexose form of a monosaccharide;
[0588] D is a drug or payload moiety; and
[0589] RL is a reactive group residue.
[0590] In some embodiments, provided is a conjugate of Formula (IA):
[0591]
[0592] or a pharmaceutically acceptable salt, solvate, stereoisomer, regioisomer, or mixture of regioisomers thereof.
[0593] In some embodiments, provided is a conjugate of Formula (IB):
[0594]
[0595] or a pharmaceutically acceptable salt, solvate, stereoisomer, regioisomer, or mixture of regioisomers thereof.
[0596] In some embodiments, provided is a conjugate of Formula (II):
[0597]
[0598] Attorney Docket No.: 108843.00627
[0599] or a pharmaceutically acceptable salt, solvate, stereoisomer, regioisomer, or mixture of regioisomers thereof; wherein Y is -XJ-C1-6 alkylene-fX^Ci-e alkylenejn-X1-, -XJ-C2-6 alkenylene-[X' -C2-6 alkenylenejn-X1-, or -XJ-C2-6 alkynylene-[X1-C2-6 alkynylenejn-X1-, wherein at least one alkylene, alkenylene or alkynylene in Y is substituted with one or more substituents selected from R50.
[0600] In some embodiments, provided is a conjugate of Formula (III):
[0601]
[0602] Formula (III)
[0603] or a pharmaceutically acceptable salt, solvate, stereoisomer, regioisomer, or mixture of regioisomers thereof;
[0604] each SP1, SP2, and SP3are independently, at each occurrence, absent or a divalent spacer group;
[0605] each W1is independently, at each occurrence, absent
[0606]
[0607] wherein the -NH- is bound to W2;
[0608] L6is independently a bond or an optionally substituted Ci-ealkylene wherein the Ci-ealkylene is optionally substituted with one, two, or three substituents selected from halogen, alkyl, haloalkyl, hydroxyl, amino, alkylamino, and alkoxy;
[0609] each W2is independently, at each occurrence, absent, an amino acid residue, or a peptide residue wherein the amino acid residue or peptide residue is optionally substituted with POLY;
[0610] each HP1, is independently, at each occurrence, absent or a divalent water-soluble polymer;
[0611] each RAis independently, at each occurrence, optionally substituted Ci-ealkyl wherein the Ci-ealkyl is optionally substituted with one, two, or three substituents selected from halogen, alkyl, haloalkyl, hydroxyl, amino, alkylamino, and alkoxy;
[0612] each RT is independently, at each occurrence, absent or a release trigger group;
[0613] y is an integer independently selected from 0, 1, and 2;
[0614] z is an integer independently selected from 0 and 1;Attorney Docket No.: 108843.00627
[0615] al is an integer selected from 1 to 10;
[0616] bl is an integer selected from 1 to 10;
[0617] represents attachment to the remainder of the compound; and
[0618] COMP, L1, Y R50, X1, X2, POLY, n, m, p, Su, RL, and D are as defined herein.
[0619] In some embodiments, provided is a conjugate of Formula (IIIA):
[0620]
[0621] Formula (IIIA)
[0622] or a pharmaceutically acceptable salt, solvate, stereoisomer, regioisomer, or mixture of regioisomers thereof.
[0623] In some embodiments, provided is a conjugate of Formula (IIIB):
[0624]
[0625] Formula (IIIB)
[0626] or a pharmaceutically acceptable salt, solvate, stereoisomer, regioisomer, or mixture of regioisomers thereof.
[0627] In some embodiments, provided is a conjugate of Formula (IIIC):
[0628]
[0629] Formula (IIIC)
[0630] or a pharmaceutically acceptable salt, solvate, stereoisomer, regioisomer, or mixture of regioisomers thereof.
[0631] In certain embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, L1is -C1-6 alkylene-, substituted with one or more substituents selected from halogen, -CN, -NO2, -OH, -N(R10)2, -C(O)N(R10)2, -C(O)-,Attorney Docket No.: 108843.00627
[0632] -C(S)-, -C(O)OCH2C6H5, -NHC(O)OCH2C6H5, CI-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-i2carbocycle, 3- to 12-membered heterocycle, and Ci-iohaloalkyl. In certain embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, L1is unsubstituted -C1-6 alkylene-. In certain embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, L1is -C1-3 alkylene-, optionally substituted with one or more substituents selected from halogen, -CN, -NO2, -OH, -N(R10)2, -C(O)N(R10)2, -C(O)-, -C(S)-, -C(O)OCH2C6H5, -NHC(O)OCH2C6H5, Ci-10 alkyl, C2-10 alkenyl, C2-io alkynyl, C3-i2carbocycle, 3- to 12-membered heterocycle, and C1-10 haloalkyl. In certain embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, L1is -CH2-. In certain embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, L1is -CH2CH2-. In certain embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, L1is -CH2CH2CH2-.
[0633] In some embodiments of Formula (I), (IA), (IB), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, p is 0. In some embodiments of Formula (I), (IA), (IB), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, p is 1.
[0634] In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, Y is -XJ-C1-6 alkylene-pC-Ci-e alkyleneJn-X1-, wherein at least one alkylene in Y is substituted with one or more substituents selected from R50. In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, Y is -XJ-C1-6 alkylene-fX^Ci-e alkylene]n-, wherein at least one alkylene in Y is substituted with one or more substituents selected from R50.
[0635] In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, Y is -X1-C2-6 alkenylene- [X1-C2-6 alkenyleneJn-X1- wherein at least one alkenylene in Y is substituted with one or more substituents selected from R50. In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, Y is -X1-C2-6 alkenylene-[X1-C2-6 alkenylene]n- wherein at least one alkenylene in Y is substituted with one or more substituents selected from R50.
[0636] In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, Y is -X1-C2-6 alkynylene-[X1-C2-6 alkynyleneJn-X1- wherein at least one alkynylene in Y is substituted with one or more substituents selected from R50. In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, Y is -X1-C2-6 alkynylene-[X1-C2-6 alkynylene]n- wherein at least one alkynylene in Y is substituted with one or more substituents selected from R50. In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of theAttorney Docket No.: 108843.00627
[0637] foregoing, n is zero. In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), n is one. In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, n is two. In some embodiments Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, n is three.
[0638] In certain embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, Y is -XJ-Ci-4 alkylene-fX'-C alkyleneJn-X1-, wherein at least one alkylene in Y is substituted with one or more substituents selected from R50. In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, n is zero. In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, n is one. In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, n is two. In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, n is three.
[0639] In certain embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, Y is -XCCi^alkylene-XCCi^alkylene-XCCi^alkylene-XCCi- 4 alkylene-X1-, wherein at least one alkylene in Y is substituted with one or more substituents selected from R50. In certain embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, Y is -XJ-Ci-4 alkylene-X1-Ci- 4 alkylene-X1-Ci- 4 alkylene-X1-, wherein at least one alkylene in Y is substituted with one or more substituents selected from R50. In certain embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, Y is -XJ-C2 alkylene-X1-CH2-X1-C4 alkylene-X1-wherein at least one alkylene in Y is substituted with one or more substituents selected from R50. In certain embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, Y is -X1-C2alkylene-X1-CH(R50)-X1-C4 alkylene-X1-. In certain embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, Y is -X1-C2 alkylene-X1-CH(R50)-X1-C4 alkylene-X1- wherein X1is independently selected from -C(O)- and -N(R10)C(O)-. In certain embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, Y is -NHC(0)-C2 alkylene-NHC(O)-CH(R50)-NHC(O)- alkylene-C(O)-. In certain embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, -I -Y- is -CH2-NHC(O)-C2alkylene-NHC(O)-CH(R50)-NHC(O)-C4alkylene-C(O)-. In certain embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, Y is -X'-Cwalkylene-X'-Cw alkylene-X1-, wherein at least one alkylene in Y is substituted with one or more substituents selected from R50.Attorney Docket No.: 108843.00627
[0640] In certain embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, R50is -C1-6 alkylene-X2-[C1-6 alkylene]m-POLY, wherein each alkylene of R50is optionally substituted with one or more substituents selected from halogen, -CN, -NO2, -OH, -N(R10)2, -C(O)N(R10)2, -C(O)-, -C(S)-, -C(O)OCH2C6H5, -NHC(O)OCH2C6H5, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, Cs-n carbocycle, 3- to 12-membered heterocycle, and Ci-iohaloalkyl. In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, R50is -Ci-4alkylene-X2-[Ci-4 alkylene]m-POLY, wherein each alkylene of R50is optionally substituted with one or more substituents selected from halogen, -CN, -NO2, -OH, -N(R10)2, -C(O)N(R10)2, -C(O)-, -C(S)-, -C(O)OCH2C6H5, -NHC(O)OCH2C6H5, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-12 carbocycle, 3- to 12-membered heterocycle, and Ci-iohaloalkyl. In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, each alkylene of R50is optionally substituted with one or more substituents selected from halogen, -OH, -N(R10)2, -C(O)N(R10)2, -C(O)-, Ci-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-12 carbocycle, 3- to 12-membered heterocycle, and Ci-iohaloalkyl. In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, m is zero. In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, m is one. In certain embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, R50is -C1-6 alkylene-X2-POLY. In certain embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, R50is -CH2-X2-POLY. In certain embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, R50is -CH2-NHC(O)-POLY. In certain embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the
[0641] foregoing, R50is -CH2-NHC(O)-POLY wherein POLY is
[0642]
[0643] and nl is 12.
[0644] In certain embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, Y is-X1-C2alkylene-X1-CH(R50)-X1-C4 alkylene-X1- wherein R50is -CH2-X2-POLY. In certain embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, Y is -NHC(O)-C2alkylene-NHC(O)-CH(R50)-
[0645] NHC(O)-C4alkylene-C(O)- wherein
[0646]
[0647] and nl is 12. In certain embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, -LJ-Y- is -CH2-NHC(O)-C2alkylene-NHC(O)-CH(R50)-Attorney Docket No.: 108843.00627
[0648] NHC(O)-C4alkylene-C(O)- wherein
[0649]
[0650] and nl is 12.
[0651] In certain embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, R50is -C2-6 alkenylene-X2-[C2-6 alkenylene]m-POLY, wherein each alkenylene of R50is optionally substituted with one or more substituents selected from halogen, -CN, -NO2, -OH, -N(R10)2, -C(O)N(R10)2, -C(O)-, -C(S)-, -C(O)OCH2C6H5, -NHC(O)OCH2C6H5, Ci-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-12 carbocycle, 3- to 12-membered heterocycle, and Ci-iohaloalkyl. In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, m is zero. In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, m is one.
[0652] In certain embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, R50is -C2-6 alkynylene-X2-[C2-6 alkynylene]m-POLY, wherein each alkynylene of R50is optionally substituted with one or more substituents selected from halogen, -CN, -NO2, -OH, -N(R10)2, -C(O)N(R10)2, -C(O)-, -C(S)-, -C(O)OCH2C6H5, -NHC(O)OCH2C6H5, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-12 carbocycle, 3- to 12-membered heterocycle, and Ci-iohaloalkyl. In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, m is zero. In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, m is one.
[0653] In certain embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, POLY is polyethylene glycol (PEG), methoxypolyethylene glycol (mPEG), polypropylene glycol) (PPG), copolymers of ethylene glycol and propylene glycol, poly(oxyethylated polyol), poly(olefinic alcohol), poly(vinylpyrrolidone), poly(hydroxyalkylmethacrylamide), poly(hydroxyalkylmethacrylate), poly(saccharides), poly(a -hydroxy acid), poly(vinyl alcohol), polyphosphazene, polyoxazolines (POZ), poly(N-acryloylmorpholine), polysarcosine, or a combination thereof. In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, POLY is polyethylene glycol (PEG). In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, POLY is methoxypolyethylene glycol (mPEG). In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, POLY is polypropylene glycol) (PPG). In some embodiments, POLY is copolymers of ethylene glycol and propylene glycol. In someAttorney Docket No.: 108843.00627
[0654] embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, POLY is poly(oxyethylated polyol). In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, POLY is poly(olefinic alcohol). In some embodiments, POLY is polyvinylpyrrolidone). In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, POLY is poly(hydroxyalkylmethacrylamide). In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, POLY is poly(hydroxyalkylmethacrylate). In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, POLY is poly(saccharides). In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, POLY is poly(a-hydroxy acid). In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, POLY is poly(vinyl alcohol). In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, POLY is polyphosphazene. In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, POLY is polyoxazolines (POZ). In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, POLY is poly(N-acryloylmorpholine). In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, POLY is polysarcosine. In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, POLY is a nonpeptidic, water-soluble polymer. In certain embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, POLY includes a polyethylene glycol (PEG) or methoxypolyethylene glycol (mPEG). In certain embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including
[0655] any of the foregoing, POLY is
[0656]
[0657] wherein
[0658]
[0659] represents attachment to the remainder of the compound, and wherein nl is an integer from one to twenty. In certain embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, nl is an integer between five to fifteen. In certain embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, nl is an integer between ten to fifteen. In certain embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, nl is an integer between eight to fourteen. In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, nl is one. In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, nl is two. In some embodiments of Formula (I), (IA),Attorney Docket No.: 108843.00627
[0660] (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, nl is three. In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, nl is four. In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, nl is five. In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, nl is six. In some embodiment of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), nl is seven. In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, nl is eight. In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, nl is nine. In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, nl is ten. In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, nl is eleven. In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, nl is twelve. In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, nl is thirteen. In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, nl is fourteen. In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, nl is fifteen. In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, nl is sixteen. In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, nl is seventeen. In some embodiments of Formula (I), (II), (IIA), or (IIB), nl is eighteen. In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, nl is nineteen. In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, nl is twenty. In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, nl is twenty-one. In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, nl is twenty-two. In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, nl is twenty-three. In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, nl is twenty-four. In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, nl is twenty-five. In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, nl is twenty-six. In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, nl is twenty-seven. In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, nl is twenty-eight. In some embodiments of FormulaAttorney Docket No.: 108843.00627
[0661] (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, nl is twenty-nine. In some embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), including any of the foregoing, nl is thirty.
[0662] In one aspect, provided herein is a conjugate of Formula (IV):
[0663]
[0664] or a pharmaceutically acceptable salt, solvate, stereoisomer, regioisomer, or mixture of regioisomers thereof; wherein
[0665] COMP is a residue of an anti-avP6 antibody;
[0666]
[0667] Ring A is an optionally substituted bridged, fused, or spirocyclic bicyclic carbocycle, or an optionally substituted bridged, fused, or spirocyclic bicyclic heterocycle, wherein the carbocycle or the heterocycle of Ring A are optionally substituted with one or more substituents selected from alkyl, alkenyl, alkynyl, cycloalkyl, halogen, alkoxy, -CN, -NO2, -OH, -N(R2R3)2, -C(O)-, -C(O)N(R2R3)2, -C(O)OR2, aminoalkyl, hydroxyalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, and heteroaryl alkyl;
[0668] Ring B is an optionally substituted N-linked bridged, fused, or spirocyclic bicyclic heterocycle, wherein Ring B is optionally substituted with one or more substituents selected from alkyl, alkenyl, alkynyl, cycloalkyl, halogen, alkoxy, -CN, -NO2, -OH, -N(R2R3)2, -C(O)-, -C(O)N(R2R3)2, -C(O)OR2, aminoalkyl, hydroxyalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl;
[0669] Raand Rbare independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, halogen, alkoxy, -CN, -NO2, -OH, -N(R2R3)2, -C(O)N(R2R3)2, -C(O)OR2, aminoalkyl, hydroxyalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl;
[0670] a is an integer independently selected from 0, 1, 2, 3, 4, 5, and 6;
[0671] b is an integer selected from 0 or 1;Attorney Docket No.: 108843.00627
[0672] R1is hydrogen or alkyl optionally substituted with one or more substituents selected from cycloalkyl, halogen, alkoxy, -CN, -NO2, -OH, -N(R2R3)2, -C(O)N(R2R3)2, -C(O)OR2, aryl, and heteroaryl;
[0673] R2and R3are independently selected from hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl;
[0674] Yais *-C(O)-(CRaRb)c-NH- or *-C(O)-(CRaRb)c-, wherein * represents where Yais bound to RL;
[0675] c is an integer selected from 1, 2, 3, 4, 5, or 6;
[0676] L2is absent or a linker comprising a hydrophilic polymer residue;
[0677] L3is absent, -C(O)-AA-, -C(O)-AA-Z-(CRaRb)a-Z-(CRaRb)a-C(O)-, -C(O)-Z-(CRaRb)a-C(O)-Z-L4-OC(O)-, -Z-AA-, -AA-, -C(O)-, -C(O)-AA-Z-(CRaRb)a-, -AA-C(O)-, -C(O)-(CRaRb)a-Z-(CRaRb)-Z-AA-C(O)-, -C(O)O-L4-Z-C(O)-(CRaRb)a-Z-C(O)-, -AA-Z-, or-(CRaRb)a-Z-AA-C(O)-;
[0678] Z is selected from -NR2- and -O-;
[0679] AA is an amino acid residue or a peptide residue;
[0680]
[0681] wherein Su is a hexose form of a monosaccharide;
[0682] d is an integer independently selected from 1, 2, and 3;
[0683] RL is a reactive group residue; and
[0684] D is a drug or payload moiety;
[0685]
[0686] attachment to the remainder of the compound.
[0687] Also provided herein is a compound of Formula (IVA):
[0688]
[0689] or a pharmaceutically acceptable salt, solvate, stereoisomer, regioisomer, or mixture of regioisomers thereof; wherein integer c, RL, Ra, Rb, Ring B, L2, L3, D, and COMP are as defined herein.
[0690] In certain embodiments, the compound of Formula (IVA) is selected from the following:Attorney Docket No.: 108843.00627
[0691]
[0692] or a pharmaceutically acceptable salt, solvate, stereoisomer, regioisomer, or mixture of regioisomers thereof.
[0693] Also provided herein is a compound of Formula (IVB):
[0694]
[0695] Attorney Docket No.: 108843.00627
[0696] or a pharmaceutically acceptable salt, solvate, stereoisomer, regioisomer, or mixture of regioisomers thereof; wherein integer c, RL, Ra, Rb, Ring B, L2, L3, D, and COMP are as defined herein.
[0697] In certain embodiments, the compound of Formula (IVB) is selected from the following:
[0698]
[0699] or a pharmaceutically acceptable salt, solvate, stereoisomer, regioisomer, or mixture of regioisomers thereof.
[0700] Also provided is a compound of Formula (IVC):
[0701]
[0702] or a pharmaceutically acceptable salt, solvate, stereoisomer, regioisomer, or mixture of regioisomers thereof; wherein integer a, integer c, RL, Ra, Rb, Ring A, L2, L3, D, and COMP are as defined herein.
[0703] In certain embodiments, the compound of Formula (IVC) is selected from the following:Attorney Docket No.: 108843.00627
[0704]
[0705] or a pharmaceutically acceptable salt, solvate, regioisomer, or mixture of regioisomers thereof.
[0706] Also provided herein is a compound of Formula (IVD):
[0707]
[0708] or a pharmaceutically acceptable salt, solvate, stereoisomer, regioisomer, or mixture of regioisomers thereof; wherein integer a, integer c, RL, Ra, Rb, Ring A, L2, L3, D, and COMP are as defined herein.
[0709] In certain embodiments, the compound of Formula (IVD) is selected from the following:Attorney Docket No.: 108843.00627
[0710]
[0711] or a pharmaceutically acceptable salt, solvate, regioisomer, or mixture of regioisomers thereof.
[0712] Also provided herein is a compound of Formula (IVE):
[0713]
[0714] or a pharmaceutically acceptable salt, solvate, regioisomer, or mixture of regioisomers thereof; wherein integer a, integer c, RL, Ra, Rb, Ring B, L3, POLY2, D, and COMP are as defined herein.
[0715] In certain embodiments, the compound of Formula (IVE) is selected from the following:
[0716]
[0717] Attorney Docket No.: 108843.00627
[0718]
[0719] Attorney Docket No.: 108843.00627
[0720]
[0721] or a pharmaceutically acceptable salt, solvate, regioisomer, or mixture of regioisomers thereof.
[0722] Also provided herein is a compound of Formula (IVF):
[0723]
[0724] or a pharmaceutically acceptable salt, solvate, regioisomer, or mixture of regioisomers thereof; wherein integer a, integer c, RL, Ra, Rb, Ring B, L3, POLY2, D, and COMP are as defined herein.
[0725] In certain embodiments, the compound of Formula (IVF) is selected from the following:
[0726]
[0727] Attorney Docket No.: 108843.00627
[0728]
[0729] or a pharmaceutically acceptable salt and / or regioisomer thereof.
[0730] Also provided herein is a compound of Formula (IVG):
[0731]
[0732] or a pharmaceutically acceptable salt, solvate, regioisomer, or mixture of regioisomers thereof; wherein integer a, integer c, RL, Ra, Rb, Ring A, L3, POLY2, D, and COMP are as defined herein.
[0733] In certain embodiments, the compound of Formula (IVG) is selected from the following:
[0734]
[0735] Attorney Docket No.: 108843.00627
[0736]
[0737] or a pharmaceutically acceptable salt, solvate, regioisomer, or mixture of regioisomers thereof.
[0738] Also provided herein is a compound of Formula (IVH):
[0739]
[0740] Attorney Docket No.: 108843.00627
[0741] or a pharmaceutically acceptable salt, solvate, regioisomer, or mixture of regioisomers thereof; wherein integer a, integer c, RL, Ra, Rb, Ring A, L3, POLY2, D, and COMP are as defined herein.
[0742] In certain embodiments, the compound of Formula (IVH) is selected from the following:
[0743]
[0744] or a pharmaceutically acceptable salt and / or regioisomer thereof.
[0745] In one aspect, provided herein is a conjugate of Formula (V):
[0746]
[0747] or a pharmaceutically acceptable salt, solvate, regioisomer, or mixture of regioisomers thereof; wherein
[0748] L5is a linker comprising an unnatural amino acid; and
[0749] RL, COMP, Ya, L2, L3, and D are as defined herein.
[0750] Also provided herein is a compound of Formula (VA):Attorney Docket No.: 108843.00627
[0751]
[0752] or a pharmaceutically acceptable salt, solvate, regioisomer, or mixture of regioisomers thereof; wherein RL, COMP, Ya, L2, L3, and D are as defined herein.
[0753] Also provided herein is a compound of Formula (VB):
[0754]
[0755] or a pharmaceutically acceptable salt, solvate, regioisomer, or mixture of regioisomers thereof; wherein integer a, integer c, RL, COMP, Ra, Rb, POLY1, AA, and D are as defined herein.
[0756] In certain embodiments, the compound of Formula (VB) is a compound of the formula:
[0757]
[0758] (VB-1)
[0759] or a pharmaceutically acceptable salt, solvate, regioisomer, or mixture of regioisomers thereof.
[0760] Also provided herein is a compound of Formula (VI):
[0761]
[0762] or a pharmaceutically acceptable salt, solvate, regioisomer, or mixture of regioisomers thereof; wherein integer D, SP1, W1, W2, SP2, HP1, SP3, RL, COMP, Ya, Lla, L2, L3, al, and bl are as defined herein.
[0763] Also provided herein is a compound of Formula (VII):
[0764]
[0765] Attorney Docket No.: 108843.00627
[0766] or a pharmaceutically acceptable salt, solvate, regioisomer, or mixture of regioisomers thereof; wherein integer D, SP1, W1, W2, SP2, HP1, SP3, RL, COMP, Ya, L5, L2, L3, al, and bl are as defined herein.
[0767] In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the
[0768]
[0769] of Formula (IV)-(IVH) and (VI), including any of the foregoing,
[0770]
[0771]
[0772] certain embodiments of Formula (IV)-(IVH) and (VI), including any of
[0773]
[0774] of Formula (IV)-(IVH) and (VI), including any of the foregoing,
[0775]
[0776]
[0777] certain embodiments of Formula (IV)-(IVH) and (VI), including any of
[0778]
[0779] Formula (IV)-(IVH) and (VI), including any of the foregoing,
[0780]
[0781]
[0782] certain embodiments of Formula (IV)-(IVH) and (VI), including
[0783] any of the foregoing,
[0784]
[0785] certain embodimentsAttorney Docket No.: 108843.00627
[0786] of Formula (IV)-(IVH) and (VI), including any of the foregoing,
[0787]
[0788]
[0789] certain embodiments of Formula (IV)-(IVH) and (VI), including
[0790] any of the foregoing, L is
[0791]
[0792] In certain embodiments of
[0793] Formula (IV)-(IVH) and (VI), including any of the foregoing, L is
[0794]
[0795] or
[0796]
[0797] . In certain embodiments of Formula (IV)-(IVH) and (VI), including any of
[0798] the foregoing, L is
[0799]
[0800] . In certain embodiments of Formula (IV)-
[0801]
[0802] (IVH) and (VI), including any of the foregoing, L is. In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the foregoing, Llais
[0803]
[0804] In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the
[0805] foregoing, Llais
[0806]
[0807] In certain embodiments of Formula (IV)-(IVH) and (VI),
[0808] including any of the foregoing, Llais
[0809]
[0810] In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the foregoing, Ring B of Llais an optionally substituted 5- to 12- membered N-linked bridged, fused, or spirocyclic bicyclic heterocycle containing 1, 2, or 3 heteroatoms independently selected from N, O, and S including the N to which the ring is attached, wherein Ring B is optionally substituted with one or more substituents selected from alkyl, alkenyl, alkynyl, cycloalkyl, halogen, alkoxy, -CN, -NO2, -OH, -N(R2R3)2, -C(O)-, -C(O)N(R2R3)2, -C(O)OR2, aminoalkyl, hydroxyalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl. In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the foregoing, Ring B of Llais an optionally substituted 5- to 12- membered N-linked spirocyclic bicyclic heterocycleAttorney Docket No.: 108843.00627
[0811] containing 1, 2, or 3 heteroatoms independently selected from N, O, and S including the N to which the ring is attached.
[0812] In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the
[0813] foregoing, Ring B of Llais selected from
[0814]
[0815] ,,, and
[0816]
[0817] wherein mais an integer selected from 1, 2, 3, 4, and 5; and
[0818] each of naand oais an integer independently selected from 1, 2, and 3.
[0819] In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the HOCH
[0820] foregoing, Ring B of Llaisma. In certain embodiments of Formula (IV)-(IVH) and
[0821]
[0822] , In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the
[0823]
[0824] Attorney Docket No.: 108843.00627
[0825]
[0826] ,. In certain embodiments of Formula (IV)-(IVH) and
[0827]
[0828]
[0829] , In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the
[0830] foregoing, Ring B of Llais
[0831]
[0832] . In certain embodiments of Formula (IV)-(IVH) and
[0833] (VI),
[0834]
[0835] wherein mais 1, 2, or 3. In certain embodiments of
[0836] Formula
[0837]
[0838] wherein mais 1, 2, or 3. In
[0839] certain embodiments of Formula (IV)-(IVH) and (VI),
[0840]
[0841] wherein mais 1, 2, or 3. In certain embodiments of Formula (IV)-(IVH) and (VI),
[0842]
[0843] wherein mais 1, 2, or 3.
[0844]
[0845] Attorney Docket No.: 108843.00627
[0846] certain embodiments of Formula (IV)-(IVH) and (VI),
[0847]
[0848]
[0849] In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the
[0850] foregoing, Ring B of Llais
[0851]
[0852] . In certain embodiments of Formula (IV)-(IVH) and
[0853] (VI),
[0854]
[0855] wherein mais 1, 2, or 3. In certain embodiments of
[0856] Formula
[0857]
[0858] wherein mais 1, 2, or 3. In
[0859] certain embodiments of Formula (IV)-(IVH) and (VI),
[0860]
[0861] wherein mais 1, 2, or 3. In certain embodiments of Formula (IV)-(IVH) and (VI),
[0862]
[0863] wherein mais 1, 2, or 3.
[0864]
[0865] Attorney Docket No.: 108843.00627
[0866] In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the
[0867]
[0868] In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the
[0869]
[0870] In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the
[0871]
[0872] In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the
[0873] foregoing, Llais selected from
[0874]
[0875] wherein mais an integer selected from 1, 2, 3, 4, and 5; and
[0876] each of naand oais an integer independently selected from 1, 2, and 3.
[0877] In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the
[0878]
[0879] In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the foregoing, Ring B of Llais selected fromAttorney Docket No.: 108843.00627
[0880]
[0881] wherein Xla, X2a, X3, and X4are independently selected from -C(R4)2-, -NH-, -O-, and -S- wherein when Xla, X2a, and X3are present, at least one of Xla-X3is -C(R4)2- and when Xla, X2a, X3, and X4are present, at least two of Xla-X4are -C(R4)2-; and
[0882] R4is independently selected from hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-12 cycloalkyl, halogen, alkoxy, -CN, -NO2, -OH, -N(R2R3)2, -C(O)N(R2R3)2, -C(O)OR2, aminoalkyl, hydroxyalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl; or two R4groups on the same carbon are taken together to form an oxo group
[0883] In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the
[0884]
[0885] wherein Xla, X2a, X3, and X4are independently selected from -C(R4)2-, -NH-, -O-, and -S- wherein when Xla, X2a, and X3are present, at least one of Xla-X3is -C(R4)2- and when Xla, X2a, X3, and X4are present, at least two of Xla-X4are -C(R4)2-; and
[0886] R4is independently selected from hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-12 cycloalkyl, halogen, alkoxy, -CN, -NO2, -OH, -N(R2R3)2, -C(O)N(R2R3)2, -C(O)OR2, aminoalkyl, hydroxyalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl; or two R4groups on the same carbon are taken together to form an oxo group.
[0887] In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the foregoing, Ring A of Llais an optionally substituted bridged, fused, or spirocyclic bicyclicAttorney Docket No.: 108843.00627
[0888] carbocycle, wherein the carbocycle or the heterocycle of Ring A are optionally substituted with one or more substituents selected from alkyl, alkenyl, alkynyl, cycloalkyl, halogen, alkoxy, -CN, -NO2, -OH, -N(R2R3)2, -C(O)-, -C(O)N(R2R3)2, -C(O)OR2, aminoalkyl, hydroxyalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl. In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the foregoing, Ring A of Llais an optionally substituted C4-12 bridged, fused, or spirocyclic bicyclic carbocycle. In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the foregoing, Ring A of Llais an optionally substituted C4-12 bridged bicyclic carbocycle. In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the foregoing, Ring A of Llais an optionally substituted C4-8 bridged bicyclic carbocycle.
[0889] In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the
[0890] foregoing, Ring A of Llais selected from
[0891]
[0892]
[0893] wherein Xla, X2a, X3, and X4are independently selected from -C(R4)2-, -NH-, -O-, and -S- wherein when Xla, X2a, and X3are present, at least one of Xla-X3is -C(R4)2- and when Xla, X2a, X3, and X4are present, at least two of Xla-X4are -C(R4)2-;
[0894] X5is CR4or N; and
[0895] R4is independently selected from hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-12 cycloalkyl, halogen, alkoxy, -CN, -NO2, -OH, -N(R2R3)2, -C(O)N(R2R3)2, -C(O)OR2, aminoalkyl, hydroxyalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl; or two R4groups on the same carbon are taken together to form an oxo group.Attorney Docket No.: 108843.00627 In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the
[0896]
[0897] In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the
[0898]
[0899] In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the
[0900]
[0901] Attorney Docket No.: 108843.00627
[0902] In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the
[0903] foregoing, Ring A of Llais selected from
[0904]
[0905]
[0906] In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the
[0907] foregoing, Ring
[0908]
[0909] certain embodiments of Formula (IV)-(IVH) and
[0910] (VI), including any of the foregoing, Ring
[0911]
[0912] In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the foregoing, Xla, X2a, X3, and / or X4is -C(R4)2-. In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the foregoing, Xlaand X2aare -C(R4)2-. In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the foregoing, Xla, X2a, and X3are -C(R4)2-. In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the foregoing, Xla, X2a, X3, and X4are -C(R4)2-. In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the foregoing, Xlais -NH-. In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the foregoing, X2ais NH-. In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the foregoing, X3is -NH-. In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the foregoing, X4is NH-. In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the foregoing, Xlais -O-. In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the foregoing, X2ais -O-. In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the foregoing, X3is -O-. InAttorney Docket No.: 108843.00627
[0913] certain embodiments of Formula (IV)-(IVH) and (VI), including any of the foregoing, X4is -O-.
[0914] In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the
[0915] foregoing,
[0916]
[0917] certain
[0918] embodiments,
[0919]
[0920] In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the foregoing, a in Lalis 0. In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the foregoing, a in Lalis 1. In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the foregoing, a in Lalis 2. In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the foregoing, a in Lalis 3. In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the foregoing, a in Lalis 4. In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the foregoing, a in Lalis 5. In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the foregoing, a in Lalis 6. In certain embodiments of Formula (IV)-(IVH) and (VI), b in Lalis 0. In certain embodiments of Formula (IV)-(IVH) and (VI), b in Lalis 1.
[0921] In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the foregoing, b is 0 and a is 0 in Lal. In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the foregoing, b is 0 and a is 1 in Lal. In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the foregoing, b is 0 and a is 2 in Lal. In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the foregoing, b is 0 and a is 3 in Lal. In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the foregoing, b is 0 and a is 4 in Lal. In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the foregoing, b is 0 and a is 5 in Lal. In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the foregoing, b is 0 and a is 6 in Lal. In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the foregoing, b is 1 and a is 1 in Lal. In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the foregoing, b is 1 and a is 2 in Lal. In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the foregoing, b is 1 and a is 3 in Lal. In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the foregoing, b is 1 and a is 4 in Lal. In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the foregoing, b is 1 and a is 5 in Lal. In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the foregoing, b is 1 and a is 6 in Lal.Attorney Docket No.: 108843.00627
[0922] In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the foregoing, R1is hydrogen. In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the foregoing, R1is unsubstituted alkyl. In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the foregoing, R1is methyl. In certain embodiments of Formula (IV)-(IVH) and (VI), including any of the foregoing, R1is alkyl optionally substituted with one or more substituent selected from cycloalkyl, halogen, alkoxy, -CN, -NO2, and -OH.
[0923] In certain embodiments of Formula (V)-(VB-l) and (VII), L5is a linker that comprises at least one amino acid selected from sulfoalanine, hydroxyproline (Hyp), beta-alanine, citrulline (Cit), ornithine (Om), norleucine (Nle), 3 -nitrotyrosine, nitroarginine, pyroglutamic acid (Pyr), naphtylalanine (Nal), 2,4-diaminobutyric acid (DAB), methionine sulfoxide, and methionine sulfone. In certain embodiments of Formula (V)-(VB-l) and (VII), L5is a linker
[0924] that comprises
[0925]
[0926] In certain embodiments of Formula (V)-(VB-l) and (VII), L5is a
[0927] linker that comprises
[0928]
[0929] In certain embodiments of Formula (V)-(VB-l) and (VII),
[0930] certain embodiments of Formula (V)-(VB-l) and (VII), L5is
[0931]
[0932] In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Rais hydrogen and Rbis independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, halogen, alkoxy, -CN, -NO2, -OH, -N(R2R3)2, -C(O)N(R2R3)2, -C(O)OR2, aminoalkyl, hydroxyalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Rais hydrogen and Rbis independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, halogen, alkoxy, -CN, -NO2, -OH, -NH2, -C(O)NH2, -C(O)OH, aminoalkyl, hydroxyalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, and heteroaryl alkyl. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Rais hydrogen and Rbis independently selected from hydrogen, alkyl, halogen, alkoxy, -CN, -NO2, -OH, -NH2, -C(O)NH2, and -C(O)OH. In certainAttorney Docket No.: 108843.00627
[0933] embodiments of Formula (IV)-(VII), including any of the foregoing, Raand Rbare both hydrogen.
[0934] In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Rais hydrogen; Rbis independently selected from hydrogen, alkyl, halogen, alkoxy, -CN, -NO2, -OH, -NH2, -C(O)NH2, and -C(O)OH; R1is hydrogen; a in Lalis 1; and b in Lalis 1. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Rais hydrogen; Rbis independently selected from hydrogen, alkyl, halogen, alkoxy, -CN, -NO2, -OH, -NH2, -C(O)NH2, and -C(O)OH; R1is hydrogen; a in Lalis 2; and b in Lalis 1. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Rais hydrogen; Rbis independently selected from hydrogen, alkyl, halogen, alkoxy, -CN, -NO2, -OH, -NH2, -C(O)NH2, and -C(O)OH; R1is hydrogen; a in Lalis 3; and b in Lalis 1.
[0935] In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Rais hydrogen; Rbis independently selected from hydrogen, alkyl, halogen, alkoxy, -CN, -NO2, -OH, -NH2, -C(O)NH2, and -C(O)OH; a in Lalis 1; and b in Lalis 0. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Rais hydrogen; Rbis independently selected from hydrogen, alkyl, halogen, alkoxy, -CN, -NO2, -OH, -NH2, -C(O)NH2, and -C(O)OH; a in Lalis 2, and b in Lalis 0. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Rais hydrogen; Rbis independently selected from hydrogen, alkyl, halogen, alkoxy, -CN, -NO2, -OH, -NH2, -C(O)NH2, and -C(O)OH; a in Lalis 3, and b in Lalis 0.
[0936] In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Rais hydrogen; Rbis independently selected from hydrogen, alkyl, halogen, alkoxy, -CN, -NO2, -OH, -NH2, -C(O)NH2, and -C(O)OH; R1is methyl; a in Lalis 1; and b in Lalis 1. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Rais hydrogen; Rbis independently selected from hydrogen, alkyl, halogen, alkoxy, -CN, -NO2, -OH, -NH2, -C(O)NH2, and -C(O)OH; R1is methyl; a in Lalis 2; and b in Lalis 1. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Rais hydrogen; Rbis independently selected from hydrogen, alkyl, halogen, alkoxy, -CN, -NO2, -OH, -NH2, -C(O)NH2, and -C(O)OH; R1is methyl; a in Lalis 3, and b in Lalis 1.
[0937] In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Raand Rbare both hydrogen; R1is hydrogen; a in Lalis 1, and b in Lalis 1. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Raand Rbare both hydrogen; R1is hydrogen; a in Lalis 2, and b in Lalis 1. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Raand Rbare both hydrogen; R1is hydrogen; a in Lalis 3, and b in Lalis 1. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, RaAttorney Docket No.: 108843.00627
[0938] and Rbare both hydrogen; R1is hydrogen; a in Lalis 4, and b in Lalis 1. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Raand Rbare both hydrogen; R1is hydrogen; a in Lalis 5, and b in Lalis 1. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Raand Rbare both hydrogen; R1is hydrogen; a in Lalis 6, and b in Lalis 1.
[0939] In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Raand Rbare both hydrogen; a is 1; and b is 0. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Raand Rbare both hydrogen; a in Lalis 2; and b in Lalis 0. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Raand Rbare both hydrogen; a in Lalis 3; and b in Lalis 0. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Raand Rbare both hydrogen; a in Lalis 4; and b in Lalis 0. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Raand Rbare both hydrogen; a in Lalis 5; and b in Lalis 0. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Raand Rbare both hydrogen; a in Lalis 6; and b in Lalis 0.
[0940] In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Raand Rbare both hydrogen; R1is methyl; a in Lalis 1; and b in Lalis 0. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Raand Rbare both hydrogen; R1is methyl; a in Lalis 2; and b in Lalis 0. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Raand Rbare both hydrogen; R1is methyl; a in Lalis 3; and b in Lalis 0. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Raand Rbare both hydrogen; R1is methyl; a in Lalis 4; and b in Lalis 0. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Raand Rbare both hydrogen; R1is methyl; a in Lalis 5; and b in Lalis 0. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Raand Rbare both hydrogen; R1is methyl; a in Lalis 6; and b in Lalis 0.
[0941] In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Rais hydrogen; Rbis independently selected from hydrogen, alkyl, halogen, alkoxy, -CN, -NO2, -OH, -NH2, -C(O)NH2, and -C(O)OH; a in Lalis 1; and c in Lalis 1. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Rais hydrogen; Rbis independently selected from hydrogen, alkyl, halogen, alkoxy, -CN, -NO2, -OH, -NH2, -C(O)NH2, and -C(O)OH; a in Lalis 2; and c in Lalis 1. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Rais hydrogen; Rbis selected from hydrogen, alkyl, halogen, alkoxy, -CN, -NO2, -OH, -NH2, -C(O)NH2, and -C(O)OH; a in Lalis 3; and c in Lalis 1.
[0942] In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Yais *-C(O)-(CRaRb)c-NH- wherein * represents where Yais bound to RL. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Yais *-C(O)-(CH2)c-NH-. In certainAttorney Docket No.: 108843.00627
[0943] embodiments of Formula (IV)-(VII), including any of the foregoing, Yais *-C(0)-(CH2)-NH-. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Yais *-C(O)-(CH2)2-NH-. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Yais *-C(O)-(CH2)3-NH-. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Yais *-C(O)-(CH2)4-NH-. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Yais *-C(O)-(CH2)5-NH-. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Yais *-C(O)-(CH2)6-NH-.
[0944] In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Yais *-C(O)-(CRaRb)-NH-. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Yais *-C(0)-(CRaRb)2-NH-. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Yais *-C(0)-(CRaRb)3-NH-. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Yais *-C(0)-(CRaRb)4-NH-. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Yais *-C(O)-(CRaRb)s-NH-. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Yais *-C(O)-(CRaRb)6-NH-.
[0945] In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Yais *-C(O)-(CRaRb)c-NH- wherein Rais hydrogen and Rbis selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, halogen, alkoxy, -CN, -NO2, -OH, -N(R2R3)2, -C(O)N(R2R3)2, -C(O)OR2, aminoalkyl, hydroxyalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Yais *-C(O)-(CRaRb)2-NH-, *-C(O)-(CRaRb)3-NH-, or *-C(O)-(CRaRb)4-NH- wherein Rais hydrogen and Rbis selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, halogen, alkoxy, -CN, -NO2, -OH, -N(R2R3)2, -C(O)N(R2R3)2, -C(O)OR2, aminoalkyl, hydroxyalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl.
[0946] In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Yais *-C(O)-(CRaRb)c- wherein * represents where Yais bound to RL. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Yais *-C(O)-(CH2)c-. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Yais *-C(0)-(CH2)-. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Yais *-C(O)-(CH2)2-. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Yais *-C(O)-(CH2)3-. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Yais *-C(O)-(CH2)4-. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Yais *-C(O)-(CH2)s-. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Yais *-C(O)-(CH2)e-.Attorney Docket No.: 108843.00627
[0947] In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Yais *-C(O)-(CRaRb)-. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Yais *-C(0)-(CRaRb)2-. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Yais *-C(0)-(CRaRb)3-. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Yais *-C(0)-(CRaRb)4-. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Yais *-C(O)-(CRaRb)s-. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Yais *-C(O)-(CRaRb)e-.
[0948] In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Yais *-C(O)-(CRaRb)c- wherein Rais hydrogen and Rbis selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, halogen, alkoxy, -CN, -NO2, -OH, -N(R2R3)2, -C(O)N(R2R3)2, -C(O)OR2, aminoalkyl, hydroxyalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Yais *-C(O)-(CRaRb)2-, *-C(O)-(CRaRb)3-, or *-C(O)-(CRaRb)4- wherein Rais hydrogen and Rbis selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, halogen,
[0949] alkoxy, -CN, -NO2, -OH, -N(R2R3)2, -C(O)N(R2R3)2, -C(O)OR2, aminoalkyl, hydroxyalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl.
[0950] In certain embodiments of Formula (IV)-(VII), including any of the foregoing, Yais *-C(O)-(CH2)2-NH- or *-C(O)-(CH2)4-.
[0951] In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L2is absent. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L2is a linker comprising a hydrophilic polymer residue.
[0952] In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L2is -(CRaRb)a-POLY1-. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L2is -CH2-POLY1-. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L2is -(C^^-POLY1-. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L2is -(CH2)3-POLY1-. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L2is -(CH2)4-POLY1-. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L2is -(C^s-POLY1-. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L2is -(C^e-POLY1-. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L2is -CRaRb-POLY1-. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L2is -(CRaRb)2-P0LY1-. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L2is -(CRaRb)3-P0LY1-. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L2is -
[0953]
[0954] 4-POLY'- In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L2is -POLY1-.Attorney Docket No.: 108843.00627
[0955] In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L2is -(CRaRb)a-POLY1-(CRaRb)a-. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L2is -(CRaRb)a-POLY1-(CRaRb)a- wherein a is independently selected from 0, 1, 2, 3, 4, 5, or 6. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L2is -(CH2)a-POLY1-(CH2)a- wherein a is independently selected from 0, 1, 2, 3, 4, 5, or 6. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L2is -(CH2)a-POLY1-(CRaRb)a- wherein a is selected from 1, 2, 3, 4, 5, or 6. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L2is -(CRaRb)a-POLY1-(CH2)a- wherein a is independently selected from 0, 1, 2, 3, 4, 5, or 6.
[0956] In certain embodiments of Formula (IV)-(VII), including any of the foregoing, POLY1is a diavalent residue of a nonpeptidic, hydrophilic polymer. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, POLY1is a diavalent residue of polyethylene glycol (PEG), polypropylene glycol) (PPG), copolymers of ethylene glycol and propylene glycol, poly(oxyethylated polyol), poly(olefinic alcohol), poly(vinylpyrrolidone), poly(hydroxyalkylmethacrylamide), poly(hydroxyalkylmethacrylate), poly(saccharides), poly(a -hydroxy acid), poly(vinyl alcohol), polyphosphazene, polyoxazolines (POZ), poly(7V-acryloylmorpholine), polysarcosine, or a combination thereof. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, POLY1is a divalent residue of polyethylene glycol (PEG), polypropylene glycol) (PPG), or a copolymer of ethylene glycol and propylene glycol.
[0957] In certain embodiments of Formula (IV)-(VII), including any of the foregoing, POLY1is a diaval ent residue of polyethylene glycol (PEG). In certain embodiments of Formula (IV)-(VII), including any of the foregoing, POLY1is a diavalent residue of polypropylene glycol) (PPG). In certain embodiments of Formula (IV)-(VII), including any of the foregoing, POLY1is a diavalent residue of copolymers of ethylene glycol and propylene glycol. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, including any of the foregoing, POLY1is a diavalent residue of polypxyethylated polyol). In certain embodiments of Formula (IV)-(VII), including any of the foregoing, POLY1is a diaval ent residue of polyplefmic alcohol). In certain embodiments of Formula (IV)-(VII), including any of the foregoing, POLY1is a diavalent residue of poly(vinylpyrrolidone). In certain embodiments of Formula (IV)-(VII), including any of the foregoing, POLY1is a diavalent residue of poly(hydroxyalkylmethacrylamide). In certain embodiments of Formula (IV)-(VII), including any of the foregoing, POLY1is a diavalent residue of poly(hydroxyalkylmethacrylate). In certain embodiments of Formula (IV)-(VII), including any of the foregoing, POLY1is a diavalent residue of poly(saccharides). In certain embodiments of Formula (IV)-(VII),Attorney Docket No.: 108843.00627
[0958] including any of the foregoing, POLY1is a diavalent residue of poly(a-hydroxy acid). In certain embodiments of Formula (IV)-(VII), including any of the foregoing, POLY1is a diavalent residue of poly(vinyl alcohol). In certain embodiments of Formula (IV)-(VII), including any of the foregoing, POLY1is a diavalent residue of polyphosphazene. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, POLY1is a diaval ent residue of polyoxazolines (POZ). In certain embodiments of Formula (IV)-(VII), including any of the foregoing, POLY1is a diavalent residue of poly(7V-acryloylmorpholine). In certain embodiments of Formula (IV)-(VII), including any of the foregoing, POLY1is a diaval ent residue of poly sarcosine.
[0959] In certain embodiments of Formula (IV)-(VII), including any of the foregoing, POLY1
[0960]
[0961] wherein R5is hydrogen or methyl, x is an integer from 1 to 100, inclusive, and represents attachment to the remainder of the conjugate. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, x is an integer between 1 to 25. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, x is an integer between 5 to 15. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, x is 1. In some embodiments of Formula (III)-(IVB), including any of the foregoing, x is 2. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, x is 3. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, x is 4. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, x is 5. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, x is 6. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, x is 7. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, x is 8. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, x is 9. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, x is 10. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, x is 11. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, x is 12. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, x is 13. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, x is 14. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, x is 15. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, x is 16. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, x is 17. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, x is 18. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, x is 19. In certainAttorney Docket No.: 108843.00627
[0962] embodiments of Formula (IV)-(VII), including any of the foregoing, x is 20. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, x is an integer between 25 and 50. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, x is an integer between 35 and 45. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, x is an integer between 50 and 75. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, x is an integer between 55 and 65. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, x is an integer between 75 and 100. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, x is an integer between 85 and 95. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, x is an integer in the range of 1 and 25, 20 and 45, 40 and 65, 60 and 85, 70 and 95, or 75 and 100.
[0963] In certain embodiments of Formula (IV)-(VII), including any of the foregoing, R5is hydrogen. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, R5is methyl.
[0964] In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L2is
[0965] -(CRaRb)a-POLY1- wherein POLY1is
[0966]
[0967] . In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L2is -(CRaRb)a-POLY1- wherein POLY1is
[0968]
[0969] . In certain embodiments of Formula (IV)-(VII), including any of the foregoing,
[0970] L2is -(CH2)a-POLY1- wherein POLY1is
[0971]
[0972] . In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L2is -(CPF)?- POLY1- wherein POLY1is
[0973]
[0974] . In certain embodiments of Formula (IV)-(VII), including any of the foregoing,
[0975] L2is -(CRaRb)a-POLY1- wherein
[0976]
[0977] certain embodiments of Formula (IV)-(VII), including any of the foregoing, L2is -(CRaRb)a-POLY1- wherein POLY1
[0978]
[0979] certain embodiments of Formula (IV)-(VII), including any of theAttorney Docket No.: 108843.00627
[0980] foregoing, L2is -(CFL^-POLY1- wherein
[0981]
[0982] certain embodiments of Formula (IV)-(VII), including any of the foregoing, L2is -(CFL^-POLY1- wherein POLY1
[0983]
[0984] certain embodiments of Formula (IV)-(VII), including any of the
[0985] foregoing, L2is -(CFL^-POLY1- wherein
[0986]
[0987] In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L2is
[0988]
[0989] . In certain embodiments of Formula (IV)-(VII), including any of the foregoing,
[0990] L2i
[0991]
[0992] . In certain embodiments of Formula (IV)-(VII), including any of the
[0993] foregoing,
[0994]
[0995] certain embodiments of Formula (IV)-(VII), including any
[0996] of the foregoing,
[0997]
[0998] certain embodiments of Formula (IV)-(VII), including any of the foregoing, L2is -(CRaRb)a-POLY1-(CRaRb)a- wherein POLY1is
[0999]
[1000] ,
[1001] foregoing, L2is -(CRaRb)a-POLY1-(CRaRb)a- wherein
[1002]
[1003] Attorney Docket No.: 108843.00627 In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L2is
[1004]
[1005] In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L2is
[1006]
[1007] , foregoing,
[1008]
[1009] certain embodiments of Formula (IV)-(VII), including any of the foregoing,
[1010]
[1011] certain embodiments of Formula (IV)-(VII), including any of the foregoing,
[1012]
[1013] Attorney Docket No.: 108843.00627
[1014] In certain embodiments of Formula (IV)-(VII), including any of the foregoing, POLY2is a residue of a nonpeptidic, hydrophilic polymer. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, POLY2is a residue of polyethylene glycol (PEG), methoxypolyethylene glycol (mPEG), poly (propylene glycol) (PPG), copolymers of ethylene glycol and propylene glycol, poly(oxyethylated polyol), poly(olefinic alcohol), poly(vinylpyrrolidone), poly(hydroxyalkylmethacrylamide), poly(hydroxyalkylmethacrylate), poly(saccharides), poly(a-hydroxy acid), poly(vinyl alcohol), polyphosphazene, polyoxazolines (POZ), poly(V-acryloylmorpholine), polysarcosine, or a combination thereof. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, POLY2is a residue of polyethylene glycol (PEG), methoxypolyethylene glycol (mPEG), polypropylene glycol) (PPG), or a copolymer of ethylene glycol and propylene glycol. In certain embodiments of Formula (IV)-(VII), including any of the foregoing g, POLY2is a residue of methoxypolyethylene glycol (mPEG).
[1015] In certain embodiments of Formula (IV)-(VII), including any of the foregoing, POLY2is a residue of polyethylene glycol (PEG). In certain embodiments of Formula (IV)-(VII), including any of the foregoing, POLY2is a residue of polypropylene glycol) (PPG). In certain embodiments of Formula (IV)-(VII), including any of the foregoing, POLY2is a residue of copolymers of ethylene glycol and propylene glycol. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, POLY2is a residue of polypxyethylated polyol). In certain embodiments of Formula (IV)-(VII), including any of the foregoing, POLY2is a residue of polypi efinic alcohol). In certain embodiments of Formula (IV)-(VII), including any of the foregoing, POLY2is a residue of poly(vinylpyrrolidone). In certain embodiments of Formula (IV)-(VII), including any of the foregoing, POLY2is a residue of poly(hydroxyalkylmethacrylamide). In certain embodiments of Formula (IV)-(VII), including any of the foregoing, POLY2is a residue of poly(hydroxyalkylmethacrylate). In certain embodiments of Formula (IV)-(VII), including any of the foregoing, POLY2is a residue of poly(saccharides). In certain embodiments of Formula (IV)-(VII), including any of the foregoing, POLY2is a residue of poly(a-hydroxy acid). In certain embodiments of Formula (IV)-(VII), including any of the foregoing, POLY2is a residue of poly(vinyl alcohol). In certain embodiments of Formula (IV)-(VII), including any of the foregoing, POLY2is a residue of polyphosphazene. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, POLY2is a residue of polyoxazolines (POZ). In certain embodiments of Formula (IV)-(VII), including any of the foregoing, POLY2is a residue of poly(V-acryloylmorpholine). In certain embodiments of Formula (IV)-(VII), including any of the foregoing, POLY2is a residue of polysarcosine.Attorney Docket No.: 108843.00627
[1016] In certain embodiments of Formula (IV)-(VII), including any of the foregoing, POLY2
[1017]
[1018] inclusive, and represents attachment to the remainder of the conjugate. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, x is an integer between 1 to 25. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, x is an integer between 5 to 15. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, x is 1. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, x is 2. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, x is 3 In certain embodiments of Formula (IV)-(VII), including any of the foregoing, x is 4. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, x is 5. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, x is 6. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, x is 7. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, x is 8. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, x is 9. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, x is 10. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, x is 11. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, x is 12. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, x is 13. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, x is 14. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, x is 15. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, x is 16. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, x is 17. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, x is 18. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, x is 19. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, x is 20. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, x is an integer between 25 and 50. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, x is an integer between 35 and 45. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, x is an integer between 50 and 75. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, x is an integer between 55 and 65. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, x is an integer between 75 and 100. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, x is an integer between 85 and 95. In certain embodiments ofAttorney Docket No.: 108843.00627
[1019] Formula (IV)-(VII), including any of the foregoing, x is an integer in the range of 1 and 25, 20 and 45, 40 and 65, 60 and 85, 70 and 95, or 75 and 100.
[1020] In certain embodiments of Formula (IV)-(VII), including any of the foregoing, R5is hydrogen. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, R5is methyl.
[1021] In certain embodiments of Formula (IV)-(VII), including any of the foregoing, including any of the foregoing, L2is selected from the group consisting of
[1022]
[1023] In certain embodiments of Formula (IV)-(VII), including any of the foregoing, including any of the foregoing, L2is selected from the group consisting of
[1024]
[1025] Attorney Docket No.: 108843.00627
[1026]
[1027] In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L2is
[1028]
[1029] In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L2is
[1030]
[1031] In certain embodiments of Formula (IV)-(VII), including any of
[1032] the foregoing,
[1033]
[1034] In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L3is -C(O)-AA-.
[1035] In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L3is -C(O)-AA-Z-(CRaRb)a-Z-(CRaRb)a-C(O)-. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L3is -C(O)-AA-NR2-(CRaRb)a-NR2-(CRaRb)a-C(O)-. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L3is -C(O)-AA-NH-Attorney Docket No.: 108843.00627
[1036] (CRaRb)a-NH-(CRaRb)a-C(O)-. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L3is -C(O)-AA-NH-(CH2)a-NH-(CH2)a-C(O)-. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L3is -C(O)-AA-NH-(CH2)a-NH-(CH2)a-C(O)- wherein a is selected from 1, 2, and 3. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L3is -C(O)-AA-NH-CH2-NH-CH2-C(O)- In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L3is -C(O)-AA-Z-(CRaRb)a. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L3is -C(O)-AA-NR2-(CH2)a. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L3is -C(O)-AA-NH-(CH2)2.
[1037] In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L3is -AA-. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L3is
[1038]
[1039] In certain embodiments of Formula (IV)-(VII), including any of the foregoing, -AA-is an amino acid residue. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, -AA-is a peptide residue. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, -AA- is a dipeptide residue, a tripeptide residue, a tetrapeptide residue, or a pentapeptide residue. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, -AA- comprises at least one amino acid residue selected from alanine, glycine, valine, and asparagine. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, -AA- comprises at least one amino acid residue selected from alanine and glycine. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, -AA- is
[1040]
[1041] Attorney Docket No.: 108843.00627
[1042]
[1043] In certain embodiments of Formula (IV)-(VII), including any of the foregoing,
[1044] -AA- is selected from the group consisting
[1045]
[1046]
[1047] In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L3is - C(O)-.
[1048] In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L3is -
[1049] C(O)-Z-(CRaRb)a-C(O)-Z-L4-OC(O)- wherein
[1050]
[1051] hexose form of a monosaccharide and d is an integer independently selected from 1, 2, and 3. InAttorney Docket No.: 108843.00627
[1052] certain embodiments of Formula (IV)-(VII), including any of the foregoing, L3is -C(O)-NR2-(CRaRb)a-C(O)-NR2-L4-OC(O)-. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L3is -C(O)-NR2-(CH2)2-C(O)-NR2-L4-OC(O)-. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L3is -C(O)-NH-(CRaRb)a-C(O)-NH-L4-OC(O)-. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L3is -C(O)-NH-(CH2)2-C(O)-NH-L4-OC(O)-.
[1053] In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L4is
[1054]
[1055] . in certain embodiments of Formula (IV)-(VII), including any of the
[1056] foregoing,
[1057]
[1058] certain embodiments of Formula (IV)-(VII), including
[1059] any of the foregoing,
[1060]
[1061] In some embodiments of Formula (I)-(VII), including any of the foregoing, Su is a sugar moiety. In some embodiments of Formula (I)-(VII), including any of the foregoing, Su is a hexose form of a monosaccharide. Su may be a glucuronic acid or mannose residue. In some
[1062] embodiments of Formula (I)-(VII), including any of the foregoing,
[1063]
[1064] wherein represents attachment to the remainder of the conjugate. In some embodiments of
[1065] Formula (I)-(VII), including any of the foregoing,
[1066]
[1067] wherein
[1068]
[1069] represents attachment to the remainder of the conjugate.Attorney Docket No.: 108843.00627
[1070] In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L4is
[1071]
[1072] In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L3is
[1073] -C(O)-NH-(CH2)2-C(O)-NH-L4-OC(O)- wherein
[1074]
[1075] embodiments of Formula (IV)-(VII), including any of the foregoing, L3is -C(O)-NH-(CH2)2-
[1076] C(O)-NH-L4-OC(O)- wherein
[1077]
[1078] In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L2is -(CRaRb)a-POLY1- and L3is -C(O)-AA-. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L2is -(CRaRb)a-POLY1-; L3is -C(O)-AA-; and, POLY1is
[1079]
[1080] In certain embodiments of Formula (IV)-(VII), including any of the foregoing,
[1081]
[1082] integer between 10 and 15. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L2is
[1083] -(CH2)2-POLY1-; L3is -C(O)-AA-; and, POLY1is
[1084]
[1085] . In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L2is -(CH2)2-POLY1-; L3is -C(O)-AA-;
[1086] POLY1is
[1087]
[1088] ; and AA is a dipeptide residue, a tripeptide residue, a tetrapeptide residue, or a pentapeptide residue.
[1089] In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L2is -(CRaRb)a-POLY1- and L3is -C(O)-AA-Z-(CRaRb)a-Z-(CRaRb)a-C(O)-. In certain embodimentsAttorney Docket No.: 108843.00627
[1090] of Formula (IV)-(VII), including any of the foregoing, L2is -(CRaRb)a-POLY1-; L3is -C(O)-
[1091]
[1092] certain embodiments of Formula (IV)-(VII), including any of the foregoing, L2is
[1093]
[1094] and x is an integer between 10 and 15. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L2is -(CFL^-POLY1-; L3is -C(O)-AA-NH-CH2-NH-CH2-
[1095] C(O)-; and, POLY1is
[1096]
[1097] In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L2is -(CH2)2-POLY1-; L3is -C(O)-AA-NH-CH2-NH-CH2-C(O)-; POLY1
[1098] is
[1099]
[1100] ; and AA is a dipeptide residue, a tripeptide residue, a tetrapeptide residue, or a pentapeptide residue.
[1101] In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L2is -(CRaRb)a-POLY1- and L3is -C(O). In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L2is -(CRaRb)a-POLY1-; L3is
[1102] -C(O); and, POLY1is
[1103]
[1104] In certain embodiments of Formula (IV)-(VII), including
[1105] any of the foregoing,
[1106]
[1107] integer between 10 and 15. In certain embodiments of Formula (IV)-(VII), including any of the
[1108] foregoing, L2is -(CFh^-POLY1-; L3is -C(O); and, POLY1is
[1109]
[1110] . In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L2is -(CFL^-POLY1-; L3
[1111] is -C(O); POLY1is
[1112]
[1113] ; and AA is a dipeptide residue, a tripeptide residue, a tetrapeptide residue, or a pentapeptide residue.
[1114] In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L2is -(CRaRb)a-POLY1- and L3is absent. In certain embodiments of Formula (IV)-(VII), includingAttorney Docket No.: 108843.00627
[1115] any of the foregoing, L2is -(CRaRb)a-POLY1-; L3is absent; and, POLY1is
[1116]
[1117] certain embodiments of Formula (IV)-(VII), including any of the foregoing, L2is -(CH2)a-
[1118] POLY1-; L3is absent; POLY1is
[1119]
[1120] ; and x is an integer between 10 and 15. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L2is -(CH2)2-
[1121] POLY1-; L3is absent; and, POLY1is
[1122]
[1123] In certain embodiments of Formula (IV)- (VII), including any of the foregoing, L2is -(CH^-POLY1-; L3is absent; POLY1is
[1124]
[1125] ; and AA is a dipeptide residue, a tripeptide residue, a tetrapeptide residue, or a pentapeptide residue.
[1126] In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L2is - (CRaRb)a-POLY1- and L3is -C(O)-AA-Z-(CRaRb)a-. In certain embodiments of Formula (IV)- (VII), including any of the foregoing, L2is -(CRaRb)a-POLY1-; L3is is -C(O)-AA-Z-(CRaRb)a-;
[1127] and, POLY1is
[1128]
[1129] In certain embodiments of Formula (IV)-(VII), including any of
[1130] the foregoing,
[1131]
[1132] x is an integer between 10 and 15. In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L2is -(CH^-POLY1-; L3is -C(O)-AA-NH-(CRaRb)a-; and, POLY1is
[1133]
[1134] In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L2
[1135]
[1136] dipeptide residue, a tripeptide residue, a tetrapeptide residue, or a pentapeptide residue.
[1137] Non-limiting examples of -L2-L3- include:
[1138]
[1139] Attorney Docket No.: 108843.00627
[1140]
[1141] Attorney Docket No.: 108843.00627 Additional non-limiting examples of -L2-L3- include:
[1142]
[1143] In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L2is
[1144]
[1145] wherein L4is
[1146]
[1147] hexose form of a monosaccharide and d is an integer independently selected from 1, 2, and 3. In certain embodiments of Formula (IV)-(VII),Attorney Docket No.: 108843.00627
[1148] including any of the foregoing,
[1149]
[1150] OC(O)-.
[1151] In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L2is
[1152]
[1153] certain embodiments of Formula (IV)-(VII), including any
[1154] of the foregoing,
[1155]
[1156] absent.
[1157] In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L2is
[1158]
[1159] L3is -C(O)-NH-(CRaRb)a-C(O)-NH-L4-OC(O)-.Attorney Docket No.: 108843.00627 In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L2is
[1160]
[1161] In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L2is
[1162]
[1163] Attorney Docket No.: 108843.00627
[1164] In certain embodiments of Formula (IV)-(VII), including any of the foregoing, L2is
[1165]
[1166] In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, SP2and SP3are divalent attaching groups that facilitate incorporation of eliminator groups, release trigger groups, hydrophobic groups, spacer groups, and / or the conjugating group into a conjugate. Spacer groups that facilitate the spacing of the conjugating group from the other groups of the compounds can lead to more efficient conjugation of the compounds described herein to a second compound as well as more efficient cleavage of the active catabolite. Spacer group can also stabilize the conjugating group and lead to improved overall antibody-drug conjugate properties. Useful attaching groups are known to, and are apparent to, those of skill in the art. Examples of useful attaching groups are provided herein. In certain embodiments, an attaching group can comprise a divalent ketone, divalent ester, divalent ether, divalent amide, divalent amine, alkylene, arylene, sulfide, disulfide, carbonylene, or a combination thereof. In certain embodiments an attaching group can comprise -C(O)-, -O-, -C(O)NH-, -C(O)NH-alkyl-, -OC(O)NH-, -SC(O)NH-, -NH-, -NH-alkyl-, -C(O)N(CH3)-, -C(O)N(CH3)-alkyl-, -N(CH3)-,-N(CH3)-alkyl-, -N(CH3)CH2CH2N(CH3)-, -C(O)CH2CH2CH2C(O)-, -S-, -S-S-, -OCH2CH2O-, or the reverse (e.g. -NHC(O)-) thereof, or a combination thereof.
[1167] In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, SP1and SP3are independently absent or selected from Ci-ealkylene-; -C(O)-, Ci-ealkylene-C(O)- wherein the -C(O)- is bound to W2or HP1, respectively; -C(O)-Ci-6alkylene-C(O)-; -C(O)(Ci-6alkylene)NR1C(O)-; -C(O)(Ci-6alkylene)OC(O)-; and -C(O)(Ci-6alkylene)SC(O)-; wherein R1is hydrogen or optionally substituted Ci-ealkyl and the Ci-ealkylene, alone or part of another group, is optionally substituted with one, two, or three substituents selected from halogen, alkyl, haloalkyl, hydroxyl, amino, alkylamino, and alkoxy.
[1168] In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, SP2is independently absent or Ci-ealkylene-C(O)- wherein the -C(O)- is bound to W2. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of theAttorney Docket No.: 108843.00627
[1169] foregoing, SP2is independently Ci-6alkylene-C(O)-. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, SP2is independently Ci-2alkylene-C(O)-. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, SP2is independently C3-4alkylene-C(O)-. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, SP2is independently Cs-ealkylene-C(O)-. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, SP2is independently -CH2-C(0)-. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, SP2is independently -CH2CH2-C(0)-. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, SP2is independently -(CH2)s-C(O)-. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, including any of the foregoing, SP2is absent.
[1170] In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, SP3is independently absent or -C(O)-Ci-6alkylene-C(O)-. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, SP3is absent. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, SP3is independently -C(O)-Ci-6alkylene-C(O)-. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, SP3is independently -C(O)-Ci-4alkylene-C(O)-. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, SP3is independently -C(O)-C4alkylene-C(O)-. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, SP3is independently -C(O)(Ci-6alkylene)NR1C(O)- wherein R1is hydrogen.
[1171] In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, SP2is independently absent or Ci-ealkylene-C(O)- and SP3is independently absent or -C(O)-Ci-6alkylene-C(O)- wherein the -C(O)- of SP2is bound to W2. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, SP2is independently absent or Ci-ealkylene-C(O)- and SP3is absent wherein the -C(O)- of SP2is bound to W2. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, SP2is independently absent or Ci-ealkylene-C(O)- wherein the -C(O)- of SP2is bound to W2; SP3is independently absent or -C(O)-Ci-6alkylene-C(O)-; and SP1is absent.
[1172] In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, SP1is a divalent attaching group that facilitates incorporation and the release of the payload. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, SP1is independently absent or selected from -NR45CH2- and -NR44-arylene-CH2-wherein R45is Ci-ealkyl-OCFF and R44is hydrogen or C1-6 alkyl. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, SP1is absent. In certainAttorney Docket No.: 108843.00627
[1173] embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, SP1is independently -NR45CH2-. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, SP1is -N(CH2CH2OCH3)CH2-. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, SP1is independently -NR44-arylene-CH2-. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, SP1is independently -NH-arylene-CIB-. In certain embodiments of
[1174] Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, SP1is
[1175]
[1176] and each is the point of attachment to the rest of the compound.
[1177] In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, SP2is independently absent or Ci-ealkylene-C(O)- wherein the -C(O)- of SP2is bound to W2and SP1is absent. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, SP2is independently absent or Ci-ealkylene-C(O)- wherein the -C(O)- of SP2is bound to W2and SP1is independently selected from -NR45CH2- and -NR44-arylene-CH2-.
[1178] In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, SP2is C2alkylene-C(O)- and SP1is -N(CH2CH2OCH3)CH2- wherein the -C(O)- of SP2is bound to W2. In certain embodiments of Formula and (VII), including
[1179] any of the foregoing, SP2is C2alkylene-C(O)- and SP1is
[1180]
[1181] wherein the -C(0)-of SP2is bound to W2.
[1182] In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, SP2is independently absent or Ci-ealkylene-C(O)- wherein the -C(O)- of SP2is bound to W2; SP3is independently absent or -C(O)-Ci-6alkylene-C(O)-; and SP1is independently absent or is selected from -NR45CH2- and -NR44-arylene-CH2-.
[1183] In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, W1is an eliminator group.
[1184] In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the
[1185] foregoing, W1is independently
[1186]
[1187] . In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, W1is independentlyAttorney Docket No.: 108843.00627
[1188]
[1189] certain embodiments of Formula (III)-(IIIB), (VI), and (VII),
[1190] including any of the foregoing, W1is independently
[1191]
[1192] . In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, W1is
[1193]
[1194] In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, z is 0. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, z is 1. When z is 1, the conjugate comprises a release trigger group, designated as RT herein, which facilitates the separation of a biologically active portion of a conjugate described herein from the remainder of the conjugate in vivo and / or in vitro.
[1195] Hydrophilic groups, designated HP1and HP2herein, facilitate increasing the hydrophilicity of the compounds described herein. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, HP1is independently a divalent poly(ethylene glycol). In certain embodiments of Formula (III)-(IIIB), (VI), and (VII),
[1196] including any of the foregoing, HP1is independently
[1197]
[1198] wherein R2is hydrogen
[1199] or methyl and xl is an integer between 1 and 50, inclusive; and each
[1200]
[1201] is the point of attachment to the rest of the compound. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, R2is hydrogen. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, R2is methyl.
[1202] In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, xl is independently an integer between 1 and 10, inclusive. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, xl is independently an integer between 1 and 5, inclusive. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, xl is 4.Attorney Docket No.: 108843.00627
[1203] In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, xl is independently an integer between 1 and 10, inclusive, and R2is hydrogen. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, xl is independently an integer between 1 and 5, inclusive, and R2is hydrogen. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, xl is 4 and R2is hydrogen.
[1204] In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, including any of the foregoing, HP1is absent.
[1205] In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, RT is a P-glucuronidase-cleavable P-glucuronide. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, RT is
[1206]
[1207] is the point of attachment to the rest of the compound. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing,
[1208]
[1209] In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, y is 0. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, y is 1. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, y is 2.
[1210] In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, L1is independently a bond. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, L1is independently unsubstituted Ci-ealkylene. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, L1is independently an optionally substituted Ci-ealkylene wherein the Ci-ealkylene is optionally substituted with one, two, or three substituents selected from halogen, alkyl, haloalkyl, hydroxyl, amino, alkylamino, and alkoxy.
[1211] In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, RAis independently, at each occurrence, unsubstituted Ci-ealkyl. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, RAis independently, at each occurrence, methyl. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, RAis independently, at each occurrence, methyl and y is 1. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), includingAttorney Docket No.: 108843.00627
[1212] any of the foregoing, RAis independently, at each occurrence, Ci-ealkyl optionally substituted with one, two, or three substituents selected from halogen, alkyl, haloalkyl, hydroxyl, amino, alkylamino, and alkoxy.
[1213] In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the
[1214] foregoing, W1is independently absent,
[1215]
[1216] certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing,
[1217] W1is independently absent,
[1218]
[1219] certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, W1is independently
[1220]
[1221] certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, W1is absent. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, W1is
[1222]
[1223] certain embodiments of Formula (III)-(IIIB), (VI), and (VII),
[1224] including any of the foregoing,
[1225]
[1226] certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, W1is
[1227]
[1228] certain embodiments of Formula (III)-(IIIB), (VI), and (VII),
[1229] including any of the foregoing,
[1230]
[1231] certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, W1isAttorney Docket No.: 108843.00627
[1232]
[1233] certain embodiments of Formula (III)-(IIIB), (VI), and (VII),
[1234] including any of the foregoing,
[1235]
[1236] certain embodiments of
[1237] Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing,
[1238]
[1239] In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing,
[1240]
[1241] certain embodiments of Formula (III)-(IIIB), (VI), and
[1242] (VII), including any of the foregoing,
[1243]
[1244] Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, W1is
[1245]
[1246] certain embodiments of Formula (III)-(IIIB), (VI), and (VII),
[1247] including any of the foregoing, W1is independently absent,
[1248]
[1249] , orAttorney Docket No.: 108843.00627
[1250]
[1251] certain embodiments of Formula (III)-(IIIB), (VI), and (VII),
[1252] including any of the foregoing, W1is independently absent,
[1253]
[1254]
[1255] In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, W2is absent. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, W2is independently an amino acid residue or a peptide residue wherein the amino acid residue or the peptide residue is optionally substituted with HP2. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, W2is independently an unsubstituted amino acid residue. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, W2is independently an amino acid residue wherein the amino acid residue is substituted with HP2. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, W2is independently an unsubstituted peptide residue. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, W2is independently a peptide residue wherein the peptide residue is substituted with HP2.
[1256] In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, W2is independently a peptide residue, and the peptide residue of W2comprises at least one non-natural amino acid. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, W2is independently a peptide residue, and the peptide residue of W2comprises one non-natural amino acid. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, W2is independently a peptide residue, and the peptide residue of W2comprises two non-natural amino acid. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, W2is independently a peptide residue, and the peptide residue of W2comprises at least one non-natural amino acid and the peptide residue is optionally substituted with HP2.Attorney Docket No.: 108843.00627
[1257] In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, the at least one non-natural amino acid of the peptide residue of W2is selected from 3 -sulfoalanine, hydroxyproline (Hyp), citrulline (Cit), ornithine (Orn), norleucine (Nle), 3-nitrotyrosine, nitroarginine, pyroglutamic acid (Pyr), naphtylalanine (Nal), 2,4-diaminobutyric acid (DAB), methionine sulfoxide, methionine sulfone, and 2,3-diaminopropionate. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, the at least one non-natural amino acid of the peptide residue of W2is selected from 3 -sulfoalanine, citrulline (Cit), 2,3-diaminopropionate, and beta-alanine.
[1258] In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, W2is independently a peptide residue wherein the peptide residue is optionally substituted with HP2and the peptide residue comprises valine, citrulline (Cit), 3 -sulfoalanine, alanine, 2,3-diaminopropionate, or beta-alanine.
[1259] In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, the peptide residue comprises citrulline (Cit). In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, the peptide residue comprises betaalanine. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, the peptide residue comprises 2,3-diaminopropionate.
[1260] In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, the peptide residue comprises citrulline (Cit) and 3 -sulfoalanine. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, the peptide residue comprises beta-alanine and 2,3-diaminopropionate.
[1261] In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, the peptide residue comprises valine and citrulline (Cit). In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, the peptide residue comprises valine, citrulline (Cit), and 3 -sulfoalanine. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, the peptide residue comprises valine and alanine. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, the peptide residue comprises valine, citrulline (Cit), and 2,3-diaminopropionate. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, the peptide residue comprises beta-alanine and 2,3-diaminopropionate.
[1262] In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, W2is independently an amino acid residue wherein the amino acid residue is optionally substituted with HP2. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, W2is independently an amino acid residue and theAttorney Docket No.: 108843.00627
[1263] amino acid residue is a beta-amino acid. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, W2is independently beta-alanine.
[1264] In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, W2is independently selected from -(C(O)CHR63NR64)aa-, -(C(O)CH2CHR63NR64)bb-, -(C(O)CHR63CH2NR64)bb-, -(C(O)CH2CHR63NR64)bb-(C(O)CHR63NR64)aa-, -(C(O)CHR63CH2NR64)bb-(C(O)CHR63NR64)aa-, -(C(O)CHR63NR64)aa-(C(O)CH2CHR63NR64)bb-, and -(C(O)CHR63NR64)aa-(C(O)CHR63CH2NR64)bb-;
[1265] wherein R63is independently an amino acid sidechain residue optionally substituted with HP2;
[1266] R64is independently hydrogen or C1-6 alkyl;
[1267] each of aa and bb is an integer independently between 1 and 10, inclusive; and the -C(O)- of W2is bound to W1.
[1268] In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, W2is independently -(C(O)CHR63NR64)aa-. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, W2is independently -(C(O)CHR63NH)aa- wherein a is 1. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, W2is independently -(C(O)CHR63NH)aa- wherein a is 2. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, W2is independently -(C(O)CHR63NH)aa- wherein a is 3. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, W2is independently -(C(O)CHR63NR64)aa- and R63is an amino acid sidechain residue independently selected from valine, citrulline, alanine, glycine, 3 -sulfoalanine and 2,3 -diaminopropionate.
[1269] In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, W2is independently -(C(O)CH2CHR63NR64)bb-. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, W2is independently -(C(O)CH2CHR63NH)-. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, W2is independently -(C(O)CH2CH2NH)-.
[1270] In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, W2is independently -(C(O)CH2CHR63NR64)bb-(C(O)CHR63NR64)aa-. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, W2is independently -(C(O)CH2CHR63NH)bb-(C(O)CHR63NH)aa-. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, W2is independently -(C(O)CH2CH2NH)-(C(O)CHR63NH)aa-. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, W2is independently -(C(O)CH2CH2NH)-Attorney Docket No.: 108843.00627
[1271] (C(O)CHR63NH)- wherein R63is an amino acid sidechain residue independently selected from valine, citrulline, alanine, glycine, 3 -sulfoalanine and 2,3 -diaminopropionate.
[1272] In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the
[1273]
[1274] In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the
[1275]
[1276] In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the
[1277]
[1278] Attorney Docket No.: 108843.00627
[1279] In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the
[1280]
[1281] In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, -W1-W2- is independently of the formula:
[1282]
[1283] In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, HP2is polyethylene glycol (PEG), methoxypolyethylene glycol (mPEG), polypropylene glycol) (PPG), copolymers of ethylene glycol and propylene glycol, poly(oxyethylated polyol), poly(olefinic alcohol), poly(vinylpyrrolidone), poly(hydroxyalkylmethacrylamide), poly(hydroxyalkylmethacrylate), poly(saccharides),Attorney Docket No.: 108843.00627
[1284] poly(a-hydroxy acid), poly(vinyl alcohol), polyphosphazene, polyoxazolines (POZ), polyCV-acryloylmorpholine), polysarcosine, or a combination thereof. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, HP2is polyethylene glycol (PEG). In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, HP2is methoxypolyethylene glycol (mPEG). In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, HP2is polypropylene glycol) (PPG). In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, HP2is copolymers of ethylene glycol and propylene glycol. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, HP2is poly(oxy ethylated polyol). In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, HP2is poly(olefinic alcohol). In some embodiments, HP2is poly(vinylpyrrolidone). In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, HP2is poly(hydroxyalkylmethacrylamide). In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, HP2is poly(hydroxyalkylmethacrylate). In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, HP2is poly(saccharides). In some embodiments, HP2is poly(a-hydroxy acid). In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, HP2is poly(vinyl alcohol). In some embodiments, HP2is polyphosphazene. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, HP2is polyoxazolines (POZ). In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, HP2is poly(7V-acryloylmorpholine). In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, HP2is polysarcosine. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, HP2is a nonpeptidic, water-soluble polymer.
[1285] In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, HP2is independently a monovalent poly(ethylene glycol). HP2, HP2is
[1286] independently
[1287]
[1288] wherein R20is hydrogen or methyl and x2is an integer
[1289] between 1 and 50, inclusive; and each
[1290]
[1291] is the point of attachment to the rest of the compound. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, R20is hydrogen. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, R20is methyl.
[1292] In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, x2is independently an integer between 1 and 20, inclusive. In certain embodimentsAttorney Docket No.: 108843.00627
[1293] of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, x2is independently an integer between 10 and 20, inclusive. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, x2is 12.
[1294] In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, x2is independently an integer between 1 and 20, inclusive, and R20is hydrogen. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, x2is independently an integer between 10 and 20, inclusive, and R20is hydrogen. In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the foregoing, x2is 12 and R20is hydrogen.
[1295] In certain embodiments of Formula (III)-(IIIB), (VI), and (VII), including any of the
[1296] foregoing, W2is independently of the formula:
[1297]
[1298]
[1299] In certain embodiments of Formula (III)-(VII), including any of the foregoing, RL includes an alkyne, cyclooctyne, a strained alkene, a tetrazine, an amine, an amide, methylcyclopropene, a thiol, a / / ra-acetyl -phenyl alanine residue, an oxyamine, a maleimide, or an azide. In certain embodiments of Formula (III)-(VII), including any of the foregoing, RL includes an alkyne. In certain embodiments of Formula (III)-(VII), including any of the foregoing, RL includes an cyclooctyne. In certain embodiments of Formula (III)-(VII), including any of the foregoing, RL includes a strained alkene. In certain embodiments of Formula (III)-(VII), including any of the foregoing, RL includes a tetrazine. In certain embodiments of Formula (III)-(VII), including any of the foregoing, RL includes an amine. In certain embodiments of Formula (III)-(VII), including any of the foregoing, RL includes an methylcyclopropene. In certain embodiments of Formula (III)-(VII), including any of the foregoing, RL includes a thiol. In certain embodiments of Formula (III)-(VII), including any of the foregoing, RL includes a / ?ara-acetyl-phenylalanine residue. In certain embodiments of Formula (III)-(VII), including any of the foregoing, RL includes an oxyamine. In certain embodiments of Formula (III)-(VII), including any of the foregoing, RL includes a maleimide.Attorney Docket No.: 108843.00627
[1300] In certain embodiments of Formula (III)-(VII), including any of the foregoing, RL includes an azide. In certain embodiments of Formula (III)-(VII), including any of the foregoing, RL is
[1301]
[1302] attachment to the remainder of the compound. In certain embodiments of Formula (III)-(VII),
[1303] including any of the foregoing,
[1304]
[1305] represents attachment to the remainder of the compound. In certain embodiments of Formula (III)-(VII),
[1306] including any of the foregoing,
[1307]
[1308] represents attachment to the remainder of the compound. In certain embodiments of Formula
[1309] (III)-(VII), including any of the foregoing,
[1310]
[1311] represents attachment to the remainder of the compound. In certain embodiments of Formula (III)-(VII), including O
[1312] any of the foregoing, RL is
[1313]
[1314] an represents attachment to the remainder of the compound. In certain embodiments of Formula (III)-(VII), including any of the foregoing, RLAttorney Docket No.: 108843.00627
[1315] is
[1316]
[1317] represents attachment to the remainder of the compound. In certain
[1318] embodiments of Formula (III)-(VII), including any of the foregoing,
[1319]
[1320]
[1321] represents attachment to the remainder of the compound. In
[1322] certain embodiments of Formula (III)-(VII), including any of the foregoing,
[1323]
[1324] and represents attachment to the remainder of the compound. In certain embodiments of
[1325] Formula (III)-(VII), including any of the foregoing,
[1326]
[1327] represents attachment to the remainder of the compound. In certain embodiments of Formula (III)-(VII),
[1328] including any of the foregoing,
[1329]
[1330] represents attachment to the remainder of the compound.
[1331] In certain embodiments of Formula (I), (IA), (IB), (II), (III), (IIIA), (IIIB), or (IIIC), D is a payload moiety as described herein. In certain embodiments, including any of the foregoing, D is a cytotoxic payload selected from a tubulin inhibitor, a DNA topoisomerase I inhibitor, and a DNA topoisomerase II inhibitor. In some embodiments, including any of the foregoing, D is a tubulin inhibitor. In some embodiments, including any of the foregoing, D is a DNA topoisomerase I inhibitor. In some embodiments, including any of the foregoing, D is a DNA topoisomerase I inhibitor selected from the group consisting of irinotecan, SN-38, topotecan, exatecan. In some embodiments, including any of the foregoing, D is irinotecan. In some embodiments, including any of the foregoing, D is SN-38. In some embodiments,Attorney Docket No.: 108843.00627
[1332] including any of the foregoing, D is topotecan. In some embodiments, including any of the foregoing, D is exatecan. In some embodiments, including any of the foregoing, D is a DNA topoisomerase II inhibitor. In some embodiments, including any of the foregoing, D is a DNA topoisomerase II inhibitor selected from the group consisting of etoposide, teniposide, and tafluposide. In some embodiments, including any of the foregoing, D is etoposide. In some embodiments, including any of the foregoing, D is teniposide. In some embodiments, including any of the foregoing, D is tafluposide. In some embodiments, including any of the foregoing, D is selected from the group consisting of hemiasterlins, camptothecins, and anthracy clines. Anthracyclines may include PNU-159682 and EDA PNU-159682 derivatives. In some embodiments, including any of the foregoing, D is an anthracy cline selected from the group consisting of daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone, and valrubicin. In some embodiments, including any of the foregoing, D is daunorubicin. In some embodiments, including any of the foregoing, D is doxorubicin. In some embodiments, including any of the foregoing, D is epirubicin. In some embodiments, including any of the foregoing, D is idarubicin. In some embodiments, including any of the foregoing, D is mitoxantrone. In some embodiments, including any of the foregoing, D is valrubicin. In some embodiments, including any of the foregoing, D is a hemiasterlin. In some embodiments, including any of the foregoing, D is a camptothecin. In some embodiments, including any of the foregoing, D is an anthracycline. In some embodiments, including any of the foregoing, D is PNU-159682. In some embodiments, including any of the foregoing, D is an EDA PNU compound. In some embodiments, including any of the foregoing, D is an EDA PNU-159682 derivative. In some embodiments, including any of the foregoing, D is hemiasterlin, exatecan, PNU-159682, or an EDA PNU-159682 derivative. In some embodiments, including any of the foregoing, D is hemiasterlin. In some embodiments, including any of the foregoing, D is exatecan. In some embodiments, including any of the foregoing, D is of PNU-159682. In some embodiments, including any of the foregoing, D is EDA PNU-159682 compound or derivative.
[1333] In some embodiments, including any of the foregoing, D is an alkylating agent. In some embodiments, including any of the foregoing, D is a bifunctional alkylator. In some embodiments, including any of the foregoing, D is a bifunctional alkylator selected from the group consisting of cyclophosphamide, mechlorethamine, chlorambucil, and melphalan. In some embodiments, including any of the foregoing, D is cyclophosphamide. In some embodiments, including any of the foregoing, D is mechlorethamine. In some embodiments, including any of the foregoing, D is chlorambucil. In some embodiments, including any of the foregoing, D is melphalan. In some embodiments, including any of the foregoing, D is a monofunctional alkylator. In some embodiments, including any of the foregoing, D is aAttorney Docket No.: 108843.00627
[1334] monofunctional alkylator selected from the group consisting of dacarbazine, nitrosourea, and temozolomide. In some embodiments, including any of the foregoing, D is dacarbazine. In some embodiments, including any of the foregoing, D is nitrosourea. In some embodiments, including any of the foregoing, D is temozolomide. In some embodiments, including any of the foregoing, D is a cytoskeletal disruptor (e.g., a taxane). In some embodiments, including any of the foregoing, D is a cytoskeletal disruptor selected from the group consisting of paclitaxel, docetaxel, abraxane, and taxotere. In some embodiments, including any of the foregoing, D is paclitaxel. In some embodiments, including any of the foregoing, D is docetaxel. In some embodiments, including any of the foregoing, D is abraxane. In some embodiments, including any of the foregoing, D is taxotere. In some embodiments, including any of the foregoing, D is an epothilone. In some embodiments, including any of the foregoing, D is an epothilone selected from the group consisting of epothilone A, epothilone B, epothilone C, epothilone D, and ixabepilone. In some embodiments, including any of the foregoing, D is epothilone A. In some embodiments, including any of the foregoing, D is epothilone B. In some embodiments, including any of the foregoing, D is epothilone C. In some embodiments, including any of the foregoing, D is epothilone D. In some embodiments, including any of the foregoing, D is ixabepilone. In some embodiments, including any of the foregoing, D is a histone deacetylase inhibitor. In some embodiments, including any of the foregoing, D is a histone deacetylase inhibitor selected from the group consisting of vorinostat and romidepsin. In some embodiments, including any of the foregoing, D is vorinostat. In some embodiments, including any of the foregoing, D is romidepsin. In some embodiments, including any of the foregoing, D is a kinase inhibitor. In some embodiments, including any of the foregoing, D is a kinase inhibitor selected from the group consisting of bortezomib, erlotinib, gefitinib, imatinib, vemurafenib, and vismodegib. In some embodiments, including any of the foregoing, D is bortezomib. In some embodiments, including any of the foregoing, D is erlotinib. In some embodiments, including any of the foregoing, D is gefitinib. In some embodiments, including any of the foregoing, D is imatinib. In some embodiments, including any of the foregoing, D is vemurafenib. In some embodiments, including any of the foregoing, D is vismodegib. In some embodiments, including any of the foregoing, D is a nucleotide analog and / or precursor analog. In some embodiments, including any of the foregoing, D is a nucleotide analog and / or precursor analog selected from the group consisting of azacitidine, azathioprine, capecitabine, cytarabine, doxifluridine, fluorouracil, gemcitabine, hydroxyurea, mercaptopurine, methotrexate, and tioguanine (formerly thioguanine). In some embodiments, including any of the foregoing, D is azacitidine. In some embodiments, including any of the foregoing, D is azathioprine. In some embodiments, including any of the foregoing, D is capecitabine. In someAttorney Docket No.: 108843.00627
[1335] embodiments, including any of the foregoing, D is cytarabine. In some embodiments, including any of the foregoing, D is doxifluridine. In some embodiments, including any of the foregoing, D is fluorouracil. In some embodiments, including any of the foregoing, D is gemcitabine. In some embodiments, including any of the foregoing, D is hydroxyurea. In some embodiments, including any of the foregoing, D is mercaptopurine. In some embodiments, including any of the foregoing, D is methotrexate. In some embodiments, including any of the foregoing, D is tioguanine (formerly thioguanine). In some embodiments, including any of the foregoing, D is a peptide antibiotic. In some embodiments, including any of the foregoing, D is a peptide antibiotic selected from the group consisting of bleomycin and actinomycin. In some embodiments, including any of the foregoing, D is bleomycin. In some embodiments, including any of the foregoing, D is actinomycin. In some embodiments, including any of the foregoing, D is a platinum-based agent. In some embodiments, including any of the foregoing, D is a platinum-based agent selected from the group consisting of carboplatin, cisplatin, and oxaliplatin. In some embodiments, including any of the foregoing, D is carboplatin. In some embodiments, including any of the foregoing, D is cisplatin. In some embodiments, including any of the foregoing, D is oxaliplatin. In some embodiments, including any of the foregoing, D is a retinoid. In some embodiments, including any of the foregoing, D is a retinoid selected from the group consisting of tretinoin, alitretinoin, and bexarotene. In some embodiments, including any of the foregoing, D is tretinoin. In some embodiments, including any of the foregoing, D is alitretinoin. In some embodiments, including any of the foregoing, D is bexarotene. In some embodiments, including any of the foregoing, D is a vinca alkaloid and derivatives thereof. In some embodiments, including any of the foregoing, D is a vinca alkaloid and derivatives thereof selected from the group consisting of vinblastine, vincristine, vindesine, vinorelbine. In some embodiments, including any of the foregoing, D is a residue of vinblastine. In some embodiments, including any of the foregoing, D is vincristine. In some embodiments, including any of the foregoing, D is vindesine.
[1336] In any of the foregoing embodiments, the conjugate comprises n2 number of linkerpayloads, wherein n2 is an integer from 1 to 10. In some embodiments, n2 is 2. In some embodiments, n2 is 3. In some embodiments, n2 is 4. In some embodiments, n2 is 5. In some embodiments, n2 is 6. In some embodiments, n2 is 7. In some embodiments, n2 is 8. In some embodiments, n2 is 9. In some embodiments, n2 is 10.
[1337] In some embodiments, provided herein are anti-avP6 conjugates having the structure of any of Conjugates A-E in the table below. In some embodiments, n2 is an integer from 1 to 8. In some embodiments, n2 is 2. In some embodiments, n2 is 4. In some embodiments, n2 is 6.Attorney Docket No.: 108843.00627
[1338] In some embodiments, n2 is 8. The present disclosure encompasses each and every regioisomer of the conjugate structures depicted below.
[1339]
[1340] Attorney Docket No.: 108843.00627
[1341]
[1342] In some embodiments, provided herein are anti-avP6 conjugates having the structure of any of Conjugates Al-El in the table below. In some embodiments, n2 is an integer from 1 to 8. In some embodiments, n2 is 2. In some embodiments, n2 is 4. In some embodiments, n2 is 6. In some embodiments, n2 is 8. The present disclosure encompasses each and every regioisomer of the conjugate structures depicted below.
[1343]
[1344] Al;Attorney Docket No.: 108843.00627
[1345]
[1346] Attorney Docket No.: 108843.00627
[1347]
[1348] El
[1349] It should be understood that in certain embodiments, other linker payloads and conjugation structures are provided such as those discussed in International Patent Application No. PCT / US2023 / 023688, filed June 27, 2023 entitled P-Glucuronide Linker-Payloads, Protein Conjugates Thereof, And Methods Thereof as well as U. S. Provisional Application No.
[1350] 61 / 516,579, filed July 31, 2023, entitled STING Agonist Compounds and Conjugates, each of which is incorporated herein by reference in its entirety. In some embodiments provided herein are anti-avP6 conjugates comprising an antibody described herein linked to one or more linkerpayloads as described in PCT Application PCT / US2023 / 26338, PCT / US / 2020 / 031052, PCT / US / 2018 / 051364, PCT / US2018 / 051322, PCT / US2017 / 015501, PCT / US2017 / 015503, and PCT / US2016 / 015844, each of which are incorporated by reference in its entirety.
[1351] In any of the foregoing embodiments wherein the anti-avP6conjugate has a structure according to any one of Conjugates A-E, the bracketed structure can be covalently bonded to one or more non-natural and / or modified amino acids of the antibody, wherein the one or more non-natural and / or modified amino acids are located at sites selected from the group consisting of HC-F404, HC-Y391, HC-Y180, HC-F241, LC-42 (e.g., LC-K42 orLC-Q42 depending on the framework), and LC-E161, according to the Kabat or EU numbering scheme of Kabat. In some embodiments, the bracketed structure is covalently bonded to one or more non-natural and / or modified amino acids at site HC-F404 of the antibody. In some embodiments, the bracketed structure is covalently bonded to one or more non-natural and / or modified amino acids at site HC-Y180 of the antibody. In some embodiments, the bracketed structure is covalently bonded to one or more non-natural and / or modified amino acids at site HC-F241 of the antibody. In some embodiments, the bracketed structure is covalently bonded to one or more non-natural and / or modified amino acids at site LC-42 (e.g., LC-K42 or LC-Q42) of the antibody. In some embodiments, the bracketed structure is covalently bonded to one or more non-natural and / or modified amino acids at site LC-E161 of the antibody. In some embodiments, the bracketed structures are covalently bonded to non-natural and / or modified amino acids at sites HC-F404 and HC-Y180 of the antibody. In some embodiments, theAttorney Docket No.: 108843.00627
[1352] bracketed structures are covalently bonded to non-natural and / or modified amino acids at sites HC-F404, HC-Y391, HC-Y180, and LC-42 (e.g., LC-K42 orLC-Q42) of the antibody. In some embodiments, the bracketed structures are covalently bonded to non-natural and / or modified amino acids at sites HC-F404, HC-Y391, HC-Y180, LC-42 (e.g., LC-K42 or LC-Q42), and LC-E161 of the antibody. In some embodiments, the bracketed structures are covalently bonded to non-natural and / or modified amino acids at sites HC-F404, HC-Y180, and HC-F241 of the antibody. In some embodiments, the bracketed structures are covalently bonded to non-natural and / or modified amino acids at sites HC-F404, HC-Y391, HC-Y180, HC-F241, and LC-42 (e.g., LC-K42 or LC-Q42) of the antibody. In some embodiments, the antibody comprises one or more non-natural and / or modified amino acids at HC-F404, HC-K121, HC-Y180, HC-F241, HC-221, HC-Y391, LC-T22, LC-S7, LC-N152, LC-K42, LC-E161, LC-D170, HC-S136, HC-S25, HC-A40, HC-S119, HC-S190, HC-K222, HC-R19, HC-Y52, HC-S70, or a combination thereof. In some embodiments, the antibody comprises one or more non-natural and / or modified amino acids at HC-Y180, HC-F241, HC-Y391, HC-F404, or a combination thereof. In one example, the antibody comprises one or more non-natural and / or modified amino acids HC-Y180, HC-F241, HC-Y391, and HC-F404.
[1353] In particular embodiments, provided herein are anti-avP6 conjugates according to any of the conjugates described herein wherein COMP indicates a residue of the non-natural amino acid according to Formula (30) ((S)-2-amino-3-(4-(azidomethyl)phenyl)propanoic acid), below. In particular embodiments, provided herein are anti-avP6 conjugates according to any of the conjugates described herein wherein COMP indicates a residue of the non-natural amino acid according to Formula (30), below, at heavy chain position 404 according to the EU numbering system. In particular embodiments, provided herein are anti-avP6 conjugates according to any of the conjugates described herein wherein COMP indicates a residue of the non-natural amino acid according to Formula (30), below, at heavy chain position 180 according to the EU numbering system. In particular embodiments, provided herein are anti-avP6 conjugates according to any of the conjugates described herein wherein COMP indicates a residue of the non-natural amino acid according to Formula (30), below, at heavy chain position 241 according to the EU numbering system. In particular embodiments, provided herein are anti-avP6 conjugates according to any of the conjugates described herein wherein COMP indicates a residue of the non-natural amino acid according to Formula (30), below, at heavy chain position 222 according to the EU numbering system. In particular embodiments, provided herein are anti-avP6 conjugates according to any of the conjugates described herein wherein COMP indicates a residue of the non-natural amino acid according to Formula (30), below, at light chain position 7 according to the Kabat or Chothia numbering system. InAttorney Docket No.: 108843.00627
[1354] particular embodiments, provided herein are anti- avP6 conjugates according to any of the conjugates described herein wherein COMP indicates a residue of the non-natural amino acid according to Formula (30), below, at light chain position 42 according to the Kabat or Chothia numbering system. In certain embodiments, PAY is selected from the group consisting of maytansine, hemiasterlin, amanitin, camptothecin, exatecan, exatecan derivative (DXd), SN-38, anthracycline, PNU-159682, PNU derivative (PNU-EDA), pyrrolobenzodiazepine (PBD), MMAF, and MMAE. In certain embodiments, PAY is maytansine. In certain embodiments, PAY is hemiasterlin. In certain embodiments, PAY is amanitin. In certain embodiments, PAY is exatecan. In certain embodiments, PAY is exatecan derivative Dxd. In certain embodiments, PAY is anthracycline. In certain embodiments, PAY is PNU-159682. In certain embodiments, PAY is PNU derivative (PNU-EDA). In certain embodiments, PAY is pyrrolobenzodiazepine. In certain embodiments, PAY is MMAF. In certain embodiments, PAY is MMAE.
[1355]
[1356] In particular embodiments, provided herein are anti-avP6 conjugates according to any of the conjugates described herein wherein COMP indicates a residue of the non-natural amino acid according to Formula (56) ((S)-2-amino-3-(6-((6-methyl-l,2,4,5-tetrazin-3-yl)amino)pyri din-3 -yl)propanoic acid), below. In particular embodiments, provided herein are anti-avP6 conjugates according to any of the conjugates described herein wherein COMP indicates a residue of the non-natural amino acid according to Formula (56), below, at heavy chain position 404 according to the EU numbering system. In particular embodiments, provided herein are anti-avP6 conjugates according to any of the conjugates described herein wherein COMP indicates a residue of the non-natural amino acid according to Formula (56), below, at heavy chain position 180 according to the EU numbering system. In particular embodiments, provided herein are anti-avP6 conjugates according to any of the conjugates described herein wherein COMP indicates a residue of the non-natural amino acid according to Formula (56), below, at heavy chain position 241 according to the EU numbering system. In particular embodiments, provided herein are anti-avP6 conjugates according to any of the conjugates described herein wherein COMP indicates a residue of the non-natural amino acid according to Formula (56), below, at heavy chain position 222 according to the EU numberingAttorney Docket No.: 108843.00627
[1357] system. In particular embodiments, provided herein are anti-avP6 conjugates according to any of the conjugates descr...
Claims
Attorney Docket No.: 108843.00627WHAT IS CLAIMED IS:
1. An antibody conjugate comprising an antibody that specifically binds to Integrin avP6 (avP6) linked site-specifically to at least one payload moiety, wherein the antibody comprises one or more non-natural amino acids.
2. The antibody conjugate of claim 1, wherein the antibody comprises one or more nonnatural amino acids at a position selected from the group consisting of (a) HC-F404, HC-K121, HC-Y180, HC-F241, HC-221, HC-Y391, LC-T22, LC-S7, LC-N152, LC-K42, LC-E161, LC-D170, HC-S136, HC-S25, HC-A40, HC-S119, HC-S190, HC-K222, HC-R19, HC-Y52, and HC-S70, according to the Kabat, Chothia, or EU numbering scheme; (b) HC-F404, HC-Y180, HC-F241, HC-Y391, LC-K42, and LC-E161, according to the Kabat, Chothia, or EU numbering scheme; or (c) HC-F404, HC-Y180, HC-Y391, LC-K42, and LC-E161, according to the Kabat or EU numbering scheme of Kabat.
3. The antibody conjugate of claim 2, wherein the antibody comprises one or more nonnatural amino acids at a position selected from the group consisting of HC-F404, HC-Y180, HC-Y391, HC-F241, and LC-K42, according to the Kabat or EU numbering scheme of Kabat.
4. The antibody conjugate of claim 2, wherein the antibody comprises two non-natural amino acids at positions HC-Y180 and HC-F404 or at positions HC-F241 and HC-F404.
5. The antibody conjugate of claim 2, wherein the antibody comprises three non-natural amino acids at positions HC-Y180, HC-F404, and LC-K42 or at positions HC-Y180, HC-F241 and HC-F404.
6. The antibody conjugate of claim 2, wherein the antibody comprises four non-natural amino acids at positions HC-Y180, HC-F404, LC-K42, and LC-E161; positions HC-Y180, HC-F241, HC-F404, and LC-K42; or, positions HC-Y180, HC-F241, HC-F404, and HC-Y391.
7. The antibody conjugate of any one of the preceding claims, wherein the antibody further comprises the amino acid substitution V264S.
8. The antibody conjugate of any one of the preceding claims, wherein a residue of the one or more non-natural amino acids is linked to the payload moiety via a linker that is hydrolytically stable.Attorney Docket No.: 108843.006279. The antibody conjugate of any one of the preceding claims, wherein a residue of the one or more non-natural amino acids is linked to the payload moiety via a linker that is cleavable.
10. The antibody conjugate of any one of the preceding claims, wherein the one or more non-natural amino acids is selected from the group consisting of / ?-acetyl-L-phenylalanine, O-methyl-L-tyrosine, an -3-(2-naphthyl)alanine, 3-methyl-phenylalanine, O-4-allyl-L-tyrosine, 4-propyl-L-tyrosine, a tri-O-acetyl-GlcNAcP-serine, L-Dopa, fluorinated phenylalanine, isopropyl-L-phenylalanine, p-azido-L-phenylalanine, / ?-azido-methyl-L-phenylalanine, (S)-2-amino-3-(6-((6-methyl-l,2,4,5-tetrazin-3-yl)amino)pyridin-3-yl)propanoic acid, (S)-2-amino-3-(4-(azidomethyl)phenyl)propanoic acid, p-benzoyl-L-phenylalanine, L-phosphoserine, phosphonoserine, phosphonotyrosine, / ?-iodo-phenylalanine, / ?-bromophenylalanine, / ?-amino-L-phenylalanine, isopropyl-L-phenylalanine, and / ?-propargyloxy-phenylalanine.
11. The antibody conjugate of any one of the preceding claims, wherein the one or more non-natural amino acids is / ?-azido-methyl-L-phenylalanine.
12. The antibody conjugate of any one of the preceding claims, wherein the at least one payload moiety is a cytotoxic payload.
13. The antibody conjugate of any one of claims 1-12, wherein the at least one payload moiety is independently selected from the group consisting of maytansines, hemiasterlins, amanitins, camptothecins, exatecans, anthracyclines, pyrrolobenzodiazepines, and auristatins, or wherein the at least one payload moiety is independently selected from the group consisting of DM1, hemiasterlin, amanitin, camptothecin, exatecan, deruxtecan (DXd), SN-38, PNU-159862, PNU-EDA, pyrrol obenzodiazepine, MMAF, and MMAE.
14. The antibody conjugate of any one of claims 1-11 and 13, wherein the at least one payload moiety is exatecan.
15. The antibody conjugate of any one of the preceding claims, according to the structure of Formula I:Attorney Docket No.: 108843.00627or a pharmaceutically acceptable salt, solvate, stereoisomer, regioisomer, or mixture of regioisomers thereof; whereinCOMP is a residue of the anti-avP6 antibody;L1is -C1-6 alkylene- optionally substituted with one or more substituents selected from halogen, -CN, -NO2, -OH, -N(R10)2, -C(O)N(R10)2, -C(O)-, -C(S)-, -C(O)OCH2C6H5, -NHC(O)OCH2C6H5, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-12 carbocycle, 3- to 12-membered heterocycle, and Ci-iohaloalkyl;Y is -XJ-C1-6 alkylene-fXkCi-e alkyleneJn-CX^p- -X1-C2-6 alkenylene-[X1-C2-6 alkenyleneJn-CX^p- -X1-C2-6 alkynylene-[X1-C2-6 alkynyleneJn-CX^p- wherein at least one alkylene, alkenylene or alkynylene in Y is substituted with one or more substituents selected from R50; andwherein the alkylene, alkenylene, or alkynylene in Y is optionally substituted with one or more substituents selected from R51;R50is -C1-6 alkylene-X2-[C1-6 alkylene]m-POLY,-C2-6 alkenylene-X2-[C2-6 alkenylene]m-POLY, or -C2-6 alkynylene-X2-[C2-6 alkynylene]m-POLY, wherein each alkylene, alkenylene or alkynylene of R50is optionally substituted with one or more substituents selected from halogen, -CN, -NO2, -OH, -N(R10)2, -C(O)N(R10)2, -C(O)-, -C(S)-, -C(O)OCH2C6H5, -NHC(O)OCH2C6H5, Ci-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-12 carbocycle, 3- to 12-membered heterocycle, and Ci-iohaloalkyl;R51is independently selected from halogen, -CN, -NO2, -OH, -N(R10)2, -C(O)N(R10)2, -C(O)-, -C(S)-, -C(O)OCH2C6H5,-NHC(O)OCH2C6H5, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-12 carbocycle, 3- to 12-membered heterocycle, and Ci-iohaloalkyl;X1and X2are independently selected from -N(R10)-, -C(O)- and -N(R10)C(O)-;R10is independently selected at each occurrence from hydrogen, C1-10 alkyl, C2-10 alkenyl, C2-io alkynyl, C3-12 carbocycle, 3- to 12-membered heterocycle, and C1-10 haloalkyl;POLY is a monovalent water-soluble polymer;n is an integer selected from zero, one, two, and three;m is an integer selected from zero and one;Attorney Docket No.: 108843.00627p is an integer selected from zero and one;Su is a hexose form of a monosaccharide;D is the payload moiety; andRL is a reactive group residue.
16. The antibody conjugate of claim 15, according to the structure of Formula II:or a pharmaceutically acceptable salt, solvate, stereoisomer, regioisomer, or mixture of regioisomers thereof; whereinY is - X1-C1-6 alkylene-[X1-C1-6 alkyl enejn-X1-, -X1-C2-6 alkenylene-[X1-C2-6 alkenylenejn-X1-, -X1-C2-6 alkynylene-[X1-C2-6 alky nyl enejn-X1-, wherein at least one alkylene, alkenylene or alkynylene in Y is substituted with one or more substituents selected from R50.
17. The antibody conjugate of claim 16, wherein the compound of Formula (II) is according to Formula (II A)or a pharmaceutically acceptable salt, solvate, stereoisomer, regioisomer, or mixture of regioisomers thereof.
18. The antibody conjugate of any one of claims 1-14, according to the structure of Formula (III) or (IIIC):Attorney Docket No.: 108843.00627Formula (IIIC)or a pharmaceutically acceptable salt, solvate, stereoisomer, regioisomer, or mixture of regioisomers thereof; wherein:COMP is a residue of the anti-avP6 antibody;each SP1, SP2, and SP3are independently, at each occurrence, absent or a divalent spacer group;each W1is independently, at each occurrence, absentwherein the -NH- is bound to W2;L6is independently a bond or an optionally substituted Ci-ealkylene wherein the Ci-ealkylene is optionally substituted with one, two, or three substituents selected from halogen, alkyl, haloalkyl, hydroxyl, amino, alkylamino, and alkoxy;each W2is independently, at each occurrence, absent, an amino acid residue, or a peptide residue wherein the amino acid residue or peptide residue is optionally substituted with HP2;each HP1, is independently, at each occurrence, absent or a divalent water-soluble polymer;each HP2, when present, is a monovalent water-soluble polymer;each RAis independently, at each occurrence, optionally substituted Ci-ealkyl wherein the Ci-ealkyl is optionally substituted with one, two, or three substituents selected from halogen, alkyl, haloalkyl, hydroxyl, amino, alkylamino, and alkoxy;Attorney Docket No.: 108843.00627each RT is independently, at each occurrence, absent or a release trigger group;y is an integer independently selected from 0, 1, and 2;z is an integer independently selected from 0 and 1;L1is -C1-6 alkylene- optionally substituted with one or more substituents selected from halogen, -CN, -NO2, -OH, -N(R10)2, -C(O)N(R10)2, -C(O)-, -C(S)-, -C(O)OCH2C6H5, -NHC(O)OCH2C6H5, Ci-io alkyl, C2-10 alkenyl, C2-10 alkynyl, Cs-n carbocycle, 3- to 12-membered heterocycle, and Ci-iohaloalkyl;Y is -XJ-C1-6 alkylene-fXkCi-e alkyleneln-, -X1-C2-6 alkenylene-[X1-C2-6 alkenyleneJn-CX^p- -XJ-C2-6 alkynylene-[X1-C2-6 alkynyleneJn-CX^p- wherein at least one alkylene, alkenylene or alkynylene in Y is substituted with one or more substituents selected from R50; andwherein the alkylene, alkenylene, or alkynylene in Y is optionally substituted with one or more substituents selected from R51;R50is -C1-6 alkylene-X2-[C1-6 alkylene]m-POLY,-C2-6 alkenylene-X2-[C2-6 alkenylene]m-POLY, or -C2-6 alkynylene-X2-[C2-6 alkynylene]m-POLY, wherein each alkylene, alkenylene or alkynylene of R50is optionally substituted with one or more substituents selected from halogen, -CN, -NO2, -OH, -N(R10)2, -C(O)N(R10)2, -C(O)-, -C(S)-, -C(O)OCH2C6H5, -NHC(O)OCH2C6H5, CI-IO alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-12 carbocycle, 3- to 12-membered heterocycle, and Ci-iohaloalkyl;R51is independently selected from halogen, -CN, -NO2, -OH, -N(R10)2, -C(O)N(R10)2, -C(O)-, -C(S)-, -C(O)OCH2C6H5,-NHC(O)OCH2C6H5, Ci-io alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-12 carbocycle, 3- to 12-membered heterocycle, and Ci-iohaloalkyl;POLY is a monovalent water-soluble polymer;X1and X2are independently selected from -N(R10)-, -C(O)- and -N(R10)C(O)-;R10is independently selected at each occurrence from hydrogen, Ci-io alkyl, C2-10 alkenyl, C2-io alkynyl, C3-12 carbocycle, 3- to 12-membered heterocycle, and Ci-io haloalkyl;n is an integer selected from zero, one, two, and three;m is an integer selected from zero and one;p is an integer selected from zero and one;Su is a hexose form of a monosaccharide;each RL is a reactive group residue;each D is independently a payload moietyal is an integer selected from 1 to 10;bl is an integer selected from 1 to 10; andAttorney Docket No.: 108843.00627represents attachment to the remainder of the compound.
19. The antibody conjugate of any one of claims 15 to 18, whereinwherein represents attachment to the remainder of the compound.
20. The antibody conjugate of any one of claims 15 to 19, whereinwherein represents attachment to the remainder of the compound.
21. The antibody conjugate of any one of claims 15 to 20, wherein L1is -C1-3 alkylene-.
22. The antibody conjugate of any one of claims 15 to 21, wherein Y is -XJ-C1-6 alkylene-fX1- C1-6 alkyl enejn-X1-, wherein at least one alkylene in Y is substituted with one or more substituents selected from R50.
23. The antibody conjugate of any one of claims 15 to 22, wherein Y is -XJ-Ci-4 alkylene-X1- Ci-4 alkylene-X1-Ci-4 alkylene-X1—, wherein at least one alkylene in Y is substituted with one or more substituents selected from R50.
24. The antibody conjugate of any one of claims 15 to 22, wherein Y is -XJ-Ci-4 alkylene-X1- C1-4 alkylene-X1-, wherein at least one alkylene in Y is substituted with one or more substituents selected from R50.
25. The antibody conjugate of any one of claims 15 to 24, wherein R50is -C1-6 alkylene-X2- [C1-6 alkylene]m-POLY, wherein each alkylene of R50is optionally substituted with one or more substituents selected from halogen, -CN, -NO2, -OH, -N(R10)2, -C(O)N(R10)2, -C(O)-, -C(S)-, -C(O)OCH2C6H5, -NHC(O)OCH2C6H5, Ci-10 alkyl, C2- 10 alkenyl, C2-10 alkynyl, C3- 12 carbocycle, 3- to 12-membered heterocycle, and Ci-iohaloalkyl.
26. The antibody conjugate of any one of claims 15 to 25, wherein m is one.Attorney Docket No.: 108843.0062727. The antibody conjugate of any one of claims 15 to 26, wherein POLY is polyethylene glycol (PEG), methoxypolyethylene glycol (mPEG), polypropylene glycol) (PPG), copolymers of ethylene glycol and propylene glycol, poly(oxyethylated polyol), poly(olefinic alcohol), polyvinylpyrrolidone), poly(hydroxyalkylmethacrylamide), poly(hydroxyalkylmethacrylate), poly(saccharides), poly(a-hydroxy acid), poly(vinyl alcohol), polyphosphazene, polyoxazolines (POZ), poly(7V-acryloylmorpholine), polysarcosine, or a combination thereof.
28. The antibody conjugate of any one of claims 15 to 27, wherein POLY comprises a polyethylene glycol (PEG) or methoxypolyethylene glycol (mPEG).
29. The antibody conjugate of any one of claims 15 to 28, wherein RL comprises an alkyne, cyclooctyne, a strained alkene, a tetrazine, a thiol, a / / ra-acetyl -phenyl alanine residue, an oxyamine, amide, amine, a maleimide, or an azide.
30. The antibody conjugate of any one of claims 15 to 29, wherein RL is selected from the31. The antibody conjugate of any one of claims 15-30, wherein D is independently a payload moiety selected from a tubulin inhibitor, DNA damaging agents, a DNA topoisomerase I inhibitor, a DNA topoisomerase II inhibitor, RNA polymerase II inhibitor, a hemiasterlin residue, a camptothecin residue, camptothexin derivatives, an anthracycline residue, PNU- 159682 and PNU-159682 derivative, PBDs, and duocarmycins or wherein D isAttorney Docket No.: 108843.00627independently selected from the group consisting of hemiasterlins, auristatins, camptothecins, anthracyclines, PNU-159682, and EDA PNU-159682 derivatives.
32. The antibody conjugate of claim 1, wherein the antibody conjugate has a structure selected from the group consisting of:Attorney Docket No.: 108843.00627wherein n2 is an integer from 1 to 10.
33. The antibody conjugate of claim 32, wherein the antibody conjugate has a structure selected from the group consisting of:Attorney Docket No.: 108843.00627Attorney Docket No.: 108843.00627wherein n2 is an integer from 1 to 10.
34. The antibody conjugate of claim 32 or 33, wherein n2 is an integer from 2 to 8, 2 to 6, 2 to 4, or 6 to 10.
35. The antibody conjugate of claim 32 or 33, wherein n2 is 2, 4, 6, 8, or 10.
36. The antibody conjugate of any one of the preceding claims, wherein the antibody comprises three heavy chain CDRs from a VH sequence selected from SEQ ID NOs: 1246, 1258, 1373, 1406, 1407, 1408, 1424, 1464, 1474, 1487, 1488, 1489, and 1491, or variants thereof, and three light chain CDRs from a VL sequence provided in SEQ ID NOs: 1495, or variants thereof.
37. The antibody conjugate of any one of the preceding claims, wherein the antibody comprises three heavy chain CDRs, or variants thereof, and three light chain CDRs, or variants thereof, from a VH / VL pair selected from the group consisting of SEQ ID NOs: 1246 / 1495, 1258 / 1495, 1373 / 1495, 1406 / 1495, 1407 / 1495, 1408 / 1495, 1424 / 1495, 1464 / 1495, 1474 / 1495, 1487 / 1495, 1488 / 1495, 1489 / 1495, and 1491 / 1495.Attorney Docket No.: 108843.0062738. The antibody conjugate of any one of the preceding claims, wherein the antibody comprises a VHselected from SEQ ID NOs: 1246, 1258, 1373, 1406, 1407, 1408, 1424, 1464, 1474, 1487, 1488, 1489, and 1491.
39. The antibody conjugate of any one of the preceding claims, wherein the antibody comprises a VL provided in SEQ ID NO: 1495.
40. The antibody conjugate of any one of the preceding claims, wherein the antibody comprises a VH / VL pair, or a variant thereof, selected from the group consisting of SEQ ID NOs: 1246 / 1495, 1258 / 1495, 1373 / 1495, 1406 / 1495, 1407 / 1495, 1408 / 1495, 1424 / 1495, 1464 / 1495, 1474 / 1495, 1487 / 1495, 1488 / 1495, 1489 / 1495, and 1491 / 1495.
41. The antibody conjugate of any one of the preceding claims, wherein the antibody conjugate comprises:(a) an antibody comprising: (1) a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 381 and 133; a CDR-H2 comprising at least one of SEQ ID NOs: 877 and 629; and a CDR-H3 comprising SEQ ID NO: 1125; and a VL comprising: a CDR-L1 comprising SEQ ID NO: 1492; a CDR-L2 comprising SEQ ID NO: 1493; and a CDR-L3 comprising SEQ ID NO: 1494; (2) a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 414 and 166; a CDR-H2 comprising at least one of SEQ ID NOs: 910 and 662; and a CDR-H3 comprising SEQ ID NO: 1158; and a VL comprising: a CDR-L1 comprising SEQ ID NO: 1492; a CDR-L2 comprising SEQ ID NO: 1493; and a CDR-L3 comprising SEQ ID NO: 1494; (3) a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 415 and 167; a CDR-H2 comprising at least one of SEQ ID NOs: 911 and 663; and a CDR-H3 comprising SEQ ID NO: 1159; and a VL comprising: a CDR-L1 comprising SEQ ID NO: 1492; a CDR-L2 comprising SEQ ID NO: 1493; and a CDR-L3 comprising SEQ ID NO: 1494; (4) a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 416 and 168; a CDR-H2 comprising at least one of SEQ ID NOs: 912 and 664; and a CDR-H3 comprising SEQ ID NO: 1160; and a VL comprising: a CDR-L1 comprising SEQ ID NO: 1492; a CDR-L2 comprising SEQ ID NO: 1493; and a CDR-L3 comprising SEQ ID NO: 1494; (5) a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 432 and 184; a CDR-H2 comprising at least one of SEQ ID NOs: 928 and 680; and a CDR-H3 comprising SEQ ID NO: 1176; and a VL comprising: a CDR-L1 comprising SEQ ID NO: 1492; a CDR-L2 comprising SEQ ID NO: 1493; and a CDR-L3 comprising SEQ ID NO: 1494; (6) a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 472 and 224; a CDR-H2 comprising at least oneAttorney Docket No.: 108843.00627of SEQ ID NOs: 968 and 720; and a CDR-H3 comprising SEQ ID NO: 1216 and a VLcomprising: a CDR-L1 comprising SEQ ID NO: 1492; a CDR-L2 comprising SEQ ID NO: 1493; and a CDR-L3 comprising SEQ ID NO: 1494; (7) a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 482 and 234; a CDR-H2 comprising at least one of SEQ ID NOs: 978 and 730; and a CDR-H3 comprising SEQ ID NOs: 1226; and a VL comprising: a CDR-L1 comprising SEQ ID NO: 1492; a CDR-L2 comprising SEQ ID NO: 1493; and a CDR-L3 comprising SEQ ID NO: 1494; (8) a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 495 and 247; a CDR-H2 comprising at least one of SEQ ID NOs: 991 and 743; and a CDR-H3 comprising SEQ ID NO: 1239; and a VL comprising: a CDR-L1 comprising SEQ ID NO: 1492; a CDR-L2 comprising SEQ ID NO: 1493; and a CDR-L3 comprising SEQ ID NO: 1494; (9) a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 496 and 248; a CDR-H2 comprising at least one of SEQ ID NOs: 992 and 744; and a CDR-H3 comprising SEQ ID NO: 1240; and a VL comprising: a CDR-L1 comprising SEQ ID NO: 1492; a CDR-L2 comprising SEQ ID NO: 1493; and a CDR-L3 comprising SEQ ID NO: 1494; (10) a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 497 and 249; a CDR-H2 comprising at least one of SEQ ID NOs: 993 and 745; and a CDR-H3 comprising SEQ ID NO: 1241; and a VL comprising: a CDR-L1 comprising SEQ ID NO: 1492; a CDR-L2 comprising SEQ ID NO: 1493; and a CDR-L3 comprising SEQ ID NO: 1494; (11) a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 499 and 251; a CDR-H2 comprising at least one of SEQ ID NOs: 995 and 747; and a CDR-H3 comprising SEQ ID NO: 1243; and a VL comprising: a CDR-L1 comprising SEQ ID NO: 1492; a CDR-L2 comprising SEQ ID NO: 1493; and a CDR-L3 comprising SEQ ID NO: 1494;(b) para-azidomethylphenylalanine residues at antibody sites selected from the group consisting of HC180, HC241, HC404, HC391, LC42, LC161 and combinations thereof; and(c) a linker-payload selected from the group consisting of:Attorney Docket No.: 108843.00627wherein n2 is 2, 4, 6, 8 or 10 and each linker-payload is bonded to one of the paraazidomethylphenylalanine residue side chains.Attorney Docket No.: 108843.0062742. The antibody conjugate of any one of the proceeding claims, wherein the antibody conjugate comprises:(a) an antibody comprising: (1) a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 381 and 133; a CDR-H2 comprising at least one of SEQ ID NOs: 877 and 629; and a CDR-H3 comprising SEQ ID NO: 1125; and a VL comprising: a CDR-L1 comprising SEQ ID NO: 1492; a CDR-L2 comprising SEQ ID NO: 1493; and a CDR-L3 comprising SEQ ID NO: 1494; (2) a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 414 and 166; a CDR-H2 comprising at least one of SEQ ID NOs: 910 and 662; and a CDR-H3 comprising SEQ ID NO: 1158; and a VL comprising: a CDR-L1 comprising SEQ ID NO: 1492; a CDR-L2 comprising SEQ ID NO: 1493; and a CDR-L3 comprising SEQ ID NO: 1494; (3) a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 415 and 167; a CDR-H2 comprising at least one of SEQ ID NOs: 911 and 663; and a CDR-H3 comprising SEQ ID NO: 1159; and a VL comprising: a CDR-L1 comprising SEQ ID NO: 1492; a CDR-L2 comprising SEQ ID NO: 1493; and a CDR-L3 comprising SEQ ID NO: 1494; (4) a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 416 and 168; a CDR-H2 comprising at least one of SEQ ID NOs: 912 and 664; and a CDR-H3 comprising SEQ ID NO: 1160; and a VL comprising: a CDR-L1 comprising SEQ ID NO: 1492; a CDR-L2 comprising SEQ ID NO: 1493; and a CDR-L3 comprising SEQ ID NO: 1494; (5) a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 432 and 184; a CDR-H2 comprising at least one of SEQ ID NOs: 928 and 680; and a CDR-H3 comprising SEQ ID NO: 1176; and a VL comprising: a CDR-L1 comprising SEQ ID NO: 1492; a CDR-L2 comprising SEQ ID NO: 1493; and a CDR-L3 comprising SEQ ID NO: 1494; (6) a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 472 and 224; a CDR-H2 comprising at least one of SEQ ID NOs: 968 and 720; and a CDR-H3 comprising SEQ ID NO: 1216 and a VL comprising: a CDR-L1 comprising SEQ ID NO: 1492; a CDR-L2 comprising SEQ ID NO: 1493; and a CDR-L3 comprising SEQ ID NO: 1494; (7) a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 482 and 234; a CDR-H2 comprising at least one of SEQ ID NOs: 978 and 730; and a CDR-H3 comprising SEQ ID NOs: 1226; and a VL comprising: a CDR-L1 comprising SEQ ID NO: 1492; a CDR-L2 comprising SEQ ID NO: 1493; and a CDR-L3 comprising SEQ ID NO: 1494; (8) a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 495 and 247; a CDR-H2 comprising at least one of SEQ ID NOs: 991 and 743; and a CDR-H3 comprising SEQ ID NO: 1239; and a VL comprising: a CDR-L1 comprising SEQ ID NO: 1492; a CDR-L2 comprising SEQ ID NO: 1493; and a CDR-L3 comprising SEQ ID NO: 1494; (9) a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 496 and 248; a CDR-H2 comprising at least one ofAttorney Docket No.: 108843.00627SEQ ID NOs: 992 and 744; and a CDR-H3 comprising SEQ ID NO: 1240; and a VLcomprising: a CDR-L1 comprising SEQ ID NO: 1492; a CDR-L2 comprising SEQ ID NO: 1493; and a CDR-L3 comprising SEQ ID NO: 1494; (10) a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 497 and 249; a CDR-H2 comprising at least one of SEQ ID NOs: 993 and 745; and a CDR-H3 comprising SEQ ID NO: 1241; and a VL comprising: a CDR-L1 comprising SEQ ID NO: 1492; a CDR-L2 comprising SEQ ID NO: 1493; and a CDR-L3 comprising SEQ ID NO: 1494; (11) a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 499 and 251; a CDR-H2 comprising at least one of SEQ ID NOs: 995 and 747; and a CDR-H3 comprising SEQ ID NO: 1243; and a VL comprising: a CDR-L1 comprising SEQ ID NO: 1492; a CDR-L2 comprising SEQ ID NO: 1493; and a CDR-L3 comprising SEQ ID NO: 1494;(b) para-azidom ethylphenylalanine residues at antibody sites HC241, HC180, HC391, and HC404;(c) the following linker-payload, wherein n2 is 8 and each linker-payload is bonded to one of the para-azidomethylphenylalanine residue side chains:
43. The antibody conjugate of any one of the proceeding claims, wherein the antibody conjugate comprises:(a) an antibody comprising: a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 381 and 133; a CDR-H2 comprising at least one of SEQ ID NOs: 877 and 629; and a CDR-H3 comprising SEQ ID NO: 1125; and a VL comprising: a CDR-L1Attorney Docket No.: 108843.00627comprising SEQ ID NO: 1492; a CDR-L2 comprising SEQ ID NO: 1493; and a CDR-L3 comprising SEQ ID NO: 1494;(b) para-azidom ethylphenylalanine residues at antibody sites HC241, HC180, HC391, and HC404;(c) the following linker-payload, wherein n2 is 8 and each linker-payload is bonded to one of the para-azidomethylphenylalanine residue side chains:
44. The antibody conjugate of any one of the proceeding claims, wherein the antibody conjugate comprises:(a) an antibody comprising: a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 495 and 247; a CDR-H2 comprising at least one of SEQ ID NOs: 991 and 743; and a CDR-H3 comprising SEQ ID NO: 1239; and a VL comprising: a CDR-L1 comprising SEQ ID NO: 1492; a CDR-L2 comprising SEQ ID NO: 1493; and a CDR-L3 comprising SEQ ID NO: 1494;(b) para-azidomethylphenylalanine residues at antibody sites HC241, HC180, HC391, and HC404;(c) the following linker-payload, wherein n2 is 8 and each linker-payload is bonded to one of the para-azidomethylphenylalanine residue side chains:Attorney Docket No.: 108843.0062745. The antibody drug conjugate of any one of the proceeding claims, wherein the antibody comprises the VH / VL pair SEQ ID NOs: 1373 / 1495.
46. The antibody drug conjugate of any one of the proceeding claims, wherein the antibody comprises the VH / VL pair SEQ ID NOs: 1487 / 1495.
47. The antibody conjugate of any of the preceding claims, wherein the antibody binds to an epitope consisting of the sequence set forth is the same epitope as the epitope of the antibody of any one of claims 36-40.
48. The antibody conjugate of any one of the preceding claims, wherein the antibody (a) comprises at least one constant region domain; (b) comprises a constant region in a heavy chain sequence set forth in one of SEQ ID NOS: 1497-1511 and in a light chain sequence set forth in SEQ ID NO: 1496; (c) is a monoclonal antibody; (d) is an IgA, an IgD, an IgE, an IgG, or an IgM; (e) is humanized or human; (f) is glycosylated; (g) an antibody fragment; (h) is selected from an Fv fragment, a Fab fragment, a F(ab’)2 fragment, a Fab’ fragment, an scFv (sFv) fragment, and an scFv-Fc fragment; and / or (i) is an scFv (sFv) fragment.
49. A pharmaceutical composition comprising the antibody conjugate of any one of claims 1- 48 and a pharmaceutically acceptable carrier.Attorney Docket No.: 108843.0062750. A kit comprising the antibody conjugate of any one of claims 1-48 or the pharmaceutical composition of claim 49, and instructions for use of the antibody conjugate or the pharmaceutical composition.
51. The pharmaceutical composition of claim 49, further comprising one or more additional active agents.
52. The pharmaceutical composition of claim 51, wherein the one or more additional active agents is one or more checkpoint inhibitors or one or more PARP inhibitors.
53. The pharmaceutical composition of claim 52, wherein the one or more checkpoint inhibitors are aPD-1 inhibitor, PD-L1 inhibitor, PD-L2 inhibitor, CTLA-4 inhibitor, LAG- 3 inhibitor, or TIM-3 inhibitor.
54. The pharmaceutical composition of claim 53, wherein the one or more PD-1 or PD LI inhibitors are selected from the group consisting of CA-170, BMS 8, BMS-202, BMS- 936558, CK-301, AUNP12, avelumab, nivolumab, pembrolizumab, atezolizumab, durvalumab, AMP 224, MEDI0680 / AMP-514, PDR001, cemiplimab, TSR-042, Tizlelizumab / BGB-A317, CK 301, BMS-936559, camrelizumab, sintilimab, toripalimab, genolimzumab, A167, MGA012, PF-06801591, LY3300054, FAZ053, PD-11, CX-072, BGB-A333, BI 754091, JNJ 63723283, AGEN2034, CA-327, CX-188, STI -Al 110, JTX- 4014, (LLY) AM0001, CBT-502, FS118, XmAb20717, XmAb23104, AB122, KY1003, RXI-762, PRS-33, ALPN-202, TSR-075, MCLA 145, MGD013, and MGD019.
55. The pharmaceutical composition of claim 52, wherein the one or more PARP inhibitors are selected from olaparib, rucaparib, niraparib, and talazoparib.
56. A method for reducing abnormal cell proliferation in a subject in need thereof, comprising administering to the subject an effective amount of an antibody conjugate of any one of claims 1-48, or a pharmaceutical composition of anyone of claims 49 and 51-55.
57. A method for treating or preventing a disease or condition in a subject in need thereof, comprising administering to the subject an effective amount of an antibody conjugate of any one of claims 1-48, or a pharmaceutical composition of anyone of claims 49 and 51-55.Attorney Docket No.: 108843.0062758. A method of diagnosing a disease or condition in a subject in need thereof, comprising administering to the subject an effective amount of an antibody conjugate of any one of claims 1-48, or a pharmaceutical composition of anyone of claims 49 and 51-55.
59. The method of any one of claims 56-58, further comprising administering to the subject one or more additional active agents.
60. The method of claim 59, wherein the one or more additional active agents is a checkpoint inhibitor or one or more PARP inhibitors.
61. The method of claim 60, wherein the checkpoint inhibitor is a PD-1 inhibitor, PD-L1 inhibitor, PD-L2 inhibitor, CTLA-4 inhibitor, LAG-3 inhibitor, or TIM-3 inhibitor.
62. The method of claim 61, wherein the PD-1 inhibitor or PD LI inhibitor is selected from the group consisting of CA-170, BMS 8, BMS-202, BMS-936558, CK-301, AUNP12, avelumab, nivolumab, pembrolizumab, atezolizumab, durvalumab, AMP 224, MEDI0680 / AMP-514, PDR001, cemiplimab, TSR-042, Tizlelizumab / BGB-A317, CK 301, BMS-936559, camrelizumab, sintilimab, toripalimab, genolimzumab, A167, MGA012, PF-06801591, LY3300054, FAZ053, PD-11, CX-072, BGB-A333, BI 754091, JNJ 63723283, AGEN2034, CA-327, CX-188, STI -Al 110, JTX-4014, (LLY) AM0001, CBT-502, FS118, XmAb20717, XmAb23104, AB122, KY1003, RXI-762, PRS-33, ALPN-202, TSR-075, MCLA 145, MGD013, and MGD019.
63. The method of claim 60, wherein the PARP inhibitor is selected from olaparib, rucaparib, niraparib, talazoparib, and talazoparib derivatives.
64. The method of any of claims 56-63, wherein the disease or condition is a cancer.
65. The method of any one of claims 56-64, wherein the disease or condition is an avP6- expressing cancer.
66. The method of any one of claims 56-65, wherein the disease or condition is a solid tumor cancer.
67. The method of any one of claims 56-65, wherein the disease or condition is selected from the group consisting of cervical cancer, breast cancer, head and neck squamous cellAttorney Docket No.: 108843.00627carcinoma, endometrial cancer, esophageal cancer, non-small cell lung cancer, gastric cancer, colon cancer, prostate cancer, bladder cancer, and pancreatic cancer.
68. A method of diagnosing and treating cancer in a subject in need thereof, comprising (a) detecting the expression of avP6 in a cell or tissue of the subject to diagnose the cancer; and(b) administering to the subject an effective amount of a pharmaceutical composition of any one of claims 49 and 51-55.
